Effectiveness of cervical lateral glide mobilization in the management of cervicobrachial pain by Salt, Emma
 
 
EFFECTIVENESS OF CERVICAL LATERAL 
GLIDE MOBILISATION IN THE MANAGEMENT 
OF CERVICOBRACHIAL PAIN 
 
by 
EMMA JUSTINE SALT 
A thesis submitted to the University of Birmingham for the degree of 
DOCTOR OF PHILOSOPHY 
 
School of Health and Population Sciences. 
College of Medical and Dental Sciences 
University of Birmingham 
August 2013  
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
 
 
Abstract 
Background 
Cervicobrachial pain is a painful condition which, when chronic, might lead to high 
levels of disability.  Limited data from small studies have reported that the lateral 
glide mobilisation is effective on reducing pain in the short-term.  The primary aim of 
this study was to establish whether the lateral glide mobilisation technique was 
effective in reducing pain in the long-term. 
Methods 
Literature reviews on cervicobrachial pain provided the rational to conduct a phase III 
trial.  An audit and a preliminary study were used to inform methods for the trial.  A 
single-centre randomised clinical trial was conducted on participants with chronic 
cervicobrachial pain.  Participants were randomised to receive either the lateral glide 
with self-management or self-management alone.  The trial was powered to detect a 
between group difference of 20mm on worst pain on a visual analogue scale (VAS) 
at 52 weeks follow-up.   
Results 
Ninety-nine participants were recruited to the trial. There was a non-significant 
between-group difference for mean VAS(worst pain) scores at 52 week follow-up 
(p=0.52; 95% CI -14.72 to 7.44).   
Conclusion 
The findings from this trial provided no evidence that the lateral glide was more 
effective than a comparator in the management of chronic cervicobrachial pain in the 
long-term.  
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1 INTRODUCTION 
Cervicobrachial (neck and arm) pain is a frequently occurring and disabling disorder 
and has been estimated to account for the majority of patients presenting for 
treatment with cervical spine disorders (Daffner et al., 2003). When the condition is 
chronic, it is likely to become a persistent or recurring problem that impacts 
unfavourably on an individual’s mental as well as physical health (Daffner et al., 
2003). The most recent study for the natural history of the condition reported 
reoccurrence rate to be as high as 32% (Radhakrishnan et al. 1994). In addition to 
the effect on individuals, persistent disablement could lead to high costs for health 
care systems and society (Karjalainen et al., 2006).  Despite its impact, there are no 
clear guidelines for the management of cervicobrachial pain.  
In cervicobrachial pain, pain can be referred to the arm from somatic structures or 
radiate to the upper limb through neuropathic mechanisms. Numerous classifications 
have been reported, including cervicobrachial pain syndrome, cervical radiculopathy 
and neck and arm pain.  For the purpose of this study, cervicobrachial pain is defined 
as the presence of arm pain associated with cervical spine pain (Jull et al., 2008).  
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1.1 Rationale for the study 
Surgical and conservative interventions are used in the management of 
cervicobrachial pain. Surgery has not been shown to be more effective compared to 
conservative management and has been reported to carry a 4% complication rate 
(Fouyas et al., 2002; Carragee et al., 2008). Conservative management has been 
advocated as the initial treatment of choice for the majority of patients with 
cervicobrachial pain (Fouyas et al., 2002; Daffner et al., 2003). Exceptions to this are 
patients with serious local pathology such as fractures, dislocations, myelopathy, 
infections or tumours that require urgent medical and/or surgical intervention (Carette 
and Fehlings, 2005). 
Conservative management of cervicobrachial pain comprises invasive techniques 
(such as injection therapy and acupuncture) or non-invasive techniques with 
physiotherapy, osteopathy and chiropractic being the three most utilised within health 
care. There is limited evidence to support the use of injection therapy (Peloso et al., 
2011) and acupuncture (Trinh et al., 2006). The Task Force on Neck Pain and 
Associated Disorders published a document in 2008 looking specifically at non-
invasive interventions for neck pain, up to 2006. It highlighted that there was 
inadequate research on cervicobrachial pain for non-invasive interventions and that 
future research should focus on non-invasive interventions for this patient group 
(Hurwitz et al, 2008 p.123). 
Manual therapy in the form of cervical mobilisation is one non-invasive intervention 
that is commonly used by physiotherapists, osteopaths and chiropractors. High 
quality systematic reviews have consistently reported mobilisation to be of value in 
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the management of cervical spine disorders, such as mechanical neck pain and 
cervicogenic headache (Gross et al., 2004; Gross et al., 2010; Miller et al., 2010).  
However, only limited research has been conducted to determine the therapeutic 
value of mobilisation for patients with cervicobrachial pain (Gross et al., 2004; Gross 
et al., 2010; Miller et al., 2010; Leininger et al., 2011).  
 Although a wide variety of mobilisation techniques are used to treat cervical spine 
dysfunction, it is unknown whether different techniques have varying therapeutic 
effect.  Small scale, short-term studies have identified that the lateral glide 
mobilisation technique reduces cervicobrachial pain (Allison et al., 2002; Cowell & 
Phillips., 2002; Coppieters et al., 2003).  
The primary research aim for the proposed trial was to identify whether the lateral 
glide cervical mobilisation was effective in reducing pain levels in the long-term for 
patients with chronic cervicobrachial pain.  Secondary aims were to evaluate any 
effects the mobilisation had on function and disability. Patient perceived recovery, 
cost analysis and harm analysis were included in planning of the phase three trial.  
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1.2 Structure of the thesis 
The thesis details processes involved in the development of a clinical trial to evaluate 
the use of a lateral glide mobilisation in the management of cervicobrachial pain.  
Methods used to conduct literature reviews are identified, followed by reporting of 
literature reviews to evaluate classification and epidemiology of cervicobrachial pain, 
to provide background information (Chapter 2).  An in-depth analysis of existing 
research relating specifically to non-invasive interventions follows.  A systematic 
literature review of non-invasive interventions for cervicobrachial pain was conducted 
and its findings reported (Chapter 3).  The review supported further investigation of 
the lateral glide technique and different approaches for performing the technique 
were evaluated to support selection of the most appropriate approach to be used in 
the main phase III trial.  A suitable comparator intervention was also identified with 
evidence to support its selection (Chapter 4).   Planning of the phase III trial was 
informed by an audit and a preliminary study. Methods used for the phase III trial are 
identified (Chapter 5) and the results are presented relating to primary and secondary 
outcome measures (Chapter 6). Trial results and their relationship to previous 
research are discussed, limitations of the trial are considered and recommendations 
for future research are identified (Chapter 7).  Throughout the thesis, the main trial 
will be referred to as the ‘trial’ to effect differentiation from the reporting of other 
studies. 
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1.3 Methods used in thesis for evaluation of evidence 
Literature reviews (including a systematic review of non- invasive management of 
cervicobrachial pain) were conducted to support the development of the proposed 
trial. During the course of the PhD, augmentations to the methods for appraising 
literature were developed and published in the research literature (Moher et al., 2009; 
Balshem et al., 2011; Guyatt et al., 2011a; Higgins and Green, 2011). For the 
presentation of this thesis, evidence has been evaluated using these updated 
methods to maximise rigour in its evaluation. Information from updated searches was 
used to provide futher evidence to support methods used and conculsions drawn 
from the study, and were used to critically evaluate the results of this study in the 
discussion.   
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2 AN OVERVIEW OF CERVICOBRACHIAL PAIN 
This chapter initially considers the methods used to search and evaluate the 
evidence using the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) approach.  The chapter then focuses on classifying 
cervicobrachial pain as a single entity, followed by a critique of frequently reported 
sub-classification systems. The chapter concludes with a discussion of epidemiology 
and economic costs of cervicobrachial pain. It considers how cervicobrachial pain 
affects individuals and the wider effects to health care systems and society.  
2.1 Method for the literature search on cervicobrachial pain 
Searches were conducted using electronic computerised databases (Cochrane 
Library, Cochrane central register of controlled trials [CENTRAL], MEDLINE, 
EMBASE, AMED and CINAHL), from inception to January 2012. 
  
For each database, key terms (cervicobrachial, cervical radiculopathy, neck and arm 
pain) were identified against classification, epidemiology, prognosis and economic 
cost.  Searches were not limited by study design because it was anticipated that 
there would be a limited amount of data for some areas such as prognosis and cost.  
Truncation, exploding, thesaurus mapping and MESH terms were used to fully 
capture all available evidence (Timmins & McCabe., 2005; Cleary et al., 2009).  This 
approach to searching has been advocated to ensure comprehensive data collection 
(CRD, 2009).   
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2.2 Method for the critical evaluation of evidence in the published 
literature 
The GRADE system (Balshem et al., 2011; Guyatt et al., 2011a) was used to rate the 
quality of evidence reported in retrieved research studies and to determine 
recommendations about its use.   GRADE was chosen because it provided the 
potential to upgrade or downgrade evidence, allowing a more flexible and 
sophisticated approach to evaluating the evidence (Balshem et al., 2011; Guyatt et 
al., 2011a).  As with all critical evaluation systems, GRADE is open to subjectivity in 
use.  However, its framework provided a systematic approach to appraising 
evidence, so that recommendations were determined through a planned method 
(Balshem et al., 2011; Guyatt et al., 2011a).  Over the last decade, several 
organisations (for example, the World Health Organization, the American College of 
Physicians and the Cochrane Collaboration) have advocated the use of GRADE over 
other tools (Guyatt et al., 2008). It has been increasingly recognised, in research 
literature, as the ‘gold standard’ for the critical evaluation of evidence (Balshem et al., 
2011; Guyatt et al., 2011a). 
In general, the GRADE system establishes the quality of evidence and the strength 
of recommendation across studies, for specific outcomes (Guyatt et al., 2011a). For 
example, in this thesis, pain as an outcome was analysed separately from function.   
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A three-part process was used to reach a recommendation: 
1. Quality of evidence was determined for eight specified domains. 
2. Grade of evidence was determined by how many domains were met. 
3. Strength of recommendation was based on the grade together with 
other determinants, for example risk versus benefit ratio.  
2.2.1 Determining quality of evidence in the retrieved literature 
Quality was based on eight key domains.  Five of the domains could have resulted in 
downgrading evidence on an outcome: study limitations, inconsistency, indirectness, 
imprecision and reporting bias (Balshem et al., 2011).  Three of the domains could 
have resulted in upgrading evidence on an outcome: large effect, dose response and 
consideration for confounders (Balshem et al., 2011).   
Fulfilment of each domain was determined by following guidance in the Cochrane 
Handbook (Schünemann et al., 2011) and the series of publications by Guyatt et al. 
in the Journal of Clinical Epidemiology (Guyatt et al., 2011b; Guyatt et al., 2011c; 
Guyatt et al., 2011d; Guyatt et al., 2011e; Guyatt et al., 2011f). Criteria per domain 
are summarised in Table 2-1.   
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Table 2-1: Summary of criteria needed to fulfil each domain in GRADE 
Domain Criteria 
Study 
limitations 
Limitations are defined in  relation to four specific types of bias:  
Selection (Focusing on the evidence of allocation sequence concealment and 
                /or lack of similarity between participants baseline characteristics) 
 Performance (Relating to whether blinding of the study participants or 
                       personnel has been reported.  Or, whether 
                       differences between groups in additional care provided e.g. 
                       differing amounts of investigations or additional treatment have 
                       been identified)                  
 Detection (Concerning the blinding of outcome assessors and how  
                  Between group differences for different outcomes have been been 
                  determined)   
 Attrition (Describing the proportion of attrition overall and between-groups. 
               High proportion of loss to follow-up can be considered as >20%.   
               An example of uneven loss to follow-up between groups would be 
               5% in one group compared to 15% in another) 
 
Inconsistency Inconsistency considers heterogeneity and study outcomes: 
Heterogeneity between studies might occur if different populations between studies 
are not comparable.  For example, acute v chronic conditions.  
Inconsistency might be where there are large differences between study outcomes 
resulting in no clear direction of effect e.g. comparable studies report an 
intervention to have a positive effect on pain compared to a placebo, whilst others 
find that the placebo has a preferential pain response to the intervention. 
 
Indirectness Indirectness relates to external validity: 
Concerning whether the studies are generalisable, transferable, applicable or 
directly comparable.  For example, the study results might not be generalisable to a 
UK population if the study was conducted in a third world country. 
 
Imprecision 
 
Imprecision relates to the size of studies, with small studies being subject to higher 
sampling variation than larger studies and, hence, statistical results are less 
precise. Imprecision is reflected in confidence intervals, with larger intervals 
indicating lower precision. In general, more precise results are obtained from 
studies that have been powered to ensure that adequate numbers of participants 
are recruited to improve precision. 
 
Publication 
bias 
Publication bias is usually suspected when primary outcomes published in a study 
protocol are not then published in the results of a completed study, especially when 
the outcomes published all report a positive result.  Findings from research studies 
that have been funded by industry need to be interpreted with caution, as do 
outcomes that favour a commercial sponsor 
   
Large effect Large effect relates to the amount of change seen in outcomes: 
the quality of evidence can be upgraded by one or two points if large or very large 
and consistent estimates of treatment effect across studies are reported. Relative 
risk reduction more than 50% or risk ratio above 2 can be considered to 
demonstrate a large effect (upgrade by one point).  More than 80% or risk ratio 
above 5 can be considered a very large effect (upgrade by 2 points) 
 
Dose response 
 
Dose response is defined as a correlation between quantity of treatment given and 
outcomes reported: 
A good dose response would be where a consistent relationship between an 
intervention and an outcome is found across similar studies. 
 
Consideration Confounders are factors that could affect study outcomes: 
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Footnote:  The above criteria were based on Guyatt et al., 2011b; Guyatt et al., 2011c; Guyatt et al., 2011d; 
Guyatt et al., 2011e; Guyatt et al., 2011f;  Schünemann et al.,  2011 - Sections 12.2.2 and 12.2.3. 
 
2.2.2 Determining the grade for retrieved studies using GRADE  
Using GRADE enabled randomised studies to be downgraded and observational 
studies to be upgraded, depending on whether the criteria for each domain were met 
(Balshem et al., 2011). From this, a grade was determined for the overall quality for 
each outcome.  There were four possible grades ranging from ‘high’ to ‘very low’ 
(Table 2-2).  GRADE’s approach to rating the quality of evidence starts with the study 
design (randomised or observational study) and evaluates five reasons to possibly 
rate down the quality of evidence and three to possibly rate up the quality (Balshem 
et al., 2011 p.404; Guyatt et al., 2011b; Guyatt et al., 2011c; Guyatt et al., 2011d; 
Guyatt et al., 2011e; Guyatt et al., 2011f).  For example, a randomised study might 
initially start with the highest possible score (4 points), however the score could be 
downgraded by using the above mentioned reasons. For instance if there were very 
serious flaws around selection and attrition bias (study limitations) up to two points 
could be deducted, a further two points could be deductive if there were inconsistent 
results across the intervention groups (inconsistency). This could potentially leave a 
study with zero (0 points).  Yet, if important covariates had been accounted for in the 
analysis the score would increase by one point resulting in the overall rating as ‘one’ 
( 1 point) and the level of evidence would be categorised as ‘very low’. 
for 
confounders 
Consideration is given to whether confounders have been identified in RCTs and 
statistical methods have been used to address confounders in the analyses.  For 
example, older age might have a significant influence on an outcome.   If, by 
chance, the mean age was older in one group compared to another, the results 
from statistical analyses could be skewed.  In this exaxmaple, age could be 
accounted for using analysis such as ANCOVA. 
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Table 2-2 Method used to establish quality of evidence in GRADE 
[Adapted from GRADE (Balshem et al., 2011, p.404)] 
The resultant grades provided an estimated level of confidence about the findings in 
the available research.  This ranged from being defined as very confident that the 
available research represented the truth (high grade) to very little confidence that the 
available research was able identify the truth (very low grade) (Balshem et al., 2011) 
(Table 2-3).    
Study design Initial quality of 
a body of 
evidence 
Lower the 
quality if 
Higher the 
quality if 
Quality of a 
body of 
evidence 
Randomised 
studies 
High Study limitations 
-1 Serious 
-2 Very serious 
 
Inconsistency 
-1 Serious 
-2 Very serious 
Large effect 
+1 Large 
+2 Very Large 
 
Dose response 
+1 evidence of a 
      gradient 
High (four plus) 
⊕⊕⊕⊕ 
 
 
Moderate (three 
plus) 
⊕⊕⊕○ 
 
Observational 
studies 
Low Indirectness 
-1 Serious 
-2 Very serious 
 
Imprecision 
-1 Serious 
-2 Very serious 
 
Reporting bias 
-1 likely 
-2 Very likely 
Consideration for 
confounders 
+1 Would  
     reduce a 
     demonstrated 
     effect 
 
+1 Would  
      suggest a 
      spurious 
      effect if  
      no effect 
     was observed 
Low (two plus) 
⊕⊕○○ 
 
Very low (one 
plus) 
⊕○○○ 
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Table 2-3 Interpretation of the grades in the GRADE approach 
 Grade Interpretation 
High Very confident of the effect estimate: The estimated effect is close to the true 
effect.  
Moderate Moderately confident in the effect estimate:  The estimated effect is likely to be 
close to the true effect, but there is a possibility that it is substantially different. 
 
Low Limited confidence in the effect estimate:  The estimated effect might be 
substantially different from the true  effect 
 
Very Low Very little confidence in the effect estimate:  The estimated effect is likely to be 
substantially different from the true effect. 
[Adapted from GRADE (Balshem et al., 2011, p.404)] 
2.2.3 Strength of recommendation used in GRADE 
Strength of recommendation on a body of research regarding the effectiveness of an 
intervention was reported as ‘high’ or ‘low’. On their own, high grades did not 
necessarily imply strong recommendations (Balshem et al., 2011).  Other factors that 
needed to be considered included:  risk of harm, patient values, patient preferences 
and cost (Balshem et al., 2011).  This was to ensure that important desirable and 
undesirable effects of an intervention were considered collectively to reach a 
recommendation (Guyatt et al., 2008).  For example, if a mobilisation (manual 
therapy) technique used in physiotherapy was consistently reported to reduce pain 
and was graded to be high (likely to represent a true effect), but, it had been reported 
as being associated with a high level of harm and the cost to provide it was large, 
then, the strength of recommendation to integrate this technique into standard 
practice might be low.  
2.2.4 Additional use of GRADE 
Prognosis of cervicobrachial pain was included in the study to aid understanding of 
the natural history of the condition.  This was for two reasons: data on the natural 
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history could be used to compare interventional effects used in the clinical trial and to 
identify an optimal time for management.  For example, if a condition improves 
spontaneously for most people within the first six weeks of onset, but fails to improve 
for symptoms extending beyond this time, could imply that delivering intervention to 
those patients whose condition has lasted beyond the six weeks is appropriate.   
Since no guidelines were available for the evaluation of prognostic studies, the use of 
GRADE was queried.  Personal correspondence with the guideline developers 
(Guyatt, 2012) confirmed that “although [GRADE] had not been developed for 
prognosis it works well with it” (Appendix 1A).   
2.3 Classification of cervicobrachial pain 
Cervicobrachial pain has been defined as the presence of arm pain associated with 
cervical spine pain (Jull et al., 2008).  This general classification is based on 
symptom presentation rather than identifying a structural, pathological or 
physiological cause.  It is sometimes impossible to determine the cause of the pain in 
cervicobrachial pain. Use of a symptom-based approach takes uncertainty into 
account when diagnosing the potential cause (Summerton, 2006), avoiding the need 
to use inappropriate diagnostic terms (Summerton, 2006; Thoomes et al., 2012; 
Zusman, 2012).  
“The clinician should be permitted and encouraged to use appropriate diagnostic 
names for what he can prove and to avoid diagnostic specifications for entities about 
which he must guess”(Feinstein, 1968 p.1060) 
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Symptom-based classifications have been endorsed by the International 
Classification of Functioning, Disability and Health (ICF) (WHO, 2002). Sub-
classifications (divisions within a classification) have often been used to identify 
whether patients with different mechanisms of cervicobrachial pain are associated 
with different responses to distinct intervention approaches (Childs et al., 2004). 
Hence, a sub-classification system could provide clearer guidance on which patients 
respond to specific treatments (Childs et al., 2004).    
A patho-anatomical sub-classification system has been used frequently in research 
on cervicobrachial pain. Terms within this system relate to pathological and 
anatomical causes, for example ‘cervical radiculopathy’ refers to disease or damage 
involving spinal nerve roots resulting in radiating arm pain and symptoms (Eubanks, 
2010; Karnath, 2012). Despite its frequent use, there was moderate evidence of a 
poor correlation between abnormal findings on investigations and a patient’s 
subjective symptoms (Max, 2000; Childs et al., 2004) and a poor correlation between 
patho-anatomical diagnosis and intervention response.  It has been questioned 
whether the identification of a patho-anatomical diagnosis is a meaningful predictor 
for outcomes in response to interventions in spinal disorders (Trudelle-Jackson et al., 
2008; Bertilson et al., 2010).    
A second sub-classification system makes use of a pain mechanism (Smart et al., 
2008).  This approach conceptualises pain as a clinical entity in itself, and provides a 
comprehensive way of analysing how pain responds to a treatment intervention 
(Woolf et al., 1998; Smart et al., 2008).    
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2.3.1 Pain mechanisms in cervicobrachial pain 
Musculoskeletal pain can be generated and perpetuated from nociceptive or 
neurogenic mechanisms (Villemure & Bushnell, 2002; Jones et al., 2003a; Hagberg, 
2005; Nijs et al., 2010; Smart et al. 2010; Yi & Zhang, 2011). These mechanisms 
may occur in isolation or collectively.   
Evidence of a nociceptive mechanism in cervicobrachial pain 
There is very low evidence that nociceptive structures such as joints, discs, ligaments 
and muscles are able to refer pain to the neck and arm.  A case series by Fukui et al. 
(1996) reported that cervicobrachial pain could be produced by chemically 
stimulating the facet joints and reduced by denervation of the joints. No other recent 
studies have evaluated the potential for facet joints to refer symptoms beyond the 
level of the shoulder.  Small case series have consistently reproduced 
cervicobrachial pain by chemically stimulating cervical muscles, ligaments and discs 
(Bogduck & Aprill., 1993; Bogduck, 1995; Simons et al., 1999).  None of these 
studies involved control groups, blinding or statistical analyses and, hence, findings 
were subject to potentially high bias.   
Evidence of a neurogenic mechanism in cervicobrachial pain 
Neurogenic pain may be generated by peripheral (peripheral nerve) or central (spinal 
cord and brain cortex) mechanisms. 
Studies on animal models have induced peripheral neuritis and found a causal link, 
but these findings are not directly transferable to human presentations (Eliav & Tal., 
1994; Tal & Eliav., 1996; Study & Kral., 1996; Eliav et al., 1999; Eliav et al., 2001).  
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No studies have been conducted on human subjects to induce a peripheral neuritis to 
evaluate whether radiating pain patterns exist in the same way as in animal models.   
There was low evidence from one small underpowered study that widespread 
sensory hypersensitivity occurred in patients with chronic cervicobrachial pain (n=38) 
compared to asymptomatic subjects (p<0.01).  The authors concluded that these 
changes were probably due to alteration in central pain processing (Chien et al., 
2008).  It was unknown whether alteration to central pain processing was a cause of, 
or, a consequence of cervicobrachial pain. 
Some musculoskeletal conditions have a dominant pain mechanism.  For example; 
current literature in fibromyalgia suggests that the pain predominantly relates to 
neurogenic supra-spinal mechanism (Petersel et al., 2011; Straud, 2011; Vierck, 
2012). This knowledge has influenced current management of fibromyalgia. 
However, it is unclear to what extent nociceptive structures or neurogenic 
mechanisms contribute to the development of cervicobrachial pain. 
There was some evidence that nociceptive and neurogenic pain mechanisms are 
interlinked (Quinn et al., 2010) and insufficient evidence to differentiate 
cervicobrachial pain into distinct sub-categories.  Consequently, cervicobrachial pain 
was considered as a collective term in this thesis. 
2.4 Epidemiology of cervicobrachial pain 
Epidemiology is the study of patterns and distribution of health or health limiting 
conditions (Davey Smith, 2001).  It is important to understand epidemiological 
characteristics for different health limiting conditions, such as cervicobrachial pain, to 
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effectively critique and evaluate research findings (Davey Smith, 2001).  For 
example, the knowledge of prognostic factors in cervicobrachial pain would identify 
what factors could have the capacity to confound results, therein enabling better 
critical analysis of existing research, and help inform the design of statistical methods 
to account for confounding effects in the planning of a clinical trial.   
Specific epidemiological factors relate to: 
• Prevalence and incidence rates in a given time 
• Risk factors (factors causing an increased risk of developing the condition)  
• Associated factors (factors connected with the presence of the condition)  
• Prognosis (the natural course of the condition over time) 
• Prognostic factors (factors that affect prognosis) 
 
Identifying the prevalence (total number of cases) and/or incidence (number of new 
cases) provides information on the extent to which cervicobrachial pain occurs in 
society and justifies the need to research the condition (Carroll et al., 2008).  
Knowledge of risk and associated factors might be used to establish characteristics 
of cervicobrachial pain patients (Carroll et al., 2008). Baseline characteristics for 
known risk and associated factors in interventional studies could be used to 
determine representativeness of a study cohort, and, hence, generalizability of 
findings from an interventional study (Burgess et al., 2003; Moher et al., 2010). 
Prognosis enables an understanding of the natural history of a condition, from which 
comparisons of outcomes from interventional studies over time can be made (Carroll 
et al., 2008) and prognostic factors identify confounding variables that might affect 
outcomes in interventional studies. 
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2.4.1 Prevalence and incidence of cervicobrachial pain 
Collectively, neck pain disorders affect approximately 332 million people, accounting 
for one fifth of all musculoskeletal conditions worldwise (Bone and Joint Decade, 
2012). These figures were based on estimates from the Global Burden of Disease 
Study 2010 that used survey data from 32,659 people across 5 different countrys 
(Salomon et al., 2012).  There was low evidence from one systematic review (based 
on reports from 8 separate epidemiology studies between 1987 to 2002; n=15,069) 
that the global mean lifetime prevalence of neck pain was 48.5% (range 14.2% to 
71.0%) (Fejer et al., 2006). Although no numerical value has been reported for the 
incidence or prevalence of cervicobrachial pain, there was moderate evidence that it 
is a frequently occurring problem, accounting for the majority of neck pain disorders. 
For example, in a sample of 1809 patients with neck and arm pain (Daffner et al., 
2003) between 1998 and 2001, 533 (30%) patients presented with neck pain in 
isolation, compared with 1183 (65%) who presented with neck and radicular 
symptoms.  Hence, cervicobrachial pain was more than twice as common as neck 
pain in isolation.  It has been reported to frequently accompany cervicogenic 
headache (Antonaci et al., 2006, Vincent, 2010).  One small study (n=81) reported 
that 67% of patients with chronic cervicobrachial pain also presented with headache 
(Persson & Carlsson, 1999).  In addition, cervicobrachial pain was reported to feature 
in 60% of chronic whiplash presentations in a study involving 156 patients (Sterling et 
al., 2002b).  Cervicobrachial pain can be estimated to affect approximately 40% of 
individuals at some time in their lives. 
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2.4.2 Risk factors in cervicobrachial pain 
Gender, age and smoking have been identified as possible risk factors in the 
development of cervicobrachial pain (Finocchietti & Trindade1973; Kostova & Koleva 
2001; Kaki, 2006). 
There was moderate evidence that gender and age were important factors in the 
development of cervicobrachial pain, with females, aged 40 years or older, being at 
greatest risk of developing the condition (Finocchietti & Trindade 1973; Kostova & 
Koleva 2001; Kaki, 2006).  Low evidence supported a possible influence of genetic, 
hormonal and psychosocial factors on pain perception and pain response 
(LeResche, 1999; LeResche, 2000; Sherman & LeResche, 2006; Keogh, 2006; 
Wijnhoven et al., 2006; Williams et al., 2010).    
There was low evidence that smoking, in some instances, increased the risk of 
developing cervicobrachial pain.  A cross-sectional study on 898 participants (Kosova 
& Koleva, 2001) reported that males who smoked more than 20 cigarettes per day 
had a greater incidence of cervicobrachial pain than those who smoked less: 14.8% 
compared to 3.4% [OR 4.95; 95% CI 1.17 to 19.32].  This finding did not hold for 
female smokers (Kosova & Koleva, 2001). Smoking is known to reduce circulation 
generally (Munger & Hawkins, 2004; Scallan et al., 2010) and there was very low 
evidence that vascular change specific to the nerve roots in the lumbar spine has led 
to the development of sciatic symptoms (Kobayashi et al., 2005).  However, no 
research has evaluated this association with cervical nerve roots and it was unclear 
why differences exist between genders. Further studies are needed to establish to 
what extent and on whom smoking is a risk factor in developing cervicobrachial pain.  
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2.4.3 Associated factors in cervicobrachial pain 
Modern-day lifestyle factors might be better considered as ‘associated’ rather than 
‘risk’ factors, since it was unclear whether changes in lifestyle cause, or result from, 
cervicobrachial pain (Carroll et al., 2008).  Psychosocial, physical fitness, posture 
and computer use were identified as possible associated factors. 
Moderate evidence existed of an association between psychosocial factors with 
cervicobrachial pain. An observation study by Daffner et al. (2003) compared the 
impact of cervicobrachial pain (n=1183) to neck pain alone (n=533).  After accounting 
for age and gender, the study found that patients with cervicobrachial pain had lower 
levels of mental health and social wellbeing than localised neck pain patients 
(p<0.0001 to p<0.005). Although no other studies had evaluated these aspects in 
cervicobrachial pain, some studies that evaluated psychosocial factors in 
heterogeneous groups of neck and arm pain syndromes (including cervicobrachial 
pain) reported similar associations (Curci et al., 1986; Oliveira, 2000; Bongers et al., 
2006). 
There was low evidence that lack of physical fitness was associated with 
cervicobrachial pain.  One observational study (Krapac et al., 1992) reported  that 
controls (participants without cervicobrachial pain) were more than four times as 
likely to spend their free time actively involved in activities such as sports and 
gardening than the participants with cervicobrachial pain (p<0.001).  Participants with 
cervicobrachial pain spent a greater proportion of their free time passively, including 
pursuits such as handicrafts (Krapac et al., 1992). No other cervicobrachial studies 
have considered this association. However, these results were consistent with other 
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musculoskeletal studies that have reported associations between increased physical 
fitness and improved health (Viori, 1995; Miranda et al., 2001; Hayes et al., 2009; 
Kharuakhorn et al., 2010; Moscato et al., 2010). 
One case-controlled study (Krapac et al., 1992) provided very low evidence that 
people with cervicobrachial pain adopted slouched postures and performed greater 
repetitive movements at work (tasks not specified) than those without the condition 
(p<0.05). No other evidence was identified in relation to the effect of posture 
There was very low evidence that computer use was associated with cervicobrachial 
pain. It has been suggested that prolonged computer use could be an associated 
factor in developing cervicobrachial pain (Finocchitti & Trimdade, 1973; Krapac, 
1989; Sauter et al., 1991). 
Overall, there was very low to moderate evidence of risk and associated factors for 
cervicobrachial pain (Table 2.4). 
2.4.4 Prognosis of cervicobrachial pain 
The natural course of any condition determines prognosis (Anderson et al., 1998). 
There is very low evidence that cervicobrachial pain reduces over time. The largest 
and most frequently cited study evaluating prognosis in cervicobrachial pain was 
undertaken in Rochester, Minnesota between 1976 - 1990 (Radhakrishnan et al., 
1994).  This epidemiological study involved 561 participants over a 13-year period.  
Although the results indicated that, in 90.5% of cases, symptoms largely resolved 
with time, all participants received some form of treatment, which could have 
interfered with the natural course. Radhakrishnan et al. (1994) has been cited in 
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many publications to support the stance that people with cervicobrachial pain are 
expected to recover naturally (Wainner & Gill, 2000; Polston, 2007; Eubanks, 2010).  
However, no well-designed study evaluating natural prognosis has been conducted 
on cervicobrachial pain to evidence this. Hence, the provision of some form of 
treatment could play an important part in recovery. 
2.4.5 Prognostic factors of cervicobrachial pain 
Chronicity (duration of symptoms), psychosocial factors and involvement in litigation 
have been identified as factors affecting prognosis. There was moderate evidence 
from a large systematic review (number of included studies = 45) that a longer 
duration of pain was associated with a worse prognosis in musculoskeletal disorders 
(Mallen et al., 2007).  However, the authors did not report how many weeks or 
months constituted a ‘long duration’.  No studies were identified on how chronicity 
may affect prognosis relating specifically to cervicobrachial pain.  A prospective 
cohort study (n=443) by Bot et al. (2005) reported that duration of neck and shoulder 
symptoms (including cervicobrachial pain) significantly affected outcomes of pain and 
disability (p<=0.005).  Paticipants with baseline durations of one week versus greater 
than six months had reported recoveries of 60% and 15%, respectively, at one year 
follow-up (Bot et al., 2005).  In the study by Bot et al. (2005), the overall recovery rate 
was low (32% recovery at one-year follow-up).  This contrasted with the findings from 
Radhakrishnan et al.’s study (1994).  One possible explanation was that only 26% of 
the sample in Radhakrishnan et al.’s study (1994) had chronic symptoms (greater 
than six weeks duration), compared to 62% of the sample in the study by Bot et al. 
(2005). 
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Psychosocial factors have been found to be the most consistent predictor for 
developing chronic musculoskeletal pain (Oliverira, 2000; Trunks et al., 2008; Lopez 
et al., 2009; Bergbom et al., 2012; Laisné et al., 2012). There was moderate 
evidence to support this association in cervicobrachial pain. Specifically, Daffner et 
al. (2003) (n=1183) reported that poor mental health (using scores from the mental 
component summary of the Short-Form 36 questionnaire) was associated with 
increased chronicity (p=0.001). Data from other cervicobrachial pain studies provided 
further evidence of an association between psychological factors and chronic 
cervicobrachial pain (Sheather-Reid, 1998; Persson & Lilja, 2001). 
There was low evidence that financial compensation, from personal claims, had a 
negative effect on outcome. A preliminary study (total n=60) (Rasmussen et al., 
2001) reported that claimants receiving physiotherapy had poor outcomes, unlike the 
comparative (non-claimant) group who improved. However, there were significant 
limitations in this study, including a lack of evaluation for confounding variables (e.g. 
chronicity and psychosocial factors) and imprecision (e.g. inadequately powered 
study).  A later, appropriately powered study by the same authors (n=202) 
(Rasmussen et al., 2008), reported that at one-year, the odds ratio for not improving 
was 17.4 [95%; CI 5.1 to - 60.1] for patients with a claim at baseline (compared with 
those not claiming), indicating that the claims process had a negative effect on 
prognosis in cervicobrachial pain. In this later study, chronicity was adjusted for using 
covariate analysis; however, psychological factors were not, which might have been 
an important confounder in the outcome (Rohling et al., 1995)  
Overall, there was low to moderate evidence to support chronicity, psychosocial 
factors and involvement in litigation as variables that affected prognosis (Table 2-4).   
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2.5 Economic costs of cervicobrachial pain 
Economic evaluation enabled a fuller appreciation of the financial impact that 
cervicobrachial pain has had on individuals, health-care systems and society 
(Korthals-de Bos et al., 2003).  Costs were related to work absenteeism and health 
care costs (Yelin et al. 1995).  
2.5.1 Work absenteeism (related to cervicobrachial pain) 
No studies were found on work absenteeism related to cervicobrachial pain.  A paper 
by Buckle & Devereux (2002) based on statistics from 40 different resources 
(including government figures, union bodies and experts) estimated that pain 
(including cervicobrachial pain) affecting the neck and/or arm collectively accounted 
for 5.4 million lost working days each year in the United Kingdom (UK).  However it 
was unclear what methods were used to resource data, how any duplication had 
been addressed and over what time period data were collected.  According to figures 
stated by Buckle & Devereux (2002), an individual would potentially lose one month’s 
earnings per episode of neck and/or arm pain.  However, accuracy of these figures 
was unknown and no recent statistics on work absenteeism were available, hence, it 
was unclear whether the reported statistics reflected current trends. In addition, no 
information was available to evaluate whether different types of neck and arm 
syndromes resulted in differing quantities of work absenteeism. 
There was moderate evidence from a cohort study (Hestbaek et al., 2009) that 
involvement in compensation compounded absenteeism from work.  Cervicobrachial 
pain patients seeking financial compensation (n=137) were four times more likely to 
be absent from work in the short and long-term compared with those not seeking 
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compensation (Hestbaek et al., 2009). The estimated odds of patients being absent 
from work were between 1.71 to 11.51 more likely when they were seeking 
compensation compared with not seeking compensation (with 95% confidence), at 
five year follow-up.  
To summarise, it is unknown how much work absenteeism could be attributed to 
cervicobrachial pain.  However, based on the study by Hestbaek et al. (2009), people 
with cervicobrachial pain have a greater amount of sickness absence if they are 
involved in litigation for that condition. 
2.5.2 Health care costs (related to cervicobrachial pain) 
There was low evidence that cervicobrachial pain impacted on health care costs.  
One study (n=3664) found that 58% of patients with chronic cervicobrachial pain 
reported seeking health care (Huisstede et al., 2008).  It has been reported that 
conservative (non-surgical) intervention is usually sought (Fouyas et al., 2002; 
Daffner et al., 2003), with non-invasive intervention in the form of physiotherapy 
frequently being the initial treatment provided (Persson et al., 1997a). No retrieved 
studies evaluated the costs of physiotherapy.  There was moderate evidence that the 
provision of physiotherapy for neck disorders used a mean of 6.82 sessions (SD 
6.55).  The wide variation in number of interventions could be due to some 
physiotherapeutic modalities consisting of brief pain management approaches e.g. 
self-management, whilst other modalities consisted of a larger quantity of intervention 
e.g. manual therapy (Hay et al., 2005).  Based on the mean figure, estimated total 
costs per patient with neck pain was £152 per year in 2006 (Manca et al., 2006).  It is 
probable that this represents a much lower figure than would be calculated on current 
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costing due to rates of inflation over the last decade. As cervicobrachial pain might 
constitute the majority of neck pain disorders, there is a need for evidence to 
substantiate the cost-effectiveness of treatment, such as physiotherapy, for this 
condition.  
Overall, there was low to moderate evidence that cervicobrachial pain was 
associated with moderate economic expenditure, particularly when compensation 
was involved and the condition was chronic (Table 2-4) 
2.5.3 Overall impact of economic costs for cervicobrachial pain 
Based on the available evidence, cervicobrachial pain was reported as causing a 
financial challenge to individuals (Buckle & Devereux (2002), industry (Buckle & 
Devereux, 2002; Hestbaek et al., 2009) and health care systems (Huisstede et al., 
2008). The full extent of the economic burden for this condition is unknown, largely 
due to the lack of data relating specifically to cervicobrachial pain.  Table 2-4 
summarises all key factors linked to cervicobrachial pain, including cost. 
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Table 2-4  Summary of evidence using GRADE for key factors linked to cervicobrachial pain 
Grade Pain 
mechanism 
Incidence Risk and associated 
factors 
Prognosis Prognostic 
factors 
Cost 
Moderate 
 
 
 
Prevalent 
condition 
(Persson & 
Carlsson, 1999; 
Sterling et al., 
2002b; Daffner et 
al., 2003;  
Antonaci et al., 
2006, Vincent, 
2010) 
Age (>40 years) 
(Finocchietti & Trindade1973; 
Kostova & Koleva 2001; Kaki, 
2006) 
Gender (female) 
(Finocchietti & Trindade1973; 
Kostova & Koleva 2001; Kaki, 
2006) 
Psychosocial factors  
(Daffner et al., 2003) 
 
 
Chronicity 
 (Bot et al.,2005)  
 
Psychosocial 
factors  
(Sheather-Reid, 
1998; Persson & 
Lilja, 2001; Daffner 
et al, 2003) 
Involvement in 
compensation 
impacts on work 
absenteeism 
(Hestback et al., 2009) 
 
Low Neurogenic 
(Chien et al., 
2008) 
 
 
 Heavy smoker (males) 
(Kostova & Koleva, 2001) 
 
 Financial 
compensation 
(Rasmussen et al., 
2001; Rasmussen 
et al., 2008) 
 
 
 
Chronic 
cervicobrachial pain 
impacts on health 
care costs 
(Huisstede et al., 
2008; Fouyas et al., 
2002; Daffner et al., 
2003; Persson et al. 
1997) 
Very low 
 
 
 
 
 
 
Nociception  
(Fukui et al., 
1996; 
Bogduck & 
Aprill, 1993; 
Bogduck, 
1995; Simons 
et al., 1999) 
 
 Slouched postures and 
repetitive activities  
(Krapac et al, 1992) 
 
Computer use  
(Finocchitti & Trimdade,1973; 
Krapac,1989; Sauter et al., 
1991) 
Cervicobrachial 
pain has a 
good natural 
prognosis 
(Radhakrishnan 
et al., 1994) 
  
Footnote:  Refer to Table 2-3 for interpretation of the grades 
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2.6 Summary of cervicobrachial pain 
This chapter has highlighted that cervicobrachial pain might derive from multiple 
mechanisms. Since there was no method for effective differentiation of sub-
categories, cervicobrachial pain was considered as a single entity, in this thesis. 
Cervicobrachial pain is a prevalent condition which, when chronic, has a significant 
physical, social and mental impact on the lives of individuals having that condition.  
Precise costs of the condition to individuals, health care systems and society are 
unclear.   
Despite being a prevalent and disabling painful disorder, there was little evidence to 
guide the effective management of cervicobrachial pain, particularly, in relation to 
non-invasive conservative management (Hurwitz et al, 2008).  Chapter 3 will report a 
systematic review of the evaluation of the effectiveness of conservative, non-invasive 
management approaches for cervicobrachial pain.  
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3 REVIEWING THE EVIDENCE FOR NON-INVASIVE 
MANAGEMENT FOR CERVICOBRACHIAL PAIN 
3.1 Introduction to reviewing the evidence  
Chapter 2 reported that cervicobrachial pain was a prevalent and disabling condition, 
for which patients usually sought conservative management.  In general, there has 
been a lack of research relating to non-invasive forms of conservative management 
for this condition (Hurwitz et al, 2008).  
An initial systematic review of relevant literature (SR) was conducted in 2006 to 
critically appraise evidence on the effectiveness of non-invasive interventions for 
cervicobrachial pain.  The systematic approach was selected because SRs were, 
and still are, widely accepted as the “gold standard” for reviewing research literature 
(Egger et al., 2003; Centre for Reviews and Dissemination, 2008, Centre for 
Evidence Based Medicine, 2009; Moher et al., 2009). Findings from the SR were 
used to support the research question addressed in this thesis and development of 
the trial design (including interventions).   
The SR was repeated in 2010 using augmented guidelines for its conduct (Maher et 
al., 2003; Foley et al., 2006) with a view to publish findings. This second review 
revealed the lack of a SR on non-invasive management of cervicobrachial pain. Five 
systematic reviews on non-invasive interventions for generalised neck pain were 
retrieved, but none of these analysed cervicobrachial pain as a sub-group, hence 
limiting interpretation of their findings for that condition (Kay et al., 2005; Haraldsson 
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et al., 2008; Graham et al. 2009; Haines et al., 2010;  Gross et al., 2010).  The 
second SR was published in 2011 (Salt et al., 2011; Appendix A).  
For the purpose of this thesis, the review was updated for the third time (at the end of 
January 2012) to include consideration of relevant new studies on effectiveness of 
non-invasive interventions for cervicobrachial pain and their findings. This chapter 
presents the methodology and findings of the most recent SR (January 2012).    
3.2 Rationale for and aim of the systematic review 
Whilst there are many ways to conduct a literature review (Dixon-Woods et al., 2005), 
narrative and systematic review methods are the most frequently used (Goldsmith et 
al., 2007).  A narrative method adopts a holistic approach to analysing research and, 
consequently, its findings could be subject to a higher level of bias (Bryman, 2012).  
Systematic reviews are more focused and structured, using methods that optimise 
the chance of finding relevant studies and aim to minimise bias at each stage in the 
process (Moher et al., 2009).  It has been argued that stronger conclusions may be 
drawn from a SR, making this approach one of the highest levels to evidence 
practice and to identify gaps in a body of research (Green et al., 2011) 
The aim of the SR was to identify what, if any, evidence existed to support 
effectiveness of non-invasive approaches in the management of cervicobrachial pain.   
To address this aim, studies of interest needed to consider effectiveness of a non-
invasive approach compared to a control or placebo, or to another comparative non-
invasive approach.  Between-group differences (in well designed and conducted 
studies) would enable meaningful comparisons to be made across the intervention 
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effects (Lubke et al., 2003). By definition, since pain was the key feature of 
cervicobrachial pain, the primary outcome to establish effectiveness of management 
needed to relate to a change in pain.  As cervicobrachial pain has been associated 
with an increased level of disability (Daffner et al., 2003), secondary outcomes 
needed to relate to disability, including the loss of function.   Additional outcomes of 
interest were risk of harm, cost and patient preference or patient perceived value of 
intervention to establish the overall strength of recommendations made (Balshem et 
al., 2011).  
3.2.1 Rationale for updating systematic review from previous published 
article  
The SR was updated in 2012. The update was based on the published version 
(conducted in 2010 and published in 2011 [Salt et al, 2011; Appendix A)].  Changes 
from the published version included an updated search to 31st January 2012 and the 
use of different methods to analyse the retrieved literature – principally that the 
Cochrane ‘risk of bias tool’ was used in preference to the PEDro scale to evaluate 
methodological quality (internal validity), and GRADE was used instead of the Oxford 
Centre for Evidence-Based Medicine Levels of Evidence (to establish the quality of 
retrieved evidence and to determine the level of recommendation).  
Justification for these changes was based on growth in the research literature 
supporting use of Cochrane’s risk of bias to assess internal validity (Higgins et al., 
2011) rather than a scoring system, such as PEDro (Rushton et al., 2011).   The 
rationale for the recommendation was based on the fact that many items in scoring 
systems are not related to internal validity (Higgins et al., 2011).  This criticism 
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applied to three of the ten items on the PEDro scale (‘intention to treat analyses’, 
‘between-group statistical comparisons’ and ‘point measures and measures of 
variability’) which related to precision of results and not to internal validity.  
Additionally, the quality of PEDro as a tool has been criticised for not considering all 
important aspects (for example, it does not include a priori specification of primary 
outcomes or consideration of inter-group imbalances in attrition rates on the primary 
outcome) limiting its validity (Rushton et al., 2011).   
The decision to use GRADE (rather than the Oxford approach) to determine the 
quality of evidence was based on arguments presented in the growing literature on 
different approaches to conduct critical appraisals (Balshem et al., 2011; Guyatt et 
al., 2011a) and publication of more user friendly guidelines on its application that 
made its use more accessible (Guyatt et al., 2011b; Guyatt et al., 2011c; Guyatt et 
al., 2011d; Guyatt et al., 2011e; Guyatt et al., 2011f;). In summary, GRADE provided 
a stronger framework, as reported in Chapter 2. 
3.2.2 Method used on updated systematic review 
The Cochrane Tool was used to critically appraise design features influencing 
internal validity of studies that were included in the review (Higgins et al., 2011).  
Design features that influence external validity were critiqued using the last section of 
the Critical Appraisal Skills Programme (CASP) tool for reporting RCTs (accessible at 
www.casp-uk.net).     Findings from these critical evaluations were used to support 
decisions about the quality of the reported evidence using GRADE.  This review has 
been reported in line with the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses: PRISMA (Moher et al., 2009), to ensure that it has followed a 
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standardised structure and provided a comprehensive coverage of key information. 
PRISMA comprises a check-list (accessible at http://www.prisma-statement.org/) for 
key features to be reported in systematic reviews and advocates the use of a flow 
diagram to clarify review stages.  Guidance on how to use the checklist effectively 
was taken from Liberati et al. (2009), which details the level of information required 
per feature.  
Eligibility criteria used in the systematic review on non-invasive therapy for 
cervicobrachial pain 
Studies 
Only randomised controlled studies were included (Lubke et al., 2003; Lefebvre et 
al., 2011). It has been demonstrated that inclusion of non-randomised studies in a 
review could lead to considerable bias, compromising estimates of intervention effect 
(Lubke et al., 2003; Lefebvre et al., 2011).   No restrictions were placed on language 
or publication date, to ensure that the review was comprehensive (Centre for 
Reviews and Dissemination, 2009; Morrison et al., 2009). 
Participants 
 Adults with cervicobrachial pain aged 16 years or over, of either gender, were 
included.  Most spines would have reached skeletal maturity by the age of 16 years 
(O’Neil, 2003).  Younger participants were not included because there was no 
evidence to support the assumption that non-invasive therapy techniques had the 
same effect on the developing spine as on fully developed ones (Hestbaek & 
Stochkendahl, 2010). 
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Participants were required to have cervicobrachial pain, defined as the presence of 
arm pain associated with cervical spine pain (Jull et al., 2008). Studies that involved 
participants with cervicobrachial pain as part of a larger study on generic neck pain 
were included if an analysis was reported on that specific sub-group. This decision 
was made to avoid increased heterogeneity in the sample to be analysed.  
Participants with cervical myelopathy, tumour, rheumatic disease or central 
neurological disorder (e.g. multiple sclerosis) were excluded, because management 
approaches would be considerably different in these cases (Jull et al., 2008).  
Interventions 
Specific non-invasive management included manual therapy, exercise, traction, 
behavioural therapy and electrotherapy. These  interventions had been consistently 
reported in the literature as a means of managing neck pain (Kay et al., 2005; Childs 
et al., 2008; Haraldsson et al., 2008; Hurwitz et al. 2008; Graham et al. 2009; Gross 
et al., 2009; Haines et al., 2009;  Gross et al., 2010).  The search strategy also 
included non-specific treatment terms, such as, physiotherapy or chiropractic, to 
encompass as many non-invasive interventions as possible.  Invasive modalities 
such as surgery, epidurals and acupuncture were excluded unless they were used as 
a comparator in a study.  Other acceptable comparators included placebo treatments 
or no-treatment control groups.  When this was not possible, one non-invasive 
intervention was compared to another. 
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Outcome measures 
Studies were included if they contained at least one outcome measure for pain, since 
pain response to intervention was the primary objective of the review.  Secondary 
outcome measures included reports on function and disability, since these have been 
recognised as co-morbidity factors affecting people with cervicobrachial pain (Daffner 
et al., 2003).  Separate publications on the same study were included when different, 
but relevant, outcomes were reported. 
Information sources 
The search strategy encompassed a wide range of information sources (summarised 
below), including published and unpublished data to reduce the potential for 
publication bias (Centre for Reviews and Dissemination, 2009).  
• Electronic search on computerised databases from inception to January 2012:  
Cochrane central register of controlled trials (CENTRAL), MEDLINE, 
EMBASE, AMED, CINAHL and the Physiotherapy Evidence Database 
(PEDro).  
• Citation search: from articles identifying cervicobrachial pain.  
• Special interest groups: the Musculoskeletal Association of Chartered 
Physiotherapists (MACP), the International Federation of Orthopaedic 
Manipulative Therapists, the British Osteopathic Association, and the United 
Chiropractic Association (UCA) were contacted by email asking if they were 
aware of any unpublished data on the subject area.  The MACP and the UCA 
forwarded the email to their members. 
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Search strategy 
A range of key words was specified under population, intervention and design 
methods (van Tulder, 2003) (Table 3-1). 
Table 3-1  Key terms in search used for systematic literature review 
Population Intervention Design methods 
Cervicobrachial, 
cervical 
radiculopathy, 
cervical neuralgia, 
neck and arm pain, 
trapezius myalgia 
 
Management, therapeutics 
(including: electro, hydro, cryo and 
heat), physical therapy, osteopathy, 
chiropractic, exercise, patient 
education and advice, behavioural 
therapy, manipulation, mobilisation, 
massage, traction 
Random allocation, 
randomised 
controlled trial 
 
 All terms were exploded in each database, where possible. In addition, thesaurus 
mapping and truncation were used.  These methods enabled an automatic expansion 
on key terms to identify papers that might be relevant, but not include a key term.  
For example, a relevant study might have been identified under a term ‘physical 
therapy’ rather than ‘physiotherapy’. Searching databases this way had been 
advocated to ensure comprehensive data collection (CRD, 2009; Rafols et al., 2010). 
Details of the Medline search can be found in Appendix B. 
Study selection and appraisal 
Two reviewers, both subject specialists (one of whom was the Principal Investigator), 
independently searched the information sources against the eligibility criteria 
(reported earlier).  Edwards et al. (2002) recommended the use of two reviewers over 
one to enable full identification of all eligible studies (Edwards et al., 2002). The two 
subject reviewers independently assessed methodological quality for each included 
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study using The Cochrane ‘risk of bias’ tool (Higgins et al., 2011). Disagreement was 
resolved by consensus using a third reviewer (a research methodologist).  Attempts 
were made to contact authors of articles for additional information when both 
reviewers agreed that there was a lack of information on which to judge compliance 
with the eligibility criteria.   
Strength of agreements between reviewers regarding study selection and 
methodological quality were evaluated using values of Cohen’s Kappa (Cohen, 
1960).  Interpretation of Kappa values was based on standards proposed by Landis 
and Koch (1977) with 0 representing poor agreement in the worst scenario, through 
to .81 to 1 representing almost perfect agreement in the best scenario (Table 3-2).   
Table 3-2 Standards for strength of agreement using kappa coefficient for 
study selection in systematic review 
Kappa value Interpretation of 
agreement 
0 None  
0.01   to   0.20 Slight 
0.21   to   0.40 Fair 
0.41   to   0.60 Moderate 
0.61   to   0.80 Substantial 
0.81   to   1 Almost perfect 
[Adapted from Landis & Koch, 1977, p.165] 
The use of Kappa has been criticised as having a lack of interpretability when 
compared with other measures of concordance, such as percentage agreement 
(McHugh, 2012).  However, unlike percentage agreement, Cohen’s Kappa takes into 
account the level of agreement that occurs by chance (Sim & Wright, 2005) and is 
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considered to be the gold-standard for establishing inter-assessor agreement 
(Strijbos et al., 2006). Hence, it was the preferred choice to measure inter-reviewer 
agreement in this study.  
A data extraction table was compiled to summarise participant characteristics, 
interventions and results for all studies included in the review.  Detailing these study 
characteristics has been advocated as being important to enable a more 
comprehensive understanding of the data to support the review process (Liberati et 
al., 2009). 
Planned method of review analysis 
The primary analysis evaluated the effects of non-invasive therapy on pain (the 
primary outcome measure). Secondary analyses evaluated the effects on function 
and disability as pain frequently leads to limitations in physical and social capability 
(Winance, 2006).   
Meta-analyses were used to pool results across studies.  This method of pooling data 
has been recommended to reduce error of interpretation, especially for small studies, 
and to produce higher precision when estimating overall intervention effects (CRD, 
2009; Morrison et al., 2009; Higgins and Green, 2011, section 9.1.4; Bryman, 2012).  
In this review, meta-analyses were conducted on comparable outcome measures 
across studies that reported interventions and comparators of a similar nature, and 
with the same or similar timing of assessments.  Comparable outcome measures 
were defined as different instruments that were developed to measure the same 
underlying construct, for example, the visual pain analogue scale and the numerical 
pain analogue scale (Hjermstad et al., 2011). To avoid selection bias, two reviewers 
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(the principal investigator and a methodological expert) independently identified 
combinations of studies and comparable outcome measures that were considered to 
be appropriate for quantitative synthesis.  
Direct pooling of the data across the different studies was inappropriate due to inter-
study variations on outcome measures, and details of the interventions and 
comparators.  Hence, a random-effects meta-analysis was conducted on 
standardised differences in mean values (Centre for Reviews and Dissemination 
(CRD), 2009; Deeks et al., 2011). Effect sizes and 95% confidence intervals were 
computed using DerSimonian-Laird random-effects (CRD, 2009; DerSimonian & 
Laird, 1986).  This method has been advocated for random-effects meta-analysis 
because it has higher power than other random-effects models (Kontopantelis & 
Reeves, 2012).  Cochrane’s Q statistic was computed to assess the effect of 
heterogeneity on intervention results for each meta-analysis (CRD, 2009). The Q 
statistic had been criticised as having low power for pooled analysis of small and/or 
few studies and overestimation of effects in large and/or multiple studies (Deeks et 
al., 2011). However, it is the most frequently used test and, providing the limitations 
are recognised, is useful when interpreting the results of meta-analysis (Biggerstaff & 
Jackson, 2008).  Results from the meta-analysis were also presented in a Forest plot, 
to provide a clear and concise summary of findings across studies (Schriger et al. 
2010).  All analyses were performed using StatsDirect software (StatsDirect, 2009). 
Qualitative analyses, using the GRADE approach, were conducted on outcomes that 
did not satisfy requirements for the conduct of meta-analyses. Quality of evidence 
was rated on a four point scale: ‘high’, ‘moderate’, ‘low’ and ‘very low’ (Table 2-3) for 
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pain, function and disability.  In addition, analysis of risk of harm, cost and perceived 
value/preference of intervention (which have been recognised as important factors to 
determine strength of recommendation (Balshem et al., 2011)) were evaluated to 
complete a comprehensive analysis and to establish strength of recommendation per 
intervention. Strength of recommendation was determined as ‘high’ or ‘low’ (Section 
2.2.3).  
3.2.3 Findings from the systematic review 
Study selection 
Figure 3-1 summarises the article selection process.  Following review of titles and 
abstracts, 21 articles were identified and full papers obtained.  Ten articles were 
excluded:  8 did not meet the ‘cervicobrachial’ definition, 1 was a commentary and 1 
did not measure pain.  No relevant unpublished studies were found.  
Substantial to perfect inter-reviewer agreement (Landis & Koch, 1977) was achieved 
for the selection of studies to be included in the review, with Kappa values of 0.96 
(SE=0.04; p<0.0005; n=50; SE=standard error) using titles, and perfect agreement 
using abstracts and full texts. 
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Figure 3-1 Systematic review study selection flow diagram [Based on Moher et al., 
2009] 
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Risk of bias within studies selected for the systematic review 
Perfect inter-rater agreement was obtained in ratings across all eight ‘risk of bias’ 
items, for all eleven studies (Kappa=1.00, SE=0.00). There was an increase in level 
of agreement using the Cochrane risk of bias approach compared to scoring with 
PEDro – as used in the previous published review (Salt et al., 2011).  Unlike PEDro, 
the Cochrane ‘risk of bias’ included an ‘unclear risk of bias’ option and that might 
account for the higher rate of agreement between reviewers. 
Overall, the quality of studies included in the review was poor.  None of the studies 
met all eight criteria for low risk of bias (Figure 3-2).  The number of criteria fulfilled, 
ranged from six indicating low risk of bias (Bernaards et al., 2007) down to two 
indicating high risk of bias (Klaber Moffett et al., 1990; Allison et al., 2002; Kuijper et 
al., 2009; Ragonese, 2009).  The variability of the Cochrane scores revealed an 
inconsistence across studies’ internal validity.  These findings were in contrast to the 
PEDro scores in the previous published review (Salt et al., 2011), where all studies 
scored 6 or above, indicating a consistently high quality of internal validity (Foley et 
al., 2006).  This discrepancy supports previous arguments (Rushton et al., 2011) that 
the choice of tool could affect the interpretation of quality of evidence found in 
published research and, hence, the strength of recommendations made on the basis 
of findings. 
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Allison et al.(2002) + ? - + ? ? ? ? 
Bernaards et al. (2007) + + - - + + + + 
Coppieters et al. (2003) + + - + + NA ? ? 
Howe et al. (1983) + + - + ? ? - - 
Klaber Moffett et al.(1990) ? ? + + ? ? ? ? 
Kuijper et al. (2009) + + - ? ? ? ? - 
Persson et al. (1997) + + - - + - ? - 
Persson & Lilja (2001) + + - - + - ? - 
Ragonese (2009) + + - ? ? ? ? - 
Walker et al. (2008) + + - + + + ? - 
Young et al. (2009) + + - + + + ? - 
Figure 3-2: Summary of risk of bias for studies used in literature review 
 (n=11 articles)  
[Based on plots in Higgins et al., 2011]   
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Risk of bias across studies used in the review 
Methodological weaknesses identified across the 11 studies included a lack of 
blinding of participants and study bias (Figure 3-3). Blinding of participants was only 
achieved in one study (Klaber Moffett et al., 1990). This was not unexpected as there 
are inherent difficulties with complete-blinding in many non-pharmaceutical treatment 
modalities (Boutron et al., 2008; Moher et al., 2010).  Other study bias related to 
intrinsic issues around the provision of intervention. For example, Howe et al., 
(1983), permitted injections to some of the participants to allow ‘manipulation to be 
carried out’ (Howe et al., 1983 p.575), yet injections are an intervention in their own 
right.  In this instance, it was unclear whether positive effects were as a result of the 
intervention under investigation (i.e.the manipulation), or due to the provision of the 
injection. Confounders such as this could bias study results. 
Selective reporting had the highest level of ‘unclear’ risk of bias.  One study fulfilled 
the criterion by publishing a full proposal, outlining methods, prior to the review 
(Bernaards et al., 2007).  However, for the majority, there was insufficient information 
to enable judgement to be made. According to the Cochrane Handbook, this finding 
was not unexpected (Higgins et al., 2011). 
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Figure 3-3: Risk of bias (n=11studies) across the 11 included articles 
 [Based on risk of bias chart in Higgins et al., 2011]  
 
Systematic review’s study characteristics 
Descriptive data for the ten studies (11 articles) included in the review are 
summarised in Table 3-3. 
Methods 
All ten studies were undertaken in a clinical setting and were randomised intervention 
studies.  Of these, one used a ‘no-intervention’ control in a cross-over study design 
(Allison et al., 2002); one used pain medication across groups to act as a control for 
the manipulation intervention (Howe et al., 1983), and, two used a placebo 
intervention as the control (Klaber Moffett et al.,1990; Young et al.,2009).  The 
remaining studies used comparative interventions ranging from no-specific treatment 
e.g. advice to stay active (Kuijper et al., 2009) to a specific therapeutic intervention 
e.g. therapeutic ultrasound (Coppieters et al., 2003).   
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Table 3-3  Characteristics of studies included in the systematic review 
Study Study design 
 
Participants 
 
Participant 
classification 
Symptom 
duration 
Interventions & assessment 
points 
 
Outcome 
measures 
Results 
Allison et al. 
(2002) 
 
Australia 
 
 
 
RCT with 
crossover 
design 
 
3 groups: 
A: Neural PT 
with exercise; 
n=10 
 
B: Articular PT 
with exercise; 
n=10 
 
C: No 
treatment; 
n=10 
 
 
n=30 
Mean age 54 
F=20 
 
Cervico-brachial 
pain syndrome 
Cervicobrachial pain 
with positive brachial 
plexus tension test. 
Chronic 
>3/12 
Mean 
36/12 
A: Cervical lateral glide, shoulder 
girdle oscillation, muscle re-
education and home exercise. 
 
B: Glenohumeral and thoracic 
mobilisation, and home exercise. 
 
 
Treatment is given over an 8/52 
period.  Quantity of treatment not 
specified.  
 
Assessment at baseline, 4/52 and 
8/52.  
 
 
Pain: VAS pain,  
SF McGill. 
 
 
 
 
 
 
 
 
Function/disability: 
NPQ. 
 
 
 
 
Pain: Statistically significant 
between-group differences in 
improvement of mean VAS pain 
for A compared to B at 8/52 
(p=0.03).   
 
No statistically significant 
between-group differences on 
SF McGill (p=0.15). 
 
Function/disability: No 
statistically significant 
differences between groups at 
any assessment period. 
Bernaards et 
al. 
(2007) 
 
Netherlands 
 
 
 
 
 
 
 
 
 
 
RcT 
 
3 groups: 
 
A: Work related 
behavioural 
change group; 
n=152 
 
B: Work and 
exercise related 
behavioural 
change group; 
n=156 
 
C: Usual care; 
n=158 
n=466   
Mean age 
44 
F=207 
 
 
 
 
 
 
 
 
Neck and upper limb 
symptoms 
Pain, tingles or 
stiffness in the neck, 
shoulders, arms, 
wrists and/or hands. 
No local somatic 
disease such as 
tennis elbow or carpel 
tunnel syndrome. 
 
 
 
 
Chronic 
IQR  14-16 
months 
 
 
 
 
 
 
 
 
 
A: Behavioural changes with regard 
to posture, workplace adjustment, 
breaks and coping with high work 
demands. 
 
B: As for group A.  In addition, 
behavioural changes with regard to 
engagement in moderate to heavy 
intensity physical activities.  
Physical exercise was not part of 
the intervention. 
 
Groups A and B receive 6 meetings 
over 6 months. 
 
Assessment at baseline, 6/12 and 
one year.  
 
Pain: NPRS 
 
 
 
 
 
 
 
 
 
Function/disability: 
DWS (numerical 
scale). 
 
 
 
 
 
Pain: No statistically significant 
between-group differences at 6 
months. 
 
Statistically significant between-
group differences for reduced 
mean pain score for A 
compared with C at 12 months 
(p<0.05).   
 
Function/disability: No 
statistically significant 
differences in changes over 
time across groups or between-
groups at 6 or 12 months 
regarding disability at work.  
 
 
 
 
 
Coppieters 
et al (2003) 
 
Australia 
 
 
 
 
RcT 
 
2 groups: 
A: Cervical 
mobilisation 
(lateral glide); 
n=10 
 
B: Therapeutic 
ultrasound; 
n=10 
n=20  
Age range 
35- 63 
Mean age 
48. 
F=16 
 
 
 
 
 
Neurogenic 
cervicobrachial pain 
An active and passive 
movement 
dysfunction related to 
non-compliance of the 
median nerve and 
adverse response to 
median nerve 
palpation.  Positive 
NTPT. 
 
Sub-
acute and 
chronic 
Range 
2/52 – 
6/12. 
A: Single session of lateral glide 
mobilisation to the cervical spine  
 
B: Single session of therapeutic 
ultrasound to most painful area. 
 
Assessment at baseline and 
immediately following treatment in 
response to the NTPT. 
 
 
Pain: NPRS  
 
 
Pain: No between-group 
differences were reported.  
Statistically significant 
immediate improvement in 
mean pain reduction pre 
compared to post treatment for 
A (p<0.005), but not for B 
(p=0.28).  
Howe et al 
(1983) 
 
UK 
 
 
 
 
 
 
 
 
 
 
 
RCT 
 
2 groups: 
A: Cervical 
manipulation 
and 
medication; 
n=26 
 
B: Medication; 
n=26 
 
 
n=52  
Age range 
16-65. 
F=31 
 
Neck and upper limb 
symptoms 
Pain in the neck, arm 
or hand related to a 
lesion in the cervical 
spine.  No other 
causes of pain in the 
shoulder or arm. 
Reduced cervical 
intervertebral joint 
movement or palpable 
asymmetry. 
 
 
Mixed 
Range of 
duration. 
Details 
not 
provided 
 
 
 
 
A: Quick Thrust manipulation +/- 
injection and treated with NSAID 
(azapropazone) 
 
B: NSAID alone.  
 
Quantity of treatment not recorded. 
 
Assessment at baseline, 
immediately following treatment, 1/52 
and 3/52. 
 
Pain: Measures 
identified as 
‘absent’, ‘same’, 
‘better’ or ‘worse’ for 
pain in the neck, 
shoulder and 
arm/hand. 
 
 
Pain: Statistically significant 
between-group differences for 
immediate improvement in pain 
in neck (p<0.005) and shoulder 
(p=0.02) for A compared to B. 
Differences are not sustained at 
one and three week follow-up 
post-treatment.  No statistically 
significant differences between-
groups for pain in the arm/hand. 
Klaber 
Moffett & 
Hughes 
(1990) 
 
UK 
RCT 
 
2 groups:  
A: Sustained  
Traction; n=44 
 
 
B: Placebo 
traction; n=50 
 
 
 
n=94  
Age range  
39–60. 
F=58 
 
 
 
 
Neck and arm pain 
Symptoms in 
the arm clinically 
indicative of a 
radiculopathy or 
brachialgia stemming 
from the neck. 
Chronic 
>3/12 
Mean 
33/52. 
A: Up to 12 sessions of sustained 
weighted traction (between 6-18 
pounds) over four weeks. 
 
B: Up to 12 sessions of placebo 
traction (2 pounds) over four weeks 
 
Neck school education (one hour 
session) given to both groups. 
 
Assessment at baseline, immediately 
after treatment and 3/12 following 
treatment. 
Pain: VAS pain 
 
 
 
 
Function/disability
: VAS  
social dysfunction 
scale and one 
individually chosen 
activity of daily 
living. GHQ and 
STAI. 
 
Pain: No statistically significant 
between-group differences for 
mean VAS pain at any 
assessment period. 
 
Function/disability:  No 
statistically significant between-
group differences for mean VAS 
social, activity of daily living, 
GHQ or STAI at any 
assessment period. 
 
 
 
 
Kuijper et al 
(2009) 
 
Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RcT 
 
3 groups: 
A: Semi-hard 
collar; n=69 
 
B: PT; n=70 
 
C: No specific 
treatment; 
n=66 
 
 
 
 
 
n=205  
Mean age  
47 
F=101 
 
 
 
 
 
 
 
 
 
 
 
Cervical 
radiculopathy 
Radiation of arm pain 
distal to elbow. 
 
Provocation of arm 
pain by at least one 
neck movement. 
 
Sensory and motor 
change in one or 
more adjacent 
dermatome / 
myotome.  Diminished 
reflexes on ipsilateral 
side. 
 
 
Acute/su
b-acute 
Mean  
3/52 
 
 
 
 
 
 
 
 
 
 
 
A: Semi-hard collar day use for up to 
6/52. 
 
B: PT with a focus on mobilising and 
stabilising the cervical spine was 
given twice weekly for 6/52. 
 
C: Advice to continue normal daily 
activities. 
 
Assessment at baseline, 3/52, 6/52 
and 6/12. 
 
 
 
 
 
 
 
Pain: Two VAS pain 
scales – neck pain 
and arm pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Function/disability
: NDI score  
 
 
 
 
 
Pain:  Statistically significant 
between-group differences for 
mean improvement in pain for A 
compared to C and for neck 
pain (p<0.00) and arm pain 
(p=0.00) during the first 6 
weeks post-intervention.  
 
Statistically significant between-
group differences for mean 
improvement in B compared to 
C for neck pain (p=0.00) and 
arm pain (p=0.00) for the first 6 
weeks post-intervention.  
 
No statistically significant 
between-group differences for 
mean improvement in pain 
between A and B for the first 6 
weeks post-intervention.  
 
No statistically significant 
between-group differences At 6 
months, between any groups. 
  
Function/disability:  
Statistically significant between-
group differences for mean 
improvement in disability for A 
compared to C (p=0.02) for the 
first 6 weeks post-intervention.  
 
No statistically significant 
between-group differences for 
any other time scale or between 
any other groups. 
 
 
 
 
 
 
 
 
 
Persson et 
al (1997) 
& 
Persson and 
Lilja (2001) 
 
Sweden 
 
RcT 
 
3 groups  
A: Surgery; 
n=27 
 
B: Rigid collar; 
n=27 
 
C: PT; n=27 
 
n=81  
Age range  
28-64. 
F=37 
 
 
Cervical 
radiculopathy 
Clinical and radiologic 
findings (plane X-rays 
and magnetic 
resonance 
tomography) 
indicating nerve root 
compression 
corresponding to the 
distribution of pain. 
 
 
 
 
Chronic 
Range  
5/12-
120/12  
(mean = 
53/12) 
 
B: Rigid collar for daytime use and  
soft collar for night for 3 months. 
 
C: General PT up to 15 treatment 
sessions over 3 months. Modalities 
include TENS, heat, US, cold, 
massage, traction, mobilisation, 
exercises, stretches, aerobic exercise, 
rest, relaxation and advice on 
ergonomics, posture and co-ordinated 
exercise.  Most commonly used 
treatments were traction, mobilisation 
and heat.  
 
 
Assessment at baseline, 15/52 & one 
year. 
 
 
Pain: Two VAS pain 
scales - ‘present 
pain’ and  ‘worst 
pain over the last 
week’ 
Function/disability
: SIP, MACL, HAD, 
CS, and DRI.. 
 
 
 
Pain: No statistically significant 
between-group differences in 
mean pain scores between B 
and C at any assessment point.  
 
 
 
Function/disability: 
Statistically significant between-
group differences for reduced 
disability in mean SIP score for 
C compared to B (p<0.05) at 15 
weeks, but not at one year.  
 
Statistically significant between-
group difference in 
improvement in mean function/ 
reduction in disability in some 
but not all of the DRI for C 
compared to B (p=<0.05) at 15 
weeks. 
 
No between-group statistical 
differences between B and C 
for any other scale at any of the 
assessment points. 
 
 
 
Ragonese 
(2009) 
 
USA 
 
 
 
 
 
 
 
 
 
RcT 
 
3 groups: 
A: Manual PT; 
n=10 
 
B: Exercise 
PT; n=10 
 
C: Combined 
manual and 
exercise PT; 
n=10 
n=30  
Age range or 
mean not 
stated. 
F=19 
 
 
 
 
 
 
 
Cervical 
radiculopathy 
Definition: neck 
and/or upper 
extremity symptoms. 
 
Presence of either a 
positive spurlings test 
or cervical distraction 
test or ipsilateral 
cervical rotation less 
than 60° or brachial 
plexus tension test. 
Not 
stated 
 
 
 
 
 
 
 
 
 
 
A: Cervical lateral glide and thoracic 
mobilisations and neural dynamic 
techniques for the median nerve. 
 
B: Deep neck flexor, lower and middle 
trapezius  and serratus anterior 
strengthening (supervised) 
 
C: combined approaches of A and B 
 
Treatment given three times a week 
for 3/52 for each intervention group. 
 
Assessment at baseline, 1/52, 2/52 
and 3/52 
Pain: NPRS  
 
 
 
 
Function/disability
:  NDI. 
 
 
 
 
 
 
 
Pain: Statistically significant 
between-group differences for 
reduced mean pain for C 
compared to A and B (p<0.01) 
at 3 week follow-up. 
 
Function/disability: 
Statistically significant between-
group differences for improved 
function for C compared to A 
and B (p<0.05) at three week 
follow-up. 
Walker et al 
(2008) 
 
USA 
 
 
 
 
 
 
 
 
 
 
 
 
RcT 
 
2 groups: 
A: Manual 
therapy and 
exercise; n=31 
 
 
B: Minimal 
intervention; 
n=27 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=58  
(a sub-group 
from 98 
patients with 
general neck 
pain). 
Mean age 
48. 
Gender 
specific to 
subgroup not 
known. 
 
Neck and upper limb 
symptoms 
Mechanical neck pain 
with neck and 
unilateral upper 
extremity symptoms 
 
Mean in 
days: 
A: 1082     
B: 521  
A: Any manual therapy technique 
commonly used in clinical practice 
(mobilisation, manipulation, muscle 
energy and stretching techniques) 
and home exercise programme 
directed at stabilising and mobilising 
the cervical spines. Most commonly 
used technique(s) not specified. 
 
B: Advice from GP on posture, 
continuation of normal daily activities 
and neck movement, and medication.  
Placebo therapeutic ultrasound to the 
neck and home exercise programme 
directed at mobilising the neck 
(provided by physical therapists).  
 
Six sessions of treatment over three 
weeks for both groups. 
 
Assessment at baseline, 3/52, 6/52 
and one year.  
 
Pain: VAS pain 
scale for upper limb 
pain 
 
 
 
 
 
 
 
 
Function/disability
:  NDI 
 
 
 
 
 
 
 
Pain:  No statistically significant 
between-group difference in 
mean pain at any assessment 
point. 
 
A has a statistically significant 
reduction in pain from baseline 
at each follow-up.  B did not 
have a statistically significant 
reduction in pain compared to 
baseline beyond 3/52. 
 
 
Function: No results were 
reported specific to sub-group 
of patients with upper limb 
symptoms with regard to NDI. 
 
 
 
 
 
 
Young et al 
(2009) 
 
USA 
 
 
 
 
 
 
 
 
 
 
RCT 
 
2 groups: 
A: Intermittent 
traction; n=45 
 
 
B: Placebo 
traction; n=36 
 
 
 
 
 
 
 
 
n=81  
Age range 
18-70 
Mean age 47 
F=55 
 
 
 
 
 
 
 
 
 
 
 
 
Cervical 
radiculopathy 
Unilateral upper-
extremity pain, 
paraesthesia and 
numbness. 
 
3 out of 4 positive 
tests for the following: 
 
1. Spurling test 
2. distraction test 
3. brachial plexus 
tension test 
4. ipsilateral neck 
rotation <60° 
 
Mixed 
< 3/12 = 
42 
>3/12 =  
39 
 
 
 
 
 
 
 
 
 
 
 
 
A: Intermittent mechanical traction 
from approx. 20 pounds to 35 pounds. 
 
B: Placebo mechanical traction using 
5 pounds or less. 
 
Both groups received postural 
education, manual therapy and 
exercises directed to the cervical 
spine and scapula. 
 
Treatment given on average 7 
occasions over an average of 4.2 
weeks. 
 
Assessment at baseline, 2/52 and 
4/52 
Pain: NPRS 
 
 
 
Function/disability
: NDI and PSFS. 
 
 
 
 
 
 
 
 
 
 
 
 
Pain: No statistically significant 
between-group difference on 
mean NRPS at 2/52 or 4/52 
follow-up. 
 
Function/disability:  No 
statistically significant between-
group difference on mean NDI 
or PSFS at 2/52 or 4/52 follow-
up. 
 
 
 
 
 
 
 
 
 
Key:  CS= Coping Strategies Questionnaire; DWS= Disability at Work Score; DRI= Disability Rating Index; F= female; GHQ= General 
Health Questionnaire; GROC= Global Rating of Change scale; HADs= Hospital and Depression scale;  
MACL= Mood Adjective Check List; NDI= Neck Disability Index; NPRS= Numeric Pain Rating Scale; NPQ= Northwick Park  
Questionnaire; NTPT= Neural Tissue Provocation Test; NSAID= Non-steroidal anti-inflammatory drug;  
PSFS= Patient Specific Functional Scale; PT= Physiotherapy; RCT= Randomised controlled trial; RcT= Randomised clinical trial;  
SF McGill= Short-form McGill Questionnaire; SIP= Sickness Impact Profile; STAI= State Trait Anxiety Inventory; VAS= Visual Analogue Scale. 
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Short-term post-intervention assessment (defined as the first assessment point 
following completion of intervention) ranged from immediately following intervention 
(Howe et al., 1983; Klaber Moffett et al., 1990; Coppieters et al., 2003) to 15 weeks 
post intervention (Persson et al., 1997, 2001).  Follow-up assessments varied 
considerably: one study had no follow-up assessment (Coppieters et al., 2003), 
whilst others evaluated outcome measures up to one year post intervention (Persson 
et al., 1997,2001; Bernaards et al., 2007; Walker et al., 2008). 
Quantity of intervention ranged from a single session of treatment (Howe et al., 1983; 
Coppieters et al., 2003) to 24 sessions (Persson et al., 1997, 2001).  Intensity and 
duration of intervention were also variable, from one treatment in isolation 
(Coppieters et al., 2003) to 3 treatment sessions a week (Klaber Moffett et al., 1990; 
Ragonese et al., 2009) and extending over a period of 6 months (Bernaards et al., 
2007). It is not clear whether this considerable variability in quantity of treatment 
reflects a true account of variability in the clinical provision on non-invasive 
management for this condition. 
Participants 
The ten studies in the review randomised 1036 participants.  From available data, 
there was a broad age range from 16 to 70 years, with marginally more females than 
males.  There was a variable duration of symptoms, but insufficient data to detail the 
range.  Diagnostic methods differed across studies.  The majority of studies stated 
selection criteria on symptom type and pattern of radiation or referral.  
53 
Interventions 
Interventions fell into five distinct groups: general physiotherapy, traction, manual 
therapy, exercise therapy and behavioural therapy.  
Outcomes 
All studies reported pain as an outcome.  Five studies used the visual analogue scale 
(VAS) and four used the numeric pain rating scale (NPRS) as an outcome measure. 
Howe at al. (1983) used a four category descriptive pain outcome measure. There 
was some variability in time frames, which ranged from evaluating ‘current pain’ 
(Persson et al., 1997, 2001) to ‘worst pain in the last four weeks’ (Bernaards et al., 
2007).  There were different areas for pain representation including: ‘neck, shoulder, 
arm pain’ (Persson et al., 1997, 2001), ‘pain in either neck or arm’ (Coppieters et al., 
2003), and separate outcome measures to represent pain in the neck and pain in the 
arm (Kuijper et al., 2009).  Allison et al. (2002) used the Short-form McGill 
questionnaire in addition to a VAS.  Howe et al. (1983) used a pain scale that 
comprised of four descriptive items. 
Functional and disability outcome measures were used by eight of the ten studies.  
The Neck Disability Index (NDI) was used in four studies.  Otherwise, there was 
considerable variation in constructs measured – including a focus on work related 
aspects (Bernaards et al., 2007), specific problems to an individual (Young et al., 
2009) and psychological and psychosocial aspects of function and disability (Persson 
and Lilja, 2001). 
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Meta-analyses of review results on post-interventional pain outcomes 
Three meta-analyses were conducted to consider the effects of treatments on short-
term (post-intervention) pain outcome (Figure 3-4).  There were no other comparable 
outcomes, time points or interventions across the studies included in the review.   
 
 
Figure 3-4: Forest plot of pain (intervention v. comparator) – short-term post-
interventional outcomes with meta-analyses 
 
Overall, there was no evidence that general physiotherapy (including electrotherapy, 
manual therapy, exercise, heat, relaxation and/or advice), or traction reduced pain in 
the short-term compared to comparators.  There was a trend towards a favourable 
response to manual therapy and exercise but this did not reach statistical 
significance (DerSimonian-Laird pooled effect size = -0.34; 95%CI -0.79 to 0.11). 
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Synthesis of systematic review results 
This systematic review found inconclusive evidence for non-invasive intervention in 
the management of cervicobrachial pain.  Evidence was assessed from 10 
randomised clinical studies (1036 participants) and conducted across 5 countries.  
Different non-invasive interventions were evaluated in terms of their effects on pain, 
disability and function for participants with cervicobrachial pain.  There was excellent 
between-reviewer agreement on study selection (Kappa 0.96) and perfect between-
reviewer agreement on methodological quality (Kappa 1).  Overall quality per 
outcome across studies was variable, ranging from high (for evaluation of function 
and disability in response to traction) to very low (for evaluation of function and 
disability in response to general physiotherapy and manual and exercise therapy) 
(Table 3-4). 
 
 Table 3-4:  GRADE evidence profile of studies in review [Outline adapted from Guyatt et al., 2011a] 
Footnote:  Refer to Table 2-2 Method used to establish quality of evidence in GRADE in GRADE [Outline adapted from Guyatt et al., 2011a] 
TYPE OF 
THERAPY 
   Outcome 
Number of 
studies/ 
participants 
(Design) 
Limitations Inconsistency Indirectness Imprecision Publication 
bias 
Effect 
size 
Dose 
response 
Confounders Quality 
GENERAL PT 
  Pain 
  Function 
  Disability 
 
Two studies 
(RCT) 
Participants 
(n=286) 
 
All 
outcomes: 
Very serious 
limitations 
 (-2) 
Function/ 
disability: 
(-1) 
No serious 
indirectness 
for all 
outcomes 
No serious 
imprecision 
None 
detected 
Small No evidence 
any outcome 
Limited 
consideration 
across 
outcomes  
Pain: 
Low  
 
Function 
& 
disability: 
Very low 
TRACTION 
  Pain 
  Function 
  Disability 
 
Two studies 
(RCT) 
Participants 
(n=175) 
All 
outcomes: 
Serious 
limitations 
 (-1) 
Pain: 
Serious 
limitations (-1) 
  
Function/ 
disability: 
consistent 
findings 
No serious 
indirectness 
for all 
outcomes 
No serious 
imprecision 
None 
detected 
Small No evidence 
of high dose 
response on 
any outcome 
Some 
consideration 
across 
outcomes 
  (+1) 
*Pain: 
Moderate 
 
Function 
& 
disability: 
High 
 
MANUAL 
THERAPY & 
EXERCISE 
  Pain  
  Function 
  Disability 
 
Five studies 
(RCT) 
Participants 
(n= 190) 
All 
outcomes: 
Serious 
limitation  
(-1) 
Pain: 
Consistent 
findings  
 
Function/ 
Disability:  
Serious 
limitations 
(-1) 
No serious 
indirectness 
for all 
outcomes 
Serious 
imprecision 
 (-1) 
None 
detected 
Small No evidence 
of high dose 
response on 
any outcome 
Limited 
consideration 
across 
outcomes 
Pain:  
Low 
 
Function 
& 
Disability: 
Very low 
 
 
BEHAVIOURAL 
THERAPY 
  Pain 
  Function 
  Disability 
One study 
(RCT) 
(n=466) 
 
All 
outcomes: 
Serious 
limitation 
 (-1) 
 
Not applicable 
(no other 
studies to 
compare) 
Unclear what 
‘usual care’ 
referred to 
 (-1) 
No serious 
imprecision 
None 
detected 
Small No evidence 
of high dose 
response on 
any outcome 
Some 
consideration 
across 
outcomes 
 (+1) 
Pain, 
function 
and 
disability: 
Moderate 
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General Physiotherapy 
Meta-analyses showed that general physiotherapy was no more beneficial than 
comparators in reducing pain in the short-term (95% CI -0.40 to 0.36) (Figure 3-4). 
There was a difference in trends between the two studies evaluated, with one 
favouring the comparator (Kuijper et al., 2009) and the other favouring the 
intervention (Persson et al., 1997, 2001).  Both studies used similar comparative 
interventions (use of collar). There was some heterogeneity between the two studies 
(Cochran Q=1.59, df=1; p=0.21) that might be explained by these opposing trends.  
This finding did not change in the long-term evaluation of pain, where there was low 
evidence that general physiotherapy was no more beneficial than comparators 
(Persson et al., 1997, 2001; Kuijper et al., 2009). 
General physiotherapy was no more beneficial than comparators in improving 
function (very low evidence): Persson and Lilja (2001) reported that participants who 
received physiotherapy performed significantly better (p<0.05) on three of the twelve 
aspects of the Disability Rating Index (walking, sitting for a long time and heavy work) 
in the short-term (at fifteen weeks) compared to those wearing a collar (Persson and 
Lilja, 2001).  They reported that sitting for a ‘long time’ (duration was not specified) 
remained improved at one year (p<0.05).  Kuijper et al. (2009) found a non-significant 
improvement in the Neck Disability Index (NDI) for participants who received 
physiotherapy compared to a ‘no-specific treatment’ comparator (p=0.09).  
General physiotherapy was no more beneficial than comparators in reducing 
disability (very low evidence): Persson et al. (1997) reported that participants who 
received physiotherapy had improved scores on the Sickness Impact Profile (SIP) 
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compared to collar use in the short-term (p<0.05), but not at one year (p>0.05) 
(Persson et al., 1997).  Findings indicated no evidence that general physiotherapy 
improved psychological or psychosocial wellbeing in the short or long-term (p>0.05) 
(Persson et al., 2001). 
Traction 
A meta-analysis showed that cervical traction was no more beneficial than 
comparators in reducing pain in the short-term (95% CI -0.39 to 0.36). There was a 
difference in trends between the two studies evaluated, with one favouring the 
comparator (Young et al.2009) and the other favouring the intervention (Klaber 
Moffett et al., 1990).  Both comparative interventions used placebo traction. There 
was potential for pain reduction in the short-term using traction in a sustained, rather 
than intermittent, form (Klaber Moffett et al., 1990), but it did not reach a statistically 
significant effect (95% CI -0.60 to 0.21). This finding did not change in the long-term 
evaluation of pain, where there was moderate evidence that cervical traction was no 
more beneficial than comparators (Klaber Moffett et al., 1990; Young et al., 2009). 
Cervical traction was no more beneficial than sham or placebo in improving function 
and reducing disability at any time point (high evidence) (Klaber Moffett et al., 1990; 
Young et al., 2009).   
Manual Therapy and exercise 
The meta-analysis showed a trend that manual therapy and exercise was favourable 
in reducing pain in the short-term (Figure 3-4) but this did not reach a statistical 
significance (95%CI  -0.79 to 0.11).  Both Walker et al. (2008) and Ragonese (2009) 
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found a reduction in pain at three weeks post-intervention following the 
commencement of manual therapy and exercise.  Statistically significant between-
group differences were only found in Ragonese’s study (p<0.01), but not in Walker et 
al.’s (2008) study (p=0.21). This finding did not change in the long-term follow-up 
evaluation of pain, where there was low evidence that manual therapy plus exercise 
was no more beneficial than comparators in changing pain (Ragonese, 2009; Walker 
et al. 2008). 
Some studies focused on evaluating specific forms of manual therapy.  Allison et al. 
(2002) found statistically significant improvements in pain at 8 weeks, for participants 
receiving neural-biased manual therapy (cervical lateral glide and shoulder girdle 
oscillation) compared to those receiving articular-biased treatments (glenohumeral 
and thoracic mobilisation) (p=0.03).  Coppieters et al. (2003) assessed the 
effectiveness of the lateral glide specifically.  They found, unlike the ultrasound 
comparator, the lateral glide intervention resulted in a statistically significant 
improved pain response to a ‘neural tissue provocation test’ for the upper limb 
immediately post intervention (p<0.0003), however no between-group differences 
were evaluated; therefore interpretation for effectiveness was limited.  Howe et al. 
(1983) found cervical manipulation significantly reduced neck pain immediately post-
intervention compared to control (p<0.001). However, there were variable responses 
to upper limb pain (p<0.02 in the shoulder; p=1.97 in the arm/hand).  No statistically 
significant improvements were found at one week follow-up (Howe et al., 1983).  Two 
participants in the manipulation group also had facet joint injections (lidocaine and 
hydrocortisone) to “allow the manipulation to be carried out”.  It was not reported 
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whether the participants who received injections made any statistically significant 
improvement compared to those who did not.   
There was very low evidence that manual therapy and exercise improved function 
and reduced disability.  Ragonese (2009) reported a statistically significant 
improvement at three week follow-up on the Neck Disability Index scores for 
participants who received manual therapy and exercise compared to those who 
received either manual therapy or exercise.  In contrast, Allison et al. (2002) reported 
no statistically significant improvements on the Northwick Park Questionnaire at the 
same follow-up point for those who received manual therapy compared to 
comparators. None of the other studies on manual therapy and exercise evaluated 
function or disability for cervicobrachial pain (Howe et al., 1983; Coppieters et al., 
2003; Walker et al., 2008).   
Behavioural Therapy 
There was ‘moderate’ evidence that behavioural therapy was more beneficial than 
comparators in reducing pain. Bernaards et al. (2007) evaluated whether behavioural 
changes towards working style with or without engagement in physical tasks was 
more effective than ‘usual care’.  The level and type of intervention in ‘usual care’ 
was not specified.  There were no statistically significant between-group differences 
on any measure in the short-term (post-intervention).  At one year follow-up, there 
were statistically significant between-group differences for pain (p<0.05), favouring 
the group receiving the working style behavioural change (without the physical task 
engagement) compared to those receiving ‘usual care’.   
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Adverse events relating to harm were not reported. Participants who received 
behavioural therapy were less likely to utilise additional health care for their 
symptoms compared to ‘usual care’ (P<0.01) over a six month duration, signifying 
cost-effectiveness. 
Discussion of systematic review findings 
To establish strength of recommendation, the level of evidence should be 
considered alongside other factors, including risk of harm, patient values, patient 
preferences and cost (Balshem et al., 2011). 
Of the selected studies included in the systematic review, only one study evaluated 
financial expenditure relating to health care costs in response to behavioural 
intervention (Bernaards et al., 2007).  None of the studies reported on adverse 
events or risk of harm. Two of the studies assessed participants’ values in the form of 
self-reported recovery in response to behavioural therapy and cervical traction 
(Bernaards et al., 2007; Young et al., 2009). 
General Physiotherapy 
From the available evidence, general physiotherapy had a low level of 
recommendation to support its use in cervicobrachial pain; however this 
recommendation was based on limited evidence. 
Meta-analyses indicated that general physiotherapy provided no additional reduction 
of pain in the short-term.  There were consistent findings that general physiotherapy 
was no more effective in reducing pain than the use of a collar or ‘no specific 
treatment’ at long-term follow-up.  There was conflicting evidence that general 
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physiotherapy reduced disability or improved function. There was no evidence of 
cost-effectiveness, risk of harm or any data to establish if participants valued one 
intervention in preference to another.   
From limited evidence, it would appear that the composite nature of generalised 
physiotherapy (including electrotherapy, traction, manual therapy and exercise) is no 
more effective that comparators.   
Traction 
Traction had a low level of recommendation to support its use in cervicobrachial pain. 
Meta-analyses indicated that cervical traction provided no additional benefit than 
placebo in reducing pain in the short-term.  There were consistent findings that 
cervical traction was no more effective in reducing pain in the long-term or, reducing 
disability and improving function in the short-term or long-term than placebo traction.  
There was limited evidence, from one study, that intermittent traction did not improve 
participant self-reported recovery compared to sham or placebo in the short-term 
(p=0.74) or long-term (p=0.58) (Young et al., 2009). There was no evidence to 
support or refute traction as a cost-effective modality and no data to evaluate any risk 
of harm associated with traction. 
Manual therapy and exercise 
Manual therapy and exercise had a low level of recommendation to support its use in 
cervicobrachial pain. Meta-analyses indicated a trend for manual therapy and 
exercise to be beneficial in reducing pain in the short-term, but this did not reach 
statistical significance.  
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There was conflicting evidence that manual therapy and exercise was advantageous 
in long-term pain reduction as well as on disability and function in the short and long-
term. No evidence evaluated risk of harm for manual therapy and exercise in 
cervicobrachial pain. One study evaluated the effects of manual therapy and exercise 
on cost-effectiveness and participant self-reported recovery (Walker et al., 2008) but 
there was no sub-group analysis for the cervicobrachial pain participants, therefore, 
interpretation was limited. 
Behavioural therapy 
Behavioural therapy had a low level of recommendation to support its use in 
cervicobrachial pain. 
According to one study (Bernaards et al., 2007), behavioural therapy improved pain 
in the long-term compared to ‘usual care’.  This study showed potentially moderate 
benefit, but it was recognised that further studies were needed to confirm this.  
Without having clear details on what treatment the ‘usual care’ group received, it was 
difficult to comment on how this treatment effect occurred.  It was, also, unclear why 
this effect was evident at the one-year follow-up and not at short-term follow-up.  
There was moderate evidence that behavioural therapy did not improve function or 
disability.  There was moderate evidence that behavioural therapy was a cost-
effective modality, as participants who received behavioural therapy were reported as 
less likely, over a six month duration, to use additional health care for their symptoms 
compared to the ‘usual care’ comparator (P<0.01).  Adverse events relating to harm 
were not reported.  
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3.2.4 Comparisons with other reviews 
A previous review on neck pain reported insufficient evidence for manual therapy for 
neck disorders with radicular findings (Gross et al., 2004).  There was some evidence 
from this review to support a positive influence of manual therapy and exercise on 
cervicobrachial pain in the short-term, although it was acknowledged that this 
evidence was weak.   Some recent systematic reviews have evaluated the effects of 
manual therapy on cervicobrachial pain (Boyles et al., 2011; Leininger et al., 2011). 
Similar conclusions were reported. 
3.2.5 Limitations of the systematic literature review 
This review was based on all the available literature at the time of conducting the 
searches (from start to January 2012).  Published and unpublished sources were 
searched.  However, a potential weakness, as for most reviews, was the risk of 
incomplete retrieval of relevant literature. 
Cervicobrachial pain is a heterogeneous term and, consequently, there was variation 
in participants’ criteria across studies. Some studies aimed to identify cervical 
radiculopathy specifically. Identifying patho-anatomical causes, such as cervical 
radiculopathy (disease pertaining to the nerve root), has not been found to be 
effective in identifying conditions that will or will not respond to therapy (Section 2.3).  
There was variability in the outcome measures, with a lack of consistency in 
assessment time frames and how scales were used (Section 3.2.3 – outcomes).   
Frequency, intensity and duration of reported interventions varied considerably. 
Pooling results in meta-analyses was, therefore, limited. Future studies should focus 
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on identifying cost-effective, clinically appropriate, low-risk interventions. In many 
studies included in this review, there was some reduction in pain and recovery of 
function, irrespective of treatment received. However, all studies used some form of 
intervention in the comparator groups; therefore, the data from this review does not 
further the understanding of the natural course of the condition.  
Three studies reported patient values and preferences in the form of global rating of 
change scores (Bernaards et al., 2007; Walker et al., 2008; Young et al., 2009).  
Global ratings of change scores have been recommended as a valid way to 
represent patient values (Kamper et al., 2009).  There was inconsistency in which 
scales were used:   Bernaards et al. (2007) used a seven-point scale, Young et al. 
(2009) a thirteen-point score and Walker et al. (2008) a fifteen-point scale.  However, 
it has been reported that scales between 7-point and 15-points are equally 
responsive (Lauridsen et al., 2007), enabling cross-analysis between study results. 
None of the studies reported harms; therefore the level of risk associated with each 
treatment modality was unknown.  The reporting of adverse events has been 
advocated (Ioannldis et al., 2004), but, it would appear from this review that it is not 
yet common practice. 
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3.3  Conclusions from evidence of non-invasive management for 
cervicobrachial pain 
There was insufficient information to make recommendations regarding the 
management of cervicobrachial pain.   
There was low evidence for the effectiveness of non-invasive management of 
cervicobrachial pain.  Potential benefits were indicated in the provision of manual 
therapy and exercise and behavioural change approaches to reduce pain (Table 3-5) 
Table 3-5 Grade of evidence to support effectiveness of non-invasive 
interventions in cervicobrachial pain 
Grade Intervention 
Moderate 
 
Behavioural therapy (long-term pain reduction) (Bernaards et al., 2007) 
 
Low Manual therapy (short and long-term pain reduction) (Howe et al., 1983; Allison 
et al., 2002; Coppieters et al., 2003; Walker et al., 2008; Ragonese et al., 2009) 
 
Very 
Low 
Manual therapy (improvement in function and disability) (Ragonese et al., 2009) 
 
Footnote:  Refer to Table 2-3 for interpretation of grades 
General physiotherapy and traction were no more effective than comparators in 
reducing pain.  Effects of non-invasive management on function and disability were 
mixed. 
3.4  Identification of need to conduct research trial on the lateral 
glide mobilisation 
Limited evidence from this review indicated that the provision of manual therapy and 
exercise and a behavioural change approach might be a cost-effective approach to 
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reduce pain in the management of cervicobrachial pain in the short- and long-term.  
The future role of manual therapy in health care was identified, in 2007, as an 
important area to research (Smith, 2007; Vernon & Humphreys, 2007). Manual 
therapy encompasses a wide range of techniques including joint mobilisation or 
manipulation, myofascial techniques, acupressure and massage.  Some techniques 
might provide enhanced therapeutic effect compared to others.  The need to evaluate 
effectiveness of specific manual therapy techniques for specific conditions has been 
reported (Hoving et al., 2001; Smith, 2007; Millar et al., 2010).  From the findings of 
this review, it was unknown whether any specific treatment techniques or approaches 
influenced outcome on pain, function or disability for cervicobrachial pain. The most 
consistently used manual therapy approach reported in studies included in the review 
was the lateral glide mobilisation technique.  The lateral glide technique (which 
involves an oscillation of one vertebra on another) has been advocated for 
management of cervicobrachial pain in clinical texts (Jull et al., 2008).  No high 
quality clinical studies have evaluated the effectiveness of the lateral glide 
mobilisation specifically in the management of cervicobrachial pain, either in the short 
or long-term. 
3.5  Summary of non-invasive management of cervicobrachial 
pain 
Cervicobrachial pain is largely managed conservatively.  There continues to be a lack 
of research substantiating what interventions constitute best practice.  The provision 
of manual therapy with exercise has a low level of evidence to support its use in 
reducing pain.  The lateral glide has been the most consistently reported specific 
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manual therapy technique used in past research, however there is very low evidence 
to support its use as a specific manual therapy intervention for cervicobrachial pain in 
the immediate-term and no evidence to support its use as a specific manual therapy 
intervention in the short or long-term.  The next chapter will consider the lateral glide 
as an intervention, and evaluate how this technique might create a hypoalgesic (pain 
relieving) effect.  
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4 AN OVERVIEW OF EXISTING NON-INVASIVE 
INTERVENTIONS FOR CERVICOBRACHIAL PAIN 
4.1 Introduction to existing interventions 
Chapter 3 identified evidence that the lateral glide mobilisation might be an effective 
intervention for patients with cervicobrachial pain.  This chapter reports a critical 
evaluation of how the lateral glide could have an effect on pain and appraises the 
different approaches to performing a lateral glide.  Justification is presented for 
selection of the approach that was used in a randomised controlled trial to assess its 
effectiveness (reported in Chapter 5).    
The second part of the chapter appraises methods that could be used to evaluate the 
effectiveness of the lateral glide on cervicobrachial pain.  The use of a self-
management approach as the comparator treatment is discussed and the 
development of a new, bio-psychosocial self-management tool is reported.  
4.2 The lateral glide mobilisation 
The lateral glide technique was originally described by Elvey (1986) as a manual 
treatment, involving a small oscillatory movement, applied to the neck with an 
element of traction.  In modern texts, the lateral glide is still considered to be a 
technique that might induce pain relief and lead to improvements in disability and, 
potentially, be useful in the management of cervicobrachial pain (Jull et al., 2008). 
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4.2.1 The lateral glide’s effect on pain 
There was moderate evidence that cervical joint mobilisation has an immediate effect 
on reducing pain in neck and upper limb musculoskeletal conditions.  A systematic 
review by Schmid et al. (2008) reported that cervical mobilisation could reduce pain 
by approximately 20% more than control approaches.  Eight of the 15 studies in 
Schmid et al.’s (2008) review used the lateral glide technique.  Consistent findings 
from studies have supported that the lateral glide has a hypoalgesic (pain reducing) 
effect beyond comparators (therapeutic ultrasound), placebos (manual contact 
intervention) and controls (no intervention) on at least one pain outcome measure 
(Table 4-1).  However, there were some inconsistencies between pain outcome 
measures, for example, statistically significant effects on VAS (pain) and on pressure 
pain thresholds were identified in some, but not all studies.  This inconsistency might 
be due to the heterogeneity of participants across the studies, or a lack of power to 
detect change within studies.  
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Table 4-1  Effectiveness of the lateral glide mobilisation on pain 
 
Key:  n= number; NFR = Nociceptive flexion reflex threshold; PFGS = Pain free grip strength; PPT = 
Pressure Pain Threshold; RCT= Randomised controlled trial; TPT= Thermal Pain Threshold; 
ULNE=Upper Limb Nerve Extensibility test; VAS=Visual Analogue Scale;  
 *= Study on cervicobrachial pain subjects 
Study Participants Comparator, 
control or 
placebo 
Pain Outcome 
measure 
Results 
Coppieters 
et al., 
(2003)* 
RCT 
 
n=20  
sub-acute and 
chronic 
neurogenic 
cervicobrachial 
pain 
Therapeutic 
ultrasound 
(comparator) 
Numerical pain 
rating score in 
response to the 
ULNE 
No between-group differences 
reported. Significant immediate 
improvement in mean pain 
reduction pre compared to post 
treatment for mobilisation group 
(p<0.00), but not for ultrasound 
group (p=0.29).  
 
McClatchie 
et al., 
(2009) 
RCT 
 
n=21 
Chronic 
shoulder pain 
Manual 
contact, 
without 
mobilisation 
(placebo) 
 
VAS pain Significant between-group 
differences favouring the 
mobilisation group (p =<0.00). 
Sterling et 
al., (2010) 
RCT 
n=39 
Chronic 
whiplash 
associated 
disorder 
Manual 
contact 
without 
mobilisation 
(placebo) 
NFR; VAS pain; 
PPT; TPT 
 
Significant between-group 
differences favouring the 
mobilisation group for NFR 
(p=0.04).  Did not reach 
statistical significance for VAS, 
PPT or TPT. 
 
Vincenzino 
et al., 
(1996) 
RCT 
n=15 
Lateral 
epicondyalgia  
Manual 
contact 
without 
mobilisation 
(placebo) and 
no contact 
(control) 
 
PPT; VAS pain Significant between-group 
differences favouring the 
mobilisation group for PPT 
(p<0.01).  Did not reach 
statistical significance for VAS 
Vincenzino 
et al., 
(1998) 
RCT 
 
n=24 
Chronic lateral 
epidondyalgia 
Manual 
contact 
without 
mobilisation 
(placebo) and 
no contact 
(control) 
PFGS; PPT; 
TPT; ULNE 
 
Significant between-group 
differences favouring the 
mobilisation group for PPT, 
ULNE, PFGS (p>0.05). Did not 
reach statistical significance for 
TPT  
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4.2.2 Theory of how the lateral glide’s effect on pain might be achieved 
It has been reported that a hypoalgesic effect (from a lateral glide) occurs in 
response to the mechanical stimulation of the cervical afferents in the joints, muscles, 
ligaments and nerves (Elvey, 1986; Coppieters et al., 2003; Jull et al., 2008).  This 
stimulation is reported in the literature to affect pain perception by altering the 
processing of pain at spinal cord and cortical levels (Schmid et al., 2008; Bialosky et 
al., 2009).  Evidence to support how the lateral glide can achieve a hypoalgesic effect 
has been focused on two key mechanisms  
 Produce a mechanical effect  
 Affect pain mechanisms 
Evidence of a mechanical effect 
There was low level evidence that the lateral glide creates a mechanical effect, but 
very low evidence that this mechanical effect occurs at the level of the cervical 
vertebrae.  Vincenzino et al. (1999) reported that application of the lateral glide 
technique to the fifth on the sixth cervical vertebra consistently produced a 
mechanical displacement of the vertebra with C5 to T1 having the largest lateral 
displacement of 3cm (95% CI 2.74 to 3.94).  Although this study had serious 
limitations (including a very small number of participants: n=8; and questionable 
reliability for use of reflective tape as markers over anatomical landmarks during the 
ultrasonic imaging) these were the only data available to evidence a mechanical 
effect for the lateral glide technique (Figure 4-1).   
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Figure 4-1:  Direction of glide applied to the 5th vertebra. 
 
 
 
 Other studies have consistently found that mobilisation (in the form of a 
posterior/anterior glide) to the cervical spine produces little to no movement of the 
vertebrae, but can produce consistent changes in the soft tissue area local to the 
application of the technique (McGregor et al., 2001; McGretor et al., 2005; Lee et al., 
2005).  It has been hypothesised that any therapeutic benefit could be the result of 
the soft tissue deformation rather than any mechanical effect at the level of the joint 
(McGregor et al., 2005). 
Direction of glide 
5
th
 cervical 
vertebra 
6
th
 cervical 
vertebra 
Cervical disc 
Cervical 
sympathetic trunk 
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Evidence of an effect on pain mechanisms 
There was a moderate level of evidence that the lateral glide could modulate pain 
mechanisms.   A randomised controlled study (n= 39) reported that application of the 
lateral glide to the fifth on sixth vertebrae resulted in changes to a spinal reflex, 
indicating a change in spinal cord hyper excitability (Sterling et al., 2010) (Figure 4-
2). This was the only study that had evaluated changes at spinal cord level.  Other 
studies evaluated changes within the sympathetic nervous system in response to the 
lateral glide.  
There was moderate evidence that sympathetic change was associated with 
alterations in activity in the periaqueductal grey region (PAG) of the midbrain, an area 
of the brain believed important in pain modulation via the descending inhibitory 
pathways (Schmid et al., 2008). Animal and human studies have consistently 
reported concurrent changes in pain, brain activity and sympathetic output (Gebber 
et al., 1999; Green et al., 2006; Dean, 2011).  Clinical studies used change in 
sympathetic output (including thermal skin changes and blood flow change) to 
demonstrate that lateral glide mobilisation affected descending cortical control. 
However, findings were inconsistent across studies.  Most studies supported a 
positive association (Vincenzino et al., 1995; Vincenzino et al., 1998); however one 
study found a mixed response (Vincenzino et al., 1994). 
 
 
75 
 
 
 
 
 
 
 
 
To summarise, there was moderate evidence that the lateral glide had a hypoalgesic 
effect.  There was very low evidence that the effect was caused by mechanical 
stimulation and moderate evidence that this resulted in altered pain processing 
(Table 4-2). It is important to recognise that these effects have been observed on a 
heterogeneous group of subjects (only one of the studies was on cervicobrachial pain 
patients) and that effects have been evaluated only in the immediate term.  It was 
unknown whether the physiological effects of the lateral glide extended into short, 
medium or long-term. 
 
 
Afferent input mobilisation 
technique causes changes 
to spinal reflex 
Spinal cord hyper 
excitability sends input to 
the PAG of midbrain 
Figure 4-2: Effects of the lateral glide on the spinal cord 
Key:  PAG= periaqueductal grey region  
Spinal cord 
Spinal nerve root 
Spinal process of 
vertebrae 
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Table 4-2 Grades of effectiveness for the lateral glide mobilisation 
Grade Evidence 
Moderate 
 
 
The lateral glide had an immediate pain reducing effect (Schmid et al., 2008) 
 
Pain was reduced by modulation to pain processes (Vincenzino et al., 1995; 1998; 
Sterling et al., 2010) 
 
Very Low The lateral glide created a mechanical effect to the internal tissues in the cervical 
spine (Vincenzino et al., 1999) 
 
Footnote:  Refer to Table 2-3 for interpretation of grades 
 
4.2.3 Different approaches when using the lateral glide mobilisation 
Standardising a mobilisation technique is controversial.  Early narrative work of Elvey 
(1986) specifically advocated using the lateral glide at the most symptomatic 
vertebral level.  However, there was a low level of evidence that equivalent effects 
result from manual therapy delivered to either a symptomatic or non-symptomatic 
level (Cleland et al., 2005; Aquino et al., 2009). It has been recommended that, in 
research, techniques should be specific and reproducible to enable findings to inform 
practice (Jull et al., 2008).   
Different approaches have been reported for administering the lateral glide (Table 4-
3).  
 
 Table 4-3 Different approaches used by studies using the lateral glide mobilisation 
Study Technique 
named 
Direction of glide Level of 
glide 
Grade and duration of 
glide 
Position 
Allison et al., 
(2002)* 
RCT 
 
Lateral 
glide 
technique 
Gentle, slow controlled lateral 
glide, away from the side of 
pain  
Level not 
specified. 
Slow oscillations into 
resistance but not pain. 
Duration not specified. 
Supine lying. Hand resting on chest or abdomen. 
Shoulder supported over the acromial region.  Head 
and neck supported. 
Coppieters et 
al., (2003 )* 
RCT 
 
Lateral 
glide 
technique 
A lateral translatory movement 
away from the involved side 
while minimising gross cervical 
side flexion or rotation. 
One or 
more 
motion 
segments 
C5, C6, 
C7 
 
Grade and duration not 
specified.  (Reference 
made to Vincenzino et al, 
1999) 
Supine lying. Shoulder girdle depressed.  Occiput and 
neck cradled. Arm either resting on abdomen or in more 
abducted positions (depending on patient’s level of 
pain) 
Cowell and 
Phillips 
(2002)* 
SCS 
 
Lateral 
glide 
technique 
A lateral glide mobilisation, 
directing the glide to the 
opposite side of the pain 
C5/6 Oscillatory mobilisation. 
Grade and duration not 
specified. 
Supine lying.  Hand resting on abdomen and then 
progressing into a more abducted and extended 
position. 
Elvey (1986) 
DP 
Lateral 
glide 
technique 
Lateral gliding, directing the 
glide  to the  opposite side of 
the pain  
Depende
nt on level 
of nerve 
root 
Oscillatory manner.  
Duration and grade not 
specified. 
Supine lying. Hand resting on thorax, by side or in 
outstretched position.  Shoulder girdle is lightly fixed. 
Gentle cervical traction may be applied.  
McClatchie et 
al., (2009) 
RCT 
Lateral 
glide 
mobilisation 
Mobilisation was directed 
towards the same  side of the 
symptoms   
C5, C6, 
C7 
Grade IV+. 120 seconds at 
each level. 
In sitting with back supported and head in neutral, 
hands on lap. 
 
 Ragonese  
(2009)* 
RCT 
 
Lateral 
glide 
mobilisation 
Lateral glide towards the side of 
the symptoms  
C2, C3, 
C4C5, 
C6, C7 
Oscillatory.  Grade III or IV 
for approximately 30-45 
seconds at each level. 
Supine position.  Head and neck cradled.   
Saranga et 
al., (2003) 
RCT 
Lateral 
glide 
technique 
The cervical lateral glide 
technique (Maitland, 1986) was 
performed on the contralateral 
side and directed towards the 
side of the arm being 
investigated  
C5/6 Grade III.  60 second 
mobilisations (x3) with one 
minute interval in between. 
Supine lying. Head and neck were kept in a neutral 
position. 
Sterling et al., 
(2010) 
RCT 
 
Cervical 
lateral glide 
Cervical lateral glide directed 
away from the nominated side 
of pain. 
C5/6 Grade not specified.  60 
second mobilisations (x3) 
with one minute interval in 
between. 
Supine lying.  Whole hand contact with the neck. 
Vincenzino et 
al., 
(1994,1995, 
1996, 
1998,1999) 
RCTs 
Lateral 
glide 
technique 
Directed contra laterally to the 
affected upper limb. The 
therapist specially emphasised 
the lateral translatory motion 
away, while minimising gross 
rotation and side flexion.   
C5/6 Oscillatory grade III glide.  
30 second mobilisations 
(x3) with one minute 
interval in between. 
Supine lying. Arm in varying positions of shoulder 
abduction, medial rotation and elbow extension. 
Shoulder girdle depressed.  Occiput and neck cradled. 
Key: C= cervical vertebra; C5/6= 5
th
 on 6
th
 cervical vertebra; DP=descriptive paper; grade III=large amplitude into resistance; grade IV+=small 
amplitude end range movement; RCT=Randomised Controlled Trial; SCS=Single Case Study; *Studies on cervicobrachial pain subjects 
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No standard approach to delivering the lateral glide was identified.  Different 
approaches related to the direction of glide, the level to which the glide was applied, 
intervention parameters (the quantity and depth of oscillation used), the therapist’s 
hand position (push or pull techniques) and, the positions in which the patient was 
positioned when receiving the glide (supine or sitting). 
Direction of glide 
The most consistently used direction of the technique involved an oscillatory glide 
away from the side of symptoms (Elvey, 1986; Vincinzino et al., 
1994,1995,1996,1998, 1999; Allison et al., 2002; Cowell & Phillips, 2002; Coppieters 
et al., 2003; Sterling et al., 2010).  Studies that used the lateral glide directed away 
from the side of symptoms have consistently reported a reduction in pain on at least 
one outcome measuring pain (Vincinzino et al., 1995, 1996, 1998; Allison et al., 
2002; Cowell & Phillips, 2002; Coppieters et al., 2003; Sterling et al., 2010). 
Level of glide 
Mobilising the fifth relative to the sixth cervical vertebrae was the most consistently 
used level for applying the lateral glide (Vincenzino et al., 1995, 1996, 1998, 1999; 
Cowell & Phillips, 2002; Coppieters et al., 2003; Saranga et al., 2003; McClatchie et 
al., 2009; Sterling et al., 2010). There was limited justification for using this level. The 
reason for using this level was unclear. A low level of evidence indicated that the 
largest amplitude of mid to lower cervical spine motion occurred between the fifth and 
sixth vertebrae in normal movement (Bogduck & Mercer, 2000; Wu, 2010), therefore 
it might be possible that mobilisation to this level had the greatest impact on 
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mechanoreceptor stimulation.  It has been theorised that an increased afferent input 
from mechanoreceptor stimulation might result in greater changes to spinal cord 
hyper excitability leading to an increased stimulation of the PAG resulting in an 
increased descending cortical control pain inhibition (Schmid et al., 2008).  
Intervention parameters 
Most of the earlier work relating to the lateral glide technique did not specify duration 
or depth of mobilisation.   These parameters have been specified in more recent 
publications, but have been variable.   Vincenzino et al. (1996, 1998, and 1999) used 
30 second mobilisations at grade III (large amplitude, through range oscillations); 
while McClatchie et al. (2009) used 120 seconds at grade IV (small amplitude, end 
range oscillations). There were no explanations to justify dose of treatment and no 
clear indications whether fewer or more mobilisations affected outcomes. The mean 
duration of treatment, across studies, was 60 seconds and the most frequently used 
grade of mobilisation was grade III.  
Therapist’s hand position 
There was some inconsistency in the placement of the therapist’s hands on the 
patient. Some studies described the therapist as supporting the head and neck (at 
the level to be treated) with the hand delivering the mobilisation to deliver a pulling-
type of mobilisation to the neck (Vincenzino et al., 1995, 1996, 1998; Cowell & 
Phillips, 2002; Coppieters et al., 2003). Sterling et al. (2010) modified this approach 
to support the head with one hand and apply the glide with the other hand, thereby 
creating a more pushing-type mobilisation.  Sterling et al. (2010) hypothesised that 
the placement and pressure of the whole hand contacting the symptomatic side had 
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the potential to add therapeutic advantage in terms of pain modulation.  This could be 
due to the increased stimulation of mechanoreceptors in the anterior and lateral 
cervical muscles, which are known to be densely populated with muscle spindles 
(Boyd Clarke et al., 2002), as well as a greater stimulation of the cutaneous afferents 
in the skin (Sterling et al., 2010). The increased stimulation could create a larger 
effect on the central pain mediating mechanisms (Section 4.2.2).  
Positioning of patient 
In all but one of the studies that evaluated lateral glide (Saranga et al., 2003), the 
technique was performed on patients in the supine lying position. Some studies 
positioned the patient’s arms in more abducted (out to the side) positions (Vincenzino 
et al., 1995, 1996, 1998), whilst others rested the patients arm on their abdomen 
(Allison et al., 2002; Cowell and Phillips, 2002).  One study had the arm either on the 
abdomen or in more abducted positions, depending on the patient’s level of pain 
(Coppieters et al., 2003).  It has been reported that sustained stretch positions to 
mechanically sensitised nerve tissue (such as an abducted arm position) should be 
avoided due to the vascular compromise to the nerve tissue (Julius et al., 2004). 
4.2.4 Methods to evaluate the lateral glide mobilisation on 
cervicobrachial pain in clinical studies 
Clinical studies that evaluated medium-term and long-term effects of intervention on 
cervicobrachial pain used the lateral glide in conjunction with other manual therapy 
(Allison et al., 2002; Ragonese et al., 2009). Since the glide technique was part of a 
package of treatment involving other manual therapy approaches, the effect of the 
lateral glide was completely confounded with any effect of that ‘package’.  
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Consequently, no conclusions about effectiveness of the lateral glide may be drawn 
using findings from these studies.   
To evaluate effectiveness of the lateral glide, a control, placebo treatment or 
comparative intervention could be used. The advantage of a no-treatment control is 
reported to eliminate most extraneous variables that could confound results of a 
study (Sim & Wright, 2000); however there were ethical issues of withholding 
treatment particularly when a study was to take place over a long period of time (De 
Deyn, 2000). Placebo interventions were considered, including a ‘sham’ mobilisation 
whereby the physiotherapist could support the neck and head as if to deliver the 
lateral glide, but not add the mobilisation.  However, it has been stated that placebos 
are ineffective when they are distinguishable, in any way (which would be the 
situation in the proposed trial) (Hróbjartsson & Boutron, 2011).  This could explain the 
differences across some of the results that used placebo to evaluate the 
effectiveness of the lateral glide on the immediate effects of pain (Table 4-1).  An 
alternative was to provide a comparative intervention.  A comparative intervention 
that could be used across both trial groups would effectively act as a ‘control’ to the 
lateral glide mobilisation.  
There was moderate evidence that self-management enables patients to understand 
and manage their condition, sustaining health in a cost-effective way (Hurwitz et al., 
2008; Patel et al., 2009).  Self-management was considered a viable across-group 
intervention.  Given that the systematic review in Chapter 3 highlighted that manual 
therapy and exercise and behavioural change might be an effective means for 
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managing cervicobrachial pain, it was considered appropriate to use an ‘exercise 
with behavioural change’ approach as the basis for self-management.  
Comparative interventions: self-management approaches 
The systematic review in Chapter 3 found moderate evidence that behavioural 
change intervention was effective in reducing pain in the long-term for patients with 
cervicobrachial pain (Bernnards et al., 2007).  Bernnards et al. (2007) delivered 
behavioural change as a group-based intervention.  Group-based interventions have 
been used in other cervicobrachial studies, for example, Klaber-Moffett et al. (1990) 
used a group-based education session in their study.  However, it was unclear 
whether a group-based approach is preferable to a one-to-one approach. A potential 
disadvantage of group intervention is that it needs adequate numbers of patients per 
group to be a realistic option.  Hence, it was anticipated that the provision of group 
intervention for cervicobrachial pain might not be viable.  Alternatives were to use 
audio-visual aids or an information booklet.   
A literature search was conducted from inception to December 2006, to establish 
what patient information sources were already available.  The search used electronic 
databases and key words (Section 2.1) as well as general search engines (Google 
and Yahoo).  The search found a DVD ‘Treat your own neck and arm pain’ (2004).  
This DVD focused on an exercise approach, with little consideration given to 
behavioural therapy.   The search was widened to include all neck pain categories.  
Two booklets: ‘Treat your own neck’ (McKenzie, 1983) and ‘The Neck Book’ (Waddell 
et al, 2004) were identified. The ‘Treat your own neck’ book follows an exercise and 
advice approach.  Whilst it provided some information on cervicobrachial symptoms, 
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little attention is given to behavioural modification.  This reflected that little was 
known about the value of psychosocial aspects relating to neck pain around the time 
the DVD was produced and the booklet written. ‘The Neck Book’ was clearly written 
and encompassed some aspects of behavioural therapy, exercises and advice; 
however the information was generic to neck pain and had few references to arm 
symptoms.  For cervicobrachial pain sufferers, a significant proportion (50%) of pain 
relates to the arm (Daffner et al., 2003).  None of the information sources were 
considered appropriate for the management of cervicobrachial pain. 
Development of a self-management booklet 
There was a low level of evidence, from a number of small studies that written 
information is an effective means of delivering information (Jull et al., 2008; Haines et 
al., 2010; Jack et al, 2010).  The author decided to produce a booklet for the purpose 
of use in the trial that encompassed three key sections:  behavioural change, home 
exercise and advice.   
Behavioural changes related to posture, workplace, breaks and coping, which was 
consistent with the study by Bernaards et al. (2007).  The coping component adopted 
a cognitive behavioural approach where the patient worked with the therapist to 
identify problems and seek solutions. This approach had been documented to be 
important in managing pain (Morley et al., 1999; McCracken & Turk, 2002; Bosy et 
al., 2009; Hansen et al. 2011).  
The home exercise component was more difficult to determine as it was unknown 
which exercises were the best to combine with manual therapy.  Studies in the 
systematic review that included home exercise in conjunction with mobilisation used 
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cervical and shoulder range of motion and cervical stabilising exercises (Allison et al. 
2002; Walker et al. 2008).   
Advice was frequently reported as a means to manage cervical conditions.   Advice 
on staying active, relaxation and self-help strategies was based on limited findings 
from small, low quality cervicobrachial studies (Kogstad, 1978; Krapac et al, 1992).   
The design of the ‘Self-treatment for neck and arm pain’ booklet was developed in 
accordance with guidelines from the Department of Health (2003). Diagrams used 
from copyrighted texts were granted permission for use. The production and funding 
of the booklet was agreed at the Trust at the main trial site. The process of 
developing the booklet involved three stages.  In the first stage, the booklet was 
reviewed by two academic researchers and two clinical specialist physiotherapists 
who advised about content and layout. In the second stage, a convenience sample of 
patients with cervicobrachial pain in a clinical setting (n=10) provided verbal and 
written feedback on their own experience of using the booklet (Table 4-4).  
Table 4-4 Feedback from patents about the self-management booklet 
Positive comments Comments requiring change 
Easy to follow, self-explanatory Take out the bit about going to the gym – I find it 
off-putting 
Clear and concise 
 
 
Everything in the leaflet is bang-on 
 
I’m not having any problems using it at all 
 
I found the leaflet easy to use 
 
This book explained why I experience neck and 
shoulder pain 
 
Can I use an ice pack instead of heat as I find ice 
helps me more? 
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Recommendations largely related to alterations in grammar and layout. In addition, 
the section on using heat was changed to using heat and cold and the ‘use of a gym’ 
was replaced by ‘other forms of exercise to improve fitness’.   This process informed 
the third and final stage.  This was piloted in the preliminary study, detailed in 
Chapter 5 (Section 5.17.5). The development for this booklet was supported by the 
Hospital Trust at the main trial site, and has since been adopted by the Trust as part 
of standard practice in the management of cervicobrachial pain. 
4.3 Summary for existing interventions for cervicobrachial pain  
There was moderate evidence to support that the lateral glide could have an 
immediate hypoalgesic effect on pain.  It was acknowledged that the majority of 
supporting evidence came from studies on patients with musculoskeletal conditions 
other than cervicobrachial pain. However, all studies were on subjects who had pain 
either in the neck or arm region making it plausible that these findings might be 
transferable to patients with cervicobrachial pain. 
A comparative intervention was required to evaluate the effectiveness of the lateral 
glide. The self-management approach was identified as the most suitable 
comparator.  There were concerns that delivering the self-management intervention 
in a group setting was not feasible. Existing audio-visual and written tools were not 
assessed to be suitable.  This led to the development of a new self-management 
booklet, based on current evidence at the time of designing it.   
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Chapter 5 will discuss how the intervention modalities identified in this chapter are 
integrated into a randomised clinical trial to evaluate the effectiveness of the lateral 
glide mobilisation on cervicobrachial pain. (Appendix E) 
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5 DESIGN AND METHODS FOR THE CLINICAL TRIAL 
5.1 Methods used in clinical trial 
Chapter 3 identified a need to assess the effectiveness of lateral glide mobilisation 
for patients with cervicobrachial pain. This chapter details the methods used in a 
clinical trial to investigate effectiveness of the lateral glide mobilisation in the 
management of cervicobrachial pain.  
An overview of different methods that were considered and a rationale for the 
selected approach are presented, together with an account of preparatory studies 
(including an audit of an NHS Hospital Trust in the West Midlands and a preliminary 
study) that were used to inform the final design and methods for the main trial.  The 
design and methods are reported in line with guidance from the Consolidated 
Standards of Reporting Trials (CONSORT) statement (Schulz et al, 2010), to ensure 
coverage of all relevant information. 
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5.2 Trial objectives 
The aim of this trial was to investigate whether a self-management intervention with 
lateral glide mobilisation was more effective than a self-management intervention on 
its own for participants with cervicobrachial pain.   
The primary objective was: 
To establish the long-term effectiveness of the lateral glide mobilisation in 
reducing pain, for patients with cervicobrachial pain. 
Secondary objectives were: 
i) To assess the short-term effectiveness and longitudinal effectiveness 
(over 12 months) of the lateral glide mobilisation to reduce pain. 
 
ii) To assess the longitudinal effectivenss (over 12 months) of the lateral 
glide mobilisation to improve function and disability. 
iii) To evaluate short-term cost-effectiveness of the lateral glide in terms of 
work absenteeism and utilisation of physiotherapy resources. 
 
iv) To identify short-term risk of harm associated with the 
lateral glide mobilisation. 
v) To explore whether participants with a dominant neuropathic 
mechanism of pain respond differently from the lateral glide than those 
without a neuropathic mechanism in the short-term. 
vi) To explore whether participant preference was associated with outcome 
in the short-term. 
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5.3 Trial design 
A prospective, randomised controlled trial (RCT) was conducted, with participants 
randomised to one of two groups: a lateral glide and self-management intervention 
(Mobilisation group) or self-management intervention alone (Comparator group).  The 
primary outcome measure was change in perceived pain as indicated using a visual 
analogue scale, with a clinically meaningful difference taken as 20mm.  Assessments 
were made on four occasions (at baseline prior to intervention and at 6, 26 and 52 
weeks post the first intervention session). The 52 week follow-up was the primary 
end point to establish the long-term effect on the primary outcome (pain).  The design 
included key features such as allocation concealment, blinding of assessors, and 
randomisation of participants to groups (Schulz et al., 2010). The key stages of the 
trial are summarised in Figure 5-1. 
A prospective RCT was selected for the trial design to establish a cause-effect 
relationship of lateral glide mobilisation on cervicobrachial pain (Sibbald & Roland, 
1998) whilst minimising the potential influence of bias and chance (Sim & Wright, 
2000). Participants in the Comparator group received the self-management 
intervention alone. Participants assigned to the Mobilisation group received the self-
management intervention and the lateral glide intervention.  This design enabled 
between-group differences to be attributed to the addition of the lateral glide 
mobilisation in the Mobilisation group. Self-management has been demonstrated to 
be an appropriate intervention for cervicobrachial pain, making it a suitable 
comparative intervention in this trial (Section 4.2.4).  
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The selected design can be described as a pragmatic trial (Hotopf, 2002; 
Patsopoulos, 2011).  Pragmatic trials have been reported to be a realistic 
compromise between observation studies (which have good external validity and 
poor internal validity) and conventional RCTs (which have good internal validity and 
poor generalisability) (Hotopf, 2002, Godwin et al., 2003; Patsopoulos, 2011). They 
are an appropriate design to assess intervention for use within a clinical setting 
(Wakefield, 2000) and are able to provide convincing evidence to practising clinicians 
(Wakefield, 2000; Godwin et al., 2003; Howick, 2009; Patsopoulos, 2011; Tonelli, 
2012).   
A preliminary study was conducted to evaluate the selected methods and to identify 
changes that could improve the quality of the main trial (Lancaster et al., 2004; 
Loscalzo, 2009; Aran et al., 2010; Cocks & Torgerson, 2013).  Details of the 
preliminary study are reported in Section 5.17. Data from the preliminary study 
informed a power calculation to determine the sample size that was required for the 
main trial, to ensure adequate precision of the estimated treatment effect for the 
primary outcome measure (Lancaster et al., 2004; Carroll et al., 2008; Cocks & 
Torgerson, 2013). 
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Figure 5-1: Key stages in the trial to assess effectiveness of the lateral glide 
with self-management compared to Self-management alone  
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5.4 Trial participants  
All prospective participants were assessed by an Assessment Physiotherapist.  In 
this trial, Assessment Physiotherapists were advanced musculoskeletal 
physiotherapists (band 7 or 8) working in the National Health Service.  
Physiotherapists working at these grades are recognised as having highly developed 
assessment skills (NHS staff council, 2010), hence, ensuring that participants were 
screened against trial criteria as effectively as possible e.g. to eliminate co-existing 
pathology such as shoulder impingement.  An Assessment Physiotherapist verbally 
informed potential participants that a clinical trial was being conducted to evaluate 
two comparative approaches of physiotherapy for neck and arm pain and ascertained 
whether they would be interested in participating. Those who were interested were 
screened by one of the Assessment Physiotherapists, using the following eligibility 
criteria.   
5.4.1 Trial eligibility criteria 
Potential participants were screened for eligibility against a set of eligibility criteria 
(Table 5-1).   
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Table 5-1 Participant eligibility criteria for trial 
 
Rationale for the eligibility criteria is reported below. The criteria were restricted to 
those supported by clear evidence, since too many criteria could affect 
generalisability of a trial’s findings (Van Spall et al., 2007; Moher et al., 2010).  
  
Inclusion  Exclusion 
Aged 18 – 65 years experiencing 
cervicobrachial pain (San Román et al., 
2002; O’Neil, 2003; Hestbaek & 
Stochkendahl, 2010 ) 
Bilateral arm symptoms 
Symptoms for greater than six weeks 
(Daffner et al., 2003) 
Symptoms indicative of serious pathology (red flags): 
History of cancer, unexplained weight loss (4.5-6.8kg 
within two weeks or less), severe unremitting night 
pain, general malaise and constant unvarying pain 
(Goodman & Snyder, 2000; Carette & Fehildings, 
2005; Moffett & McLead, 2006) 
Adequate knowledge of English language 
Verbally consented to consider being 
involved in the trial and attend review 
appointments (Woolard et al., 2004) 
Symptoms of vascular thoracic outlet syndrome 
(Bearn et al., 1993; Fassiadis et al., 2005; Fiorentini et 
al., 2005; Elman & Kahn, 2006) 
 Co-existing musculoskeletal upper limb pathology 
(Lauder, 2002; Polston, 2007; Cannon, 2007) 
 Systemic condition affecting nerve or joint function e.g. 
rheumatoid arthritis, multiple sclerosis (Williams et al, 
2003; Goldenberg, 2010) 
 Previous surgically invasive techniques to the neck 
(Fouyas et al., 2002; Carragee, 2008) 
 Receiving  (or planned to receive) alternative 
interventions for cervicobrachial pain  
 Involved in litigation associated with cervicobrachial 
pain (Rasmussen et al., 2001; Rasmussen et al., 
2008) 
 Already involved in a research studies (Ulrich et al, 
2005) 
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Trial inclusion criteria: 
Cervicobrachial pain 
The main inclusion criterion was cervicobrachial pain defined as arm pain associated 
with cervical spine pain (Jull et al., 2008). The additional requirement of a positive 
upper limb nerve extensibility test was considered because all previous 
cervicobrachial pain studies using the lateral glide mobilisation had included nerve 
extensibility as a prerequisite (Allison et al., 2002; Cowell & Phillips., 2002; 
Coppieters et al., 2003; Ragonese, 2009).  However, this trial aimed to include 
somatic referred, as well as, neurogenic radiating causes of the problem, as it was 
considered possible that somatic referred pain could be affected by mobilisation.  
This has since been supported in a publication by Jull et al. (2008).  Hence, a 
positive upper limb extensibility test was not included as an inclusion criterion, but 
was recorded so that association between a positive test and outcome on pain could 
be explored.  
Age 
Eligible age range was specified as 18 to 65 years, inclusive.  The lower age limit 
ensured that patients entering the trial had reached skeletal maturity (San Román et 
al., 2002; O’Neil, 2003). This was important since it was unknown whether manual 
therapy techniques on developing spines had the same outcome as on fully 
developed ones (O’Neil, 2003; Hestbaek & Stochkendahl, 2010).  The upper age limit 
of 65 was selected because, in people over this age, there was low evidence that 
pain could be processed differently due to reduced psychosocial and physical pain 
modulation (Riley et al., 2000; Karp et al., 2008).  Alterations in pain processing could 
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potentially affect response to trial intervention, particularly as the lateral glide is 
thought to affect pain through neurophysiological modulation and physical effect 
(Section 4.2.2).  Most published clinical studies on cervicobrachial pain, at the time of 
planning the trial and more recently, had not included patients over the age of 65 
(Howe et al, 1983; Klaber Moffett et al., 1990; Persson et al., 1997/2001; Allison et 
al., 2002; Coppieters et al., 2003; Bernaards et al., 2007; Walker et al., 2008).   
Symptom duration 
Patients were eligible if they had experienced symptoms for more than six weeks. 
There was a low level of evidence in the published literature that patients with 
symptoms of less than six weeks had a naturally good prognosis (Daffner et al., 
2003; Vos et al., 2008; Kuijper et al., 2009), perhaps due to natural recovery 
occurring within this time (Boswell et al., 2007).    There was a low level of evidence 
that cervicobrachial pain persisting for longer than six weeks had a less favourable 
prognosis (Daffner et al., 2003).  
It was considered more appropriate to evaluate the effectiveness of the lateral glide 
when it was provided at a time when natural recovery was less likely to occur. 
Excluding acute presentations was consistent with several previous studies 
evaluating the lateral glide technique for cervicobrachial pain (Allison et al., 2002; 
Cowell and Phillips, 2002; Coppieters et al., 2003).   
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Language 
All participants needed to have adequate understanding of written and spoken 
English to enable their comprehension of the Self-management Booklet and 
completion of the self-reported participant outcome measures. 
Compliance 
Patients were explicitly informed that the trial would continue for one year.  They 
were included if they demonstrated a willingness to attend all follow-up assessments.  
The importance of information gathered at follow-up appointments was carefully 
explained to potential participants, since this approach had been reported to reduce 
attrition rate at follow-up (Woolard et al., 2004). 
Trial Exclusion criteria: 
Serious pathology.  
It has been recognised that patients with serious pathology require urgent medical 
attention and, therefore, are usually unsuitable for physiotherapy intervention 
(Greenhalgh & Selfe, 2006). Although rare, some serious pathology may present with 
cervicobrachial pain, including Pancoast tumour (Vargo & Flood, 1990; Owen & 
Ameen, 1993), spinal metastasis (Vecht, 1990) and Cervical Potts disease (a form of 
tuberculosis) (Achouri et al., 1997).  ‘Red flags’ comprise a collection of progressive 
symptoms that help to identify serious pathology of the spine (Goodman & Snyder, 
2000; Carette & Fehildings, 2005; Moffett & McLead, 2006).  They include a history 
of cancer, unexplained dramatic weight loss, severe unremitting night pain, constant 
unvarying pain and general ill health (Vecht 1990; Owen & Ameen, 1993; Goodman 
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& Snyder, 2000; Carette & Fehlings, 2005; Moffett & McLean, 2006; Binder, 2007; 
Nordin et al, 2008; Greenhalgh & Selfe, 2010).  These criteria were used to exclude 
patients who could be exposed to increased risk if they were involved in the trial. 
Bilateral arm symptoms 
The lateral glide technique is a unilateral technique described as gliding away from 
the side of pain (Hall & Elvey, 1999; Vincenzino et al, 1994, 1995, 1998, 1999; 
Allison et al, 2002; Cowell & Phillips, 2002; Sterling et al, 2010). Hence, participants 
needed to have symptoms in one arm only. Patients with bilateral symptoms were 
not recruited to the trial. 
Symptoms strongly suggestive of thoracic outlet syndrome 
There was evidence to suggest that thoracic outlet syndrome was associated with an 
increased risk of thromboembolism (Bearn et al., 1993; Fassiadis et al., 2005; 
Fiorentini et al., 2005; Elman & Kahn, 2006) and that this was more likely to be 
associated with the vascular rather than neurogenic forms of the condition (Fugate et 
al., 2009).  Consequently, Assessment Physiotherapists were informed to exclude 
patients with cervicobrachial pain that presented with signs and symptoms of 
vascular compromise.  It was recognised that a level of vascular monitoring would 
have been required for these patients that was not within the scope of the trial 
protocol. It would also have been a confounding variable to include these patients. 
Co-existing musculoskeletal upper limb pathology  
Narrative texts have reported an association between cervicobrachial pain and co-
existing upper limb pathology (Lauder, 2002; Polston, 2007). There was low evidence 
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from one prospective observational study (Cannon, 2007; n=191) that patients with 
cervicobrachial pain frequently have co-existing upper limb pathology.  Shoulder 
impingement has been reported to be the most frequent co-existing condition with 
cervicobrachial pain (p<0.001) (Cannon, 2007).  Clinically, multiple musculoskeletal 
conditions are managed collectively through numerous physiotherapy modalities, of 
which the lateral glide could be one.  Adding additional treatment to address other 
pathology would have had the potential to confound results from the trial.  
Withholding additional treatment for a co-existing pathology would have been 
unethical (De Deyn, 2000).  For these reasons, patients with known co-existing 
pathologies were excluded from the trial. 
Systemic conditions affecting nerve or joint function.   
Conditions such as multiple sclerosis or rheumatoid arthritis are progressive 
pathological disorders that impact on pain, physical and mental health (Williams et al, 
2003; Goldenberg, 2010).  Hence, including these conditions could have had a 
negative impact on outcome and confounded results. 
Previous cervical spine surgery.  
Surgery structurally alters cervical mechanics and has the potential to interfere with 
normal anatomical and physiological processes (Fouyas et al., 2002; Carragee, 
2008).  The lateral glide technique is thought to affect pain by affecting cervical 
mechanics and changing pain by influencing physiological processes (see Section 
4.2.2).   
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Alternative management 
Other interventions to manage cervicobrachial pain could have affected outcome and 
confounded results from the proposed trial. Patients were excluded when there was a 
known plan for alternative intervention e.g. surgery or injections.  
Involvement in litigation issues regarding cervicobrachial pain.  
There was moderate evidence that involvement in litigation has compounding effects 
on prognosis and outcome in conservative management of cervicobrachial pain 
(Rasmussen et al., 2001; Rasmussen et al., 2008) (Section 2.4.5). Hence, patients 
involved in litigation were excluded from the trial. 
Current involvement in another clinical study. 
Additional commitments are often required by patients who are involved in clinical 
studies.  It was considered important not to cause additional burden for individuals 
who were already participating in a research study elsewhere (Ulrich et al, 2005).  
Hence, potential candidates who were involved in other clinical studies were 
excluded. 
5.4.2 Consenting process used in clinical trial 
A patient with cervicobrachial pain and who matched the eligibility criteria (i.e. a 
potential trial participant) was informed about the trial by an Assessment 
Physiotherapist.  The information provided by Assessment Physiotherapists was 
standardised to reduce the potential for bias during this information giving process 
(Buckley et al., 2007; Junghans & Jones, 2007). The information covered what 
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participation would involve (including a description of the two interventions), data 
collection time frames, the number of follow-up appointments required, the 
consenting process, and the option to withdraw at any time without any 
consequences for their treatment.   
A potential participant who was interested in taking part was given detailed, written 
information about the trial (Appendix C) by the Assessment Physiotherapist. 
A physiotherapy appointment was made with a Trial Physiotherapist, who would be 
providing the intervention. Trial Physiotherapists were band 6 clinical musculoskeletal 
physiotherapists. Band 6 physiotherapists are considered to have the necessary 
skills to deliver manual and self-management interventions effectively (NHS staff 
council, 2010). When a potential participant attended the first appointment with the 
Trial Physiotherapist, the Trial Physiotherapist ascertained whether the potential 
participant remained interested in being involved in the trial and/or required further 
clarification about participation.  This was achieved by inviting the potential 
participant to ask questions and providing further clarification to them, as required.  
The aim of this process was to ensure each participant had been fully informed, as 
far as possible, prior to commencing the trial (Knifed et al., 2007; Singh, 2008). 
Arguably, the process of seeking consent could have influenced the way that a 
potential participant responded to intervention (Sim & Wright, 2000).  However, to 
fulfil ethical requirements, individuals have the right to be fully informed before 
making a decision about participation (Nuremberg Code, 1949). 
Patients who declined to participate in the trial continued to receive their 
physiotherapy care (from the Trial Physiotherapist) as per standard practice. Patients 
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wishing to be involved in the trial signed a consent form (Appendix C) and became a 
trial participant.  
To address consistency, all Trial Physiotherapists were trained on the consenting 
process by the Principal Investigator.  This was in line with the Good Clinical 
Research Practice Guidelines (2002).   
5.5 Ethical approval and registration for preliminary study and 
main trial 
Obtaining ethical approval prior to commencing a clinical research study is a legal 
requirement in the United Kingdom for all studies that involve human subjects 
(Central Office for Research Ethics Committees (COREC), 2000; National Research 
Ethics Service (NRES), 2009).  Formal approval is designed to protect the rights, 
safety and dignity of research participants (COREC, 2000; National Patient Safety 
Agency, 2009). Before commencement of both the preliminary study and the main 
trial, approval was obtained from South Staffordshire Local Research Ethics 
Committee: preliminary study reference number (06/Q2602/50); main trial reference 
number (09/H1203/45) (Appendix D).  
The preliminary study and the main trial were registered, independently, with “Current 
Controlled Trials” (http://www.controlled-trial.com): preliminary study 
(ISRCTN87397856); main trial (ISRCTN62431186).  Trial registration was important 
to enable transparency of the planned methods from the outset (Riis, 2000; Moher et 
al., 2010). The World Health Organisation has stated that “the registration of all 
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interventional trials is a scientific, ethical and moral responsibility” 
(www.who.int/ictrp/en; Accessed 14 July 2009).   
5.6 Funding for main trial 
An application for Elsevier Research Award was successful, and an award of £2000 
was given by the Manipulation Association of Chartered Physiotherapists (now the 
Musculoskeletal Association of Chartered Physiotherapists) in December 2009 for 
the costs of the cervicobrachial pain trial. 
5.7 Settings and locations of trial 
The trial was located in the United Kingdom (UK).  Involvement in research has been 
recognised as important to the National Health Service (NHS) as it drives innovation 
and develops high standards of patient care (National Institute for Health Research, 
2013). The NHS, therefore, was an appropriate setting in which to conduct the trial. 
5.8 Trial interventions 
The primary aim of the trial was to evaluate effectiveness of the lateral glide 
mobilisation.  Both groups in the trial received a self-management intervention and 
one group also received lateral glide mobilisation.  
Participants were randomised to one of two groups that were identified as: 
 Self-management only (Comparator) 
 Lateral glide mobilisation with self-management (Mobilisation)  
Interventions (as per randomised group) were provided for up to a maximum of six 
weeks (the intervention period), regardless of group allocation.  Intervention 
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commenced at the first visit to the Trial Physiotherapist. It was difficult to determine 
the optimum dose (number and frequency) of self-management or mobilisation 
interventions in this trial. No consistent dose of treatment for either intervention had 
been identified in previous cervicobrachial pain studies (Section 3.2.3). An electronic 
literature search (using methods described in Section 2.1) from inception to January 
2009 identified no literature to identify an optimum dose of non-invasive intervention 
for cervicobrachial pain.  Information was also limited for neck pain generally. Mean 
values reported for the optimum number of interventions to achieve clinical 
effectiveness in neck pain ranged from 2.78 (SD 4.55) (Klaber-Moffett et al., 2005) to 
6.4 (SD 5.4) (Skargren et al., 1998). There were no reported figures for frequency of 
interventions (chiropractic and physiotherapy treatment).  A pragmatic approach was 
adopted for this trial, with the Trial Physiotherapist and participant jointly determining 
the amount of intervention, as per standard practice in the participating sites involved 
in the clinical trial.  
5.8.1 Self-management intervention 
Participants in both intervention groups received a self-management booklet, 
specifically developed for the trial, as described in Section 4.2.4  (Appendix E).  
A Trial Physiotherapist discussed each section of the booklet with a participant to 
ensure understanding of the booklet’s content (RAND group, 2007).  The participant 
was taught the exercises and given opportunity to practise them under supervision of 
the Trial Physiotherapist. The Trial Physiotherapists were requested to spend a 
consistent time on the booklet with each participant.  This was important to ensure, 
as far as possible, that provision of self-management was delivered equally across 
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trial groups, so that any between-group differences could be attributed to the lateral 
glide mobilisation. 
5.8.2 Lateral glide intervention   
In addition to the self-management intervention, the Mobilisation group received 
lateral glide mobilisations.  Justification that the lateral glide could be considered a 
legitimate approach was given in Section 4.2. 
The lateral glide mobilisations were performed with the patient in a supine position, 
with the glide directed away from the side of pain, for duration of 60 seconds and for 
three repetitions (Figure 5-2). A grade III mobilisation was used to aid consistency in 
the delivery of the technique. The rationale for choosing this dose was to align with 
evidence in previous research (Section 4.2.3).  Each participant was treated by the 
same Trial Physiotherapist on each treatment session to align with standard practice 
at the participating site in the trial. 
 
Figure 5-2: Lateral glide mobilisation technique for right cervicobrachial pain    
                Footnote: The arrow shows the direction of movement 
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5.8.3  Intervention period used in trial 
The intervention period was defined as the first six weeks following commencement 
of intervention. Participants who elected to return for subsequent appointments 
during this period were given the opportunity to check aspects of the self-
management booklet (to ensure that the exercises and advice had been correctly 
interpreted) and, if assigned to the Mobilisation group, to continue with the lateral 
glide mobilisation intervention. When the participant, in conjunction with the Trial 
Physiotherapist, decided that no further appointments were necessary, the 
participant was placed on an ‘open’ appointment until the first follow-up appointment 
(six week follow-up).  An open appointment enabled a participant to return for further 
intervention (as per randomised protocol) during the intervention period (i.e. up to the 
sixth week post baseline). The Trial Physiotherapists were informed not to add 
additional treatment modalities during the intervention period (Section 5.8) because 
such addition might confound any effect of the lateral glide therapy, thereby, reducing 
the power to detect its short-term effect.  As the trial treatment did not extend beyond 
the intervention period (six weeks post baseline), it was considered unethical to 
discourage any additional treatment beyond this point.  It was accepted, therefore, 
that additional treatment beyond the short-term (six week follow-up) was permitted as 
this was standard practice at the participating trial site.  Additional treatment was 
recorded at follow-up appointments as involving ‘more physiotherapy/osteopathy 
etc.’, ‘acupuncture’, ‘injections to the cervical spine’, ‘cervical spine surgery’ or ‘a 
combination of treatment’.  Consideration was given to recording the quantity of 
additional treatment; however, some additional treatment could have been provided 
off-site making it difficult to obtain reliable information. 
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5.8.4 Trial Physiotherapists 
The Trial Physiotherapists delivering the intervention were Band 6 musculoskeletal 
physiotherapists.  A Band 6 physiotherapist is considered to have sufficient skills to 
deliver manual and self-management interventions effectively (NHS staff council, 
2010). Trial Physiotherapists were not masked to allocation (this was not feasible due 
to the nature of the interventions) which might have led to performance bias 
(Geddes, 2009). This has been recognised as a frequent issue in pragmatic studies 
(Godwin et al., 2003). To reduce performance bias as much as possible, Trial 
Physiotherapists were screened out of the trial if they declared a strong preference 
on how cervicobrachial pain should be managed. Minor preferences were recorded 
at the start of the trial. Preferences at the end of the trial were recorded to determine 
whether the therapists had changed their opinions over the duration of their 
involvement in the trial. 
5.8.5 Standardisation of intervention for the Trial Physiotherapists 
A half-day training session was provided to all Trial Physiotherapists, during which 
they were given a copy of the trial protocol (Appendix F), instructed on the use of the 
self-management booklet and taught the lateral glide technique, and asked not to 
add additional interventions during the intervention period.  The Principal Investigator 
taught the lateral glide treatment to all Trial Physiotherapists, to ensure consistency 
of training.  Each Trial Physiotherapist practised the technique until the Principal 
Investigator assessed that they could demonstrate a standardised application of the 
technique.     
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The half-day training session on the manual therapy technique and behavioural 
intervention was shorter than training sessions reported in other research studies 
(Curtis et al., 2000; Lamb et al., 2010).  The reason was that the lateral glide 
mobilisation was a single technique and the behavioural intervention (in the self-
management booklet) was within the scope of standard physiotherapy practice 
(Thacker & Gifford, 2005). In contrast, in the study by Curtis et al. (2000), generalist 
physicians (who would not usually deliver manual therapy) were trained to deliver 
mobilisation techniques and, in the study by Lamb et al. (2010), nurses, 
physiotherapists and psychologists were trained to provide six sessions of group 
cognitive behavioural therapy using a range of techniques (e.g. guided discovery) 
that would have been unfamiliar to some of these professionals. 
Six-monthly update training sessions were repeated for the Trial Physiotherapists 
during the recruitment phase, to ensure that standardisation of intervention was 
maintained.  No guidance was found recommending the frequency of repeat training 
sessions. It was decided that six months was practicable to fit with the time 
requirements of the participating therapists. 
5.9 Assessment periods during the trial 
Assessment for the main trial was at baseline and at follow-up intervals 6, 26 and 52 
weeks from baseline. A questionnaire was sent to patients comprising outcome 
measures at each follow-up time point. A postal method of data collection was 
selected over an appointment as it had been reported that participants with symptom 
resolution were less likely to attend follow-up appointments (Dawson et al., 2010).    
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The initial follow-up at six weeks represented the short-term post-intervention effects.  
Six weeks was selected to represent the end of the intervention period, based on 
participants receiving up to six, weekly appointments.  Six or fewer appointments had 
been identified in the literature as the mean number of appointments needed to 
achieve clinical effectiveness in neck pain (Klaber-Moffett et al., 2005; Skargren et 
al., 1998).  
The 26 week follow-up represented a mid-point review that evaluated change 
between the short-term and long-term outcomes, to provide more detailed, 
longitudinal information on intervention effects. The 52 week follow-up was the 
primary end point in this trial, in-line with other cervicobrachial studies (Walker et al., 
2008; Ragonese et al., 2009) – enabling a comparison of findings.  Long-term 
outcomes have also been reported as being important to justify the efficacy of 
treatment modalities used in neck pain (Hurwitz et al., 2008) and for chronic 
musculoskeletal conditions (Derry et al., 2012). The effects of manual therapy on 
cervicobrachial pain in the short (6 weeks) and long-term (52 weeks) also reflects 
assessments of clinical interest in previous studies (Persson et al., 2001; Bernaards 
et al., 2007; Walker et al., 2008; Kuijper et al. 2009).  
5.10 Baseline measurements of trial participants  
Baseline measures on participant characteristics were recorded at the start of the 
trial. This established how representative the study cohort was, to determine 
generalisability (Burgess et al., 2003; Moher et al., 2010).   
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5.10.1 Demographic baseline data 
Key demographic data included age and gender.  These variables had previously 
been identified (with a moderate level of evidence) to predispose or be associated 
with the development of cervicobrachial pain (Finocchietti & Trindade,1973; Kostova 
& Koleva, 2001; Kaki, 2006).  Additional information included smoking status and 
occupational status, which have been associated (a low/ very low level of evidence) 
with cervicobrachial pain were collected (Finocchietti & Trindade, 1973; Krapac, 
1989; Sauter et al., 1991; Kostova & Koleva, 2001).  Details on absence from work 
due to cervicobrachial pain were included as a baseline measure for cost analysis. 
5.10.2 Clinical baseline data 
Key clinical data included pain scores (using a VAS scale), as the primary outcome 
measure (Section 5.11.1). Psychosocial well-being (SF36, mental component) and 
level of chronicity both had a moderate level of evidence to support their association 
with prognosis (Sheather-Reid, 1998; Persson & Lilja, 2001; Daffner et al, 2003, Bot 
et al. 2005) and, therefore, were important to assess at baseline. Any history of 
whiplash associated disorder (WAD) and the distribution and type of symptoms were 
also assessed because of their potential relevance when interpreting results from the 
trial. 
5.10.3 Identification of participants with a dominant neuropathic pain 
state and mechanical nerve sensitivity 
A secondary objective of this trial was to explore whether a neuropathic pain state or 
mechanical nerve sensitivity affected outcome on pain response to intervention. 
Identification of neuropathic pain was made using the The Self-report Leeds 
Assessment of Neuropathic Signs and Symptoms (S-LANSS) questionnaire 
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(Bennett, 2001; Bennett et al., 2005; Bennett et al., 2006; Jensen, 2006), while nerve 
mechanosensitivity was identified using the upper limb nerve extensibility test (ULNE) 
(Wainner et al., 2003). 
The Self-report Leeds Assessment of Neuropathic Signs and Symptoms (S-LANSS) 
questionnaire was developed to identify neuropathic dominant pain states (Bennett, 
2001), and its scores range from 0 to 24, with a score of 12 or more represented a 
“probable” neurogenic cause (Bennett, 2001; Bennett et al., 2005; Bennett et al., 
2006; Jensen, 2006). There was a low level of evidence that S-LANSS had better 
reliability than other pain assessment tools, such as the Neuropathic Pain Scale, to 
identify patients with chronic neuropathic pain (Jensen, 2006).    
 
The upper limb nerve extensibility test (ULNE) is a physical measure used to identify 
whether patients with cervicobrachial pain have mechanical nerve sensitivity (Figure 
5-3).  This test has been used as a prerequisite in studies investigating manual 
therapy intervention on neurogenic cervicobrachial pain (Allison et al., 2002; Cowell 
& Phillips., 2002; Coppieters et al., 2003; Ragonese, 2009).  In this trial, participants 
with both neurogenic (i.e. those with a positive ULNE test and scores on S-LANSS of 
12 or higher) and somatic cervicobrachial pain were included to provide a 
comparison of findings across these two sub-groups and a comparison of findings for 
the neurogenic sub-group with those from previous studies on that sub-group.   
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Figure 5-3: Picture to show the application of the upper limb nerve 
extensibility test (ULNE) 
 
There was low evidence to support the accuracy of ULNE for diagnosing neuropathic 
cervicobrachial pain (Rubinstein et al., 2007).  The test was defined as positive when 
symptoms were reproducible or when there was a reduction in elbow extension by 
greater than 10° compared to the asymptomatic side (Wainner et al., 2003).   The 
approach described by Wainner et al. (2003) (resulting in either a positive or negative 
test) has greater reliability and smaller measurement error than using a goniometer 
to measure range of elbow extension, as used previously (Coppieters et al., 2003). 
Standardisation of how Assessment Therapists applied the Upper limb nerve 
extensibility test 
The ULNE was a physical baseline measure (unlike other baseline measures in the 
trial), consequently, training was conducted to ensure that the ULNE was used and 
interpreted in a consistent way.  The Principal Investigator taught Assessment 
Physiotherapists how to perform and interpret the test (i.e. what would constitute a 
positive test) for use in the trial. Assessment Physiotherapists practised the 
technique until they were able to demonstrate its application and could verbally 
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support what they would classify as a positive test. The method of applying the test 
was written on the assessment sheet as a reminder to all Assessment 
Physiotherapists on how to conduct the test.  Follow-up training was done at six 
monthly intervals during the course of the trial. 
5.10.4 Identification of patient preference for trial intervention 
A secondary objective in this trial was to explore whether patient preference affected 
outcome on pain response to intervention.  It was recognised that participants with a 
preference for one of the interventions might bias the trial positively if they believed 
that they had received the more effective treatment, or negatively if they believed that 
they had received the less effective treatment (Brewin and Bradley 1989; Klaber-
Moffett et al., 1999; Klaber-Moffett et al. 2005; Adamson et al., 2008).  Asking for 
patient preference at baseline enabled post trial consideration to be made on 
whether preference was associated with change on the primary outcome measure 
(Adamson et al., 2008). This approach has been used in previous RCTs within 
physiotherapy research (Klaber-Moffett et al., 1999; Klaber-Moffett et al. 2005).  
5.11 Outcome measures used in trial 
Selection of appropriate outcome measures was based on recommendations from 
the International Classification of Functioning, Disability and Health (ICF) framework 
(World Health Organisation, 2002) and supported by the CONSORT group (Moher et 
al., 2010). 
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5.11.1 Primary outcome measure - Pain 
VAS 
The primary outcome measure was pain perception measured on a visual analogue 
scale (VAS). Pain is the key feature of cervicobrachial pain (Jull et al., 2008). A high 
level of pain perception leads to increased disability and reduced function, having an 
adverse effect on health and wellbeing (Daffner et al., 2003).  Consequently, pain 
has been the single most consistently used outcome across all studies evaluating 
effectiveness of intervention on cervicobrachial pain. 
Pain is an inherently subjective measure.  Self-report outcome measures have been 
considered a clinically relevant and reliable means for assessing pain perception 
(Dworkin et al., 2005; Dawson et al., 2010) and have been used consistently in 
previous studies to establish effectiveness of interventions to manage cervicobrachial 
pain (Howe et al., 1983; Klaber Moffett et al., 1990;  Persson et al., 1997; Persson & 
Lilja, 2001; Allison et al., 2002; Coppieters et al., 2003; Bernaards et al., 2007;Walker 
et al., 2008; Kuijper et al., 2009; Ragonese, 2009, Young et al., 2009).  The visual 
analogue scale (VAS, using a 10 centimetre line, scaled 0 -100) was selected as the 
primary outcome measure in this trial.  This intensity scale has been used frequently 
to assess pain perception in research studies (Dworkin et al., 2005).  Numerical and 
verbal rating scales were considered, however, it has been reported that previous 
responses on these scales are easier to remember than on a VAS and, therefore, 
could have had a greater potential for recall bias across time points (Petrou et al., 
2002; Dodonco McDonald, 2008). Hence, a visual analogue scale was used in this 
trial. 
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The visual analogue scale for pain VAS (pain) has good reported construct validity 
for this patient population when compared to the McGill questionnaire (van Kleef 
1996; Allison et al., 2002) and responsiveness to change in pain to interventions for 
cervicobrachial pain at six weeks (p<0.01) (Walker et al., 2008; Kuijuper et al., 2009), 
and at one year (p=0.000) (Walker et al., 2008).   
This trial used two visual analogue scales. Each scale comprised a 100mm 
horizontal line marked “no pain” at 0 and “worst pain imaginable” at 100 (hence, 
higher scores related to higher pain perception).  Participants were asked to mark a 
cross on each scale to indicate the intensity of their pain.  One scale represented 
worst pain in their neck and arm, and a second scale represented average pain in 
their neck and arm.  Both scales were representative of pain over the preceding 
week. There was low evidence to support using ‘worst’ and ‘average’ pain on VAS 
over a proceeding week (Persson et al., 1997; 2001; Allison et al., 2002; Bolton et al., 
2010). In addition, VAS pain scales have been used in this way by other 
cervicobrachial studies (Persson et al., 1997; 2001; Allison et al., 2002).  
Global rating of change score 
The Global Rating of Change score (GROC) provided an overall perception of 
change in pain, ranging from -6 (a great deal worse from baseline) to +6 (a great deal 
better from baseline); with 0 indicating no change (Jaeschke et al., 1989; Michener et 
al. 2013). GROC provided information relating to patient self-perceived change in 
pain, therein indicating a participant’s value of interventional effect.  This has been 
reported to be an important consideration when interpreting study findings (Balsham 
et al., 2011; Guyatt et al., 2011a).  Other versions of global rating of change scores 
116 
were considered, including those with fewer and more points; however the 13-point 
scale has been validated for use in upper limb disorders, has established clinically 
meaningful differences for this population (Jaeschke et al., 1989; Mitchener et al. 
2013). 
Assessment of pain medication in conjunction with VAS and GROC completed a 
comprehensive evaluation of change in pain (Doleys & Doherty, 2000).  Pain 
medication used a self-complete descriptive scale at follow-up to identify any change 
requirements to pain medication. Other methods for assessment were considered, 
including the ranking of pain medication according to the ‘pain ladder’ (Lawrie & 
Simpson, 2006; Sarzi-Puttini et al., 2012), but, adjuvant analgesics such as tricyclic 
medications, that might be given for patients with chronic cervicobrachial pain (Furlan 
et al., 2006), are not part of the ladder (World Health Organisation, 2008), potentially 
leading to some ambiguity.  
5.11.2 Secondary outcome measures 
Secondary outcomes were measured under three constructs: 
 Function and disability  
 Harm 
 Costs 
Outcome measures on function & disability  
Neck pain is considered the second highest cause of disability in the world from all 
musculoskeletal conditions (Bone and Joint Decade, 2012). There was moderate 
evidence, in the literature that cervicobrachial pain could negatively impact on 
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function and disability (Daffner et al., 2003). Function can be affected by personal 
factors whereas disability has a more encompassing affect from environmental 
factors (World Health Organisation, 2002).  Function and disability can be assessed 
using condition-specific or generic outcome measures.  Condition-specific measures 
provide more detailed information on limitations particular to that condition, whereas 
generic outcome measures can evaluate the effect of an intervention on overall well-
being (Guyatt et al., 1999, Guyatt, 2002). Both specific and generic outcome 
measures were used in this trial. 
The Neck and Upper Limb Index (NULI) (Stock et al., 2003) was selected as the 
condition-specific outcome measure to evaluate function and disability. This was 
chosen because it was the only tool that evaluated symptoms in the neck and arm, 
collectively, making the content validity high for patients with cervicobrachial pain 
(Stock et al., 2003; Jull et al., 2008).  Additionally, the NULI evaluated psychosocial, 
occupation and sleep-disturbance to incorporate multiple aspects of function and 
disability.  
The NULI comprised twenty questions, divided into four sub-scales:  physical 
activities, work, psychosocial factors, and, sleep. Scores range from 0 to 100, with 
high scores indicating worse function/disability. It was developed for patients with 
conditions affecting both the neck and arm (Stock et al., 2003) and was reported to 
have high levels of reliability and validity in a patient population with cervicobrachial 
pain referred for physiotherapy (Stock et al., 2003).  Additionally, it has been reported 
to have good construct validity when compared to the SF36 and high sensitivity to 
change (Stock et al., 2003).   
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The RAND Short-form 36 (SF-36) version 2 was selected as the generic outcome 
measure to evaluate function and disability.  The SF-36 has been reported as having 
good construct validity and better responsiveness to change when compared to the 
Euroqol and Nottingham Health Profile (McDowell & Newell 1996; Oga et al., 2003).   
The SF-36 comprised 36 items, subdivided into 8 dimensions: physical function, role 
limitation, bodily pain, general health perception, mental health, social function, 
emotional role and vitality (Jenkinson et al., 1999). In addition, it has been validated 
for use as two main sub-scales: the mental component scale (MCS) and the physical 
component scale (PCS). Each sub-scale is scaled from 0 to 100, with higher scores 
representing good health (Jenkinson et al., 1999).  Version 2 (1996) of the scale was 
selected for use in this trial due to its improved measurement properties and 
established norm-based scoring (Jenkinson et al., 1999; Ware, 2002).  UK norm-
based scoring was standardised to have a mean of 50 (SD =10) across each sub-
scale (Jenkinson et al., 1999).  Hence, a group mean score of 50 or less could be 
interpreted as being below the average health of the population (Jenkinson et al., 
1999).  The same figure has been found for US population norms (Ware, 2002).   
The MCS component of the SF-36 included questions relating to mental health, 
social function, emotional role and vitality (Jenkinson et al., 1999).  There was 
moderate evidence from a study by Daffner et al. (2003) that the MCS component 
was sensitive in detecting reduced scores in patients with cervicobrachial pain (mean 
score= 45), and, when adjusted for age and gender, the reduction from norm-based 
scores was significantly lower than for neck or arm symptoms in isolation.   The same 
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study (Daffner et al., 2003) reported that chronicity of symptoms had a larger impact 
on the MCS than the PCS. Hence, only the MCS sub-scale was included in the trial.  
 
Outcome measure on harm 
 ‘Harm’ has been defined as the ‘the totality of possible adverse consequences of an 
intervention’ (Ioannidis et al., 2004. p782).  For this trial, levels of harm were 
categorised based on the Common Terminology Criteria for Adverse Events (2006) 
(Table 5-2). 
 Table 5-2: Criteria for ‘risk of harm’ 
Criteria Description 
Mild (low) harm Any temporary minor negative treatment responses that are recorded 
on the comments sheet by the Trial Physiotherapists and collated 
during the intervention period (Appendix G). 
 
Moderate harm Participants who withdraw/ are withdrawn from the study as a direct 
result of the intervention they received, but have not been subject to 
any serious or permanent harm.  Reasons for discontinuation (when 
possible) are established by the Trial Physiotherapist, Assessment 
Physiotherapist or Principal Investigator. 
 
Severe (high) harm This is recorded on a separate document by the Trial Physiotherapist 
and is defined as the participant suffering serious injury, major 
permanent harm or unexpected death in response to the intervention 
during the course of intervention (Appendix H).   
[Based on Common Terminology Criteria for Adverse Events v3.0, (Cancer Therapy Evaluation 
Programme, 2006] 
 
The risk of harm was evaluated against any benefit (compared to the primary 
outcome measure) per intervention group (Ioannidis et al., 2004). This perspective 
was taken to broaden interpretation of the results from clinical outcome measures. 
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Outcome measures on cost 
Chronic musculoskeletal pain has been reported to be a significant burden to the UK 
economy (Phillips et al., 2008) and it has been recommended that studies evaluating 
chronic musculoskeletal pain include an evaluation of cost (Lewis et al., 2007).  In 
this trial, work-absenteeism was used to evaluate socio-economic costs (Phillips et 
al., 2008).  Resource use (quantity of physiotherapy interventions) was used to 
evaluate cost-effectiveness of the interventions (Cooper et al., 2005; Balshem et al., 
2011; Brunetti et al., 2013). Work-absenteeism was recorded as ‘time off work in the 
preceding month’ at each time point (Waddell & Waddell, 2000; Phillips et al., 2008).  
Resource use was recorded as the quantity of intervention per participant during the 
intervention period (up to the 6 week follow-up). Physiotherapy utilisation cost was 
expressed as the mean number of physiotherapy appointments needed per group 
and calculated in terms of mean monetary value of unit costs for therapist time 
(Waddell & Waddell, 2000; Phillips et al., 2008).   
The total cost for participants’ use of physiotherapy across the whole trial period was 
not analysed, since no data were collected on visits to physiotherapists (or other 
musculoskeletal practitioners) external to the trial.  Participants were asked whether 
they had received any further treatment following the intervention period; however it 
was anticipated that participants would be unable to accurately recall the number of 
interventions they had received across a longer duration such as between weeks 26 
and 52 (Paulhus, 1991; Dodorico McDonald 2008). 
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5.12 Clinically meaningful difference on the primary outcome 
measure 
The minimal clinically meaningful difference has been defined as the smallest 
difference that patients and clinicians recognise as a worthwhile change (Maughan & 
Lewis, 2010). The minimal clinically meaningful difference on VAS pain was taken as 
20mm (on a 0 to 100mm scale) (Hayes & Wooley, 2000; Dworkin et al., 2008; Vernan 
& Humphreys, 2008), and, therefore, it was important to be able to detect a 
difference or change of 20mm or more as statistically significant in the proposed trial 
(Hayes & Wooley, 2000). More recent non-invasive cervicobrachial pain studies 
(Walker et al. 2008; Kuijuper et al. 2009) used a value of 12mm to identify meaningful 
differences across groups.   However, the justification for 12mm was based on 
findings from studies in emergency medicine which focused on important differences 
over time rather than establishing between-group differences.  It was questionable 
whether using the figures for difference in pain across time in the acute medicine 
setting was transferable to be used for between-group differences on interventional 
studies for chronic pain (Dworkin et al., 2008).  
5.13 Randomisation strategy used in trial 
Randomisation procedures were used to reduce the risk of bias by balancing 
potential confounders (variables that could influence results) between groups and, 
therein, improved the quality of the trial (Krnz et al., 2007). Initially web-based and 
telephone randomisation systems were considered as these had been reported as 
superior methods to ensure allocation concealment (Viera & Bangdiwala, 2007). 
However, due to the lack of resources available for this trial, neither of these methods 
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was viable.  Instead, a computer number table generator was used to determine the 
sequence of treatment allocation. This method of allocation has been recognised as 
acceptable and effective (Schulz & Grimes, 2002a; Kelley et al., 2003). 
5.13.1 Sequence generation used in trial 
An independent researcher generated the random order list.  There was a moderate 
level of evidence that higher scores on VAS pain at baseline needed to be reduced 
by a larger amount to detect a change meaningful for a participant (Bird and Dickson, 
2001; Tubach et al., 2004; Emshoff et al., 2011). Stratified randomisation procedures 
were used to balance baseline pain severity scores across the two intervention 
groups, within each of three classifications of baseline pain: low= 0-25 on VAS scale, 
moderate= 26-74 on VAS scale and high= 75-100 on VAS scale. The independent 
researcher generated the random order within each classification of baseline pain 
using a minimisation procedure that allowed for a maximum difference of 3 
participants across intervention groups, within each pain stratum, to prevent sample 
size imbalance (Schulz  & Grimes, 2002a). This approach ensured similarity between 
intervention groups in terms of initial presenting pain scores and group sizes at the 
beginning of the trial (Sim & Wright, 2000). 
5.13.2 Allocation concealment in trial 
Treatment allocation was printed on slips of paper and placed in sealed opaque 
envelopes, by an independent researcher. The envelopes were numbered 
sequentially to ensure that the Trial Physiotherapists opened them in the correct 
order, and, thereby, adhered to the planned randomisation. 
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The above approaches to sequence generation and allocation concealment 
endeavoured to avoid selection bias (Hernán et al., 2004; Higgins et al., 2011). 
5.13.3 Implementation of trial 
Participants were recruited by trained Assessment Physiotherapists and treatment 
allocation was revealed to participants by trained Trial Physiotherapists (Figure 5-1) 
(Sections 5.8.5 and 5.10.3).   
5.14 Blinding strategy 
The Assessment Physiotherapists were blind to group allocation, enabling unbiased 
recruitment of participants.   
It was impossible to blind the participants and the Trial Physiotherapists to treatment 
allocation.  There is a high level of evidence from multiple systematic reviews (Sculz 
et al., 1995; Juni et al., 2001; Balk et al., 2002) that failure to blind participants and 
intervention providers may exaggerate effect-estimate by up to 25% (18-39%) (Sculz 
et al., 1995; Juni et al., 2001; Balk et al., 2002; Hróbjartsson & Boutron, 2011).  It 
was not feasible to blind the Trial Physiotherapists because they were the providers 
of the intervention.  Ways to blind participants were considered: for example, a 
placebo intervention could have involved the Trial Physiotherapist supporting the 
neck and head as if to deliver the lateral glide, but not add the mobilisation.  
However, it has been reported that placebos are ineffective if they can be 
distinguished from the intervention, as would be the likely situation here (participants 
are likely to distinguish an oscillatory pressure from a non-oscillatory pressure) 
(Schulz & Grimes, 2002b; Hróbjartsson & Boutron, 2011). Consequently, participants 
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were not blinded to intervention and the consequential risk of bias was noted as a 
potential weakness in the trial.   
5.15 Data processing 
The data were input into SPSS (version 19), by a research assistant who had no 
other role in the trial. Data with regards to the group (i.e. intervention) were recorded 
using a code (0 and 1), to ensure that the Principal Investigator, who analysed the 
data, remained blind to group allocation and to enable unbiased judgement of the 
conclusions drawn (Schulz & Grimes, 2002b; Karanicolas et al., 2010).  The 
intervention groups were revealed to the Principal Investigator only after completion 
of all statistical tests and consideration of the results (Schulz & Grimes, 2002b; 
Karanicolas et al., 2010).   
5.16 Audit of throughput of chronic cervicobrachial patients to 
inform trial 
No information was available to determine key characteristics of the target 
population, such as the prevalence of cervicobrachial pain (Section 2.4.1) and the 
number of patients with this condition who presented with chronic manifestations.  
Consequently, an audit was conducted to determine whether a sufficient number of 
patients were likely to be available to potentially participate in a trial, and to inform 
the potential rate of recruitment. 
The audit was conducted in the acute hospital where the Principal Investigator 
worked, in the West Midlands. It was based on electronic referral data from the year 
2005 (the earliest point at which electronic data were available) to 2006.   
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The audit revealed that 126 patients with chronic cervicobrachial pain had been 
referred to the physiotherapy department at the site during 2005, with a mean referral 
rate of 10.5 (SD 5) patients per month (minimum n=4; maximum n=23). This 
condition accounted for 5% of the total musculoskeletal referrals to the site, during 
2005. However, there was a concern that a downward trend occurred during this 
period (Figure 5-4). Therefore, the audit of referrals was extended to December 
2007(Figure 5-6), which led up to, and continued during the duration of the 
preliminary study (Section 5.17.2).  
 
Figure 5-4: Number of patients with chronic cervicobrachial pain referred to 
trial site in 2005 (with trend line) 
 
5.17 Preliminary study to inform trial 
A preliminary study provided further information to inform planning of the main 
randomised controlled trial (Lancaster et al., 2004). The preliminary study was 
located in a physiotherapy department in an acute hospital in the West Midlands. 
Data from the 2005 audit indicated that the selected physiotherapy department had 
sufficient patient referrals to recruit to the preliminary study (Section 5.16) and that a 
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minimum of 30 participants (Lancaster et al., 2004) could be recruited to the study 
over a period of six months. 
Aims of the preliminary study were to evaluate the following, in preparation for the 
main trial: 
 Participant flow 
 Recruitment rate  
 Randomisation strategy 
 Appropriateness of outcome measures 
 Acceptability of interventions and outcome measures   
 Contribute to establishing a sample size for the main RCT   
(Lancaster et al., 2004; Arain et al., 2010; Thabane et al., 2010).  
Use of preliminary studies was in concordance with recent recommendations from 
the National Institute for Health Research (NIHR) (2012). 
5.17.1 Participant flow during preliminary study 
Participant flow was evaluated up to the first follow-up (6 weeks post-intervention).  
Running the preliminary study to include follow-up at one year (as planned for the 
main trial) was considered, however this was impractical due to time constraints.   
Assessment Physiotherapists identified a total of 50 patients with cervicobrachial 
pain who were suitable for physiotherapy.  Thirty-two patients were ineligible to 
participate due to co-existing upper limb pathology (n=14), multiple reasons (from 
criteria) (n=8), bilateral symptoms (n=3), red flags (n=3), planned surgery (n=1), co-
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existing rheumatic condition (n=1), being involved in litigation (n=1) and, age (n=1).  
(Figure 5-5). 
Eligible participants (n=18) gave informed consent and were randomised to receive 
lateral glide mobilisation and self-management (n=8; Mobilisation group) or self-
management alone (n=10; Comparator group).  
Eight (80%) participants in the Comparator group and 7 (87%) in the Mobilisation 
group completed assessments at follow-up (6 weeks) (Figure 5-5). All returned 
questionnaires had been fully completed. 
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Three participants did not return their questionnaires, two from the Comparator group 
and one from the Mobilisation group, resulting in an overall loss to follow-up of 17%. 
A loss greater than a 20% has been reported to be an unacceptable level of attrition 
(Sackett et al., 2000; Schulz & Grimes, 2002c).  The preliminary follow-up rate was 
only just within this parameter; therefore, a strategy was required to ensure a better 
level of follow-up in the main trial.  
Randomised and registered into the preliminary study (n=18) 
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Did not receive allocated treatment (n=0) 
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Excluded (n=32) 
    Upper limb pathology (n=14);  
multiple reasons (n=8);  
bilateral symptoms(n=3);   
red flags (3); planned surgery  
(n=1); co-existing rheumatic  
condition (n=1);  litigation (n=1);  
age (n=1); 
 
    
 
 
 
Individuals assessed for eligibility (n=50) 
 
Allocated to lateral glide and self-
management (Mobilisation) 
(n=8) 
Did not receive allocated treatment (n=0) 
Withdrew from trial (n=0) 
 
Received allocated intervention (n=8) 
 
 
 
Loss to follow-up at 6 weeks 
n=1 (13%) 
Analysis for primary outcome measure at 
6 weeks 
 (n=7; 87%)  
 
  
Figure 5-5: Participant flowchart of the preliminary study (adapted from Moher et al., 2010) 
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5.17.2 Recruitment during preliminary study 
Eighteen participants were recruited from January 2007 to April 2008.  This was less 
than the expected number of 30 (based on data from the 2005 audit), despite the 
expected time-frame being increased.   
As planned, auditing referral rate for patients with chronic cervicobrachial pain was 
continued, leading up to and during the preliminary study (2007).  Overall, the mean 
number of referrals per year for chronic cervicobrachial pain was 74, however as 
2005 had an atypical referral pattern (the unexplained high referral rate peeking in 
April 2005; n=23), the mean was re-calculated based on data from 2006 and 2007.  
The revised mean referral rate was 48 per year (Figure 5-6), which accounted for 2% 
of all musculoskeletal referrals to the preliminary study site. This number was below 
that estimated from previous data (Section 2.4.1).  
 
Figure 5-6:  Audit of patients referred to physiotherapy with chronic 
cervicobrachial pain between 2005 to 2007 
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5.17.3 Randomisation in preliminary study 
The randomisation procedure (Section 5.13) produced comparable groups at 
baseline with respect to age (a key demographic variable) and pain, mental health 
and chronicity (key clinical variables) (Table 5-3).  Some differences were apparent 
on gender (more females in the Comparator group).  However, it was anticipated that 
this difference would balance out with the much larger sample size required for the 
main trial.  
Table 5-3: Key demographic and clinical variables in the preliminary study, by 
intervention group 
 
Intervention  
 
Key demographic 
variables 
Comparator (n=10)  Mobilisation (n=8) 
Mean (SD) 
Min
n
, 
Max
m
 
Missing  Mean (SD) 
Min
n
, 
Max
m
 
Missing 
Age(years)  49 (17) 28, 
65 
0  49 (12) 29, 60 0 
 
n(%)   n(%)  
Gender 
 Females  
8 (44) 0  2 (12) 0 
        
Key clinical variables 
Comparator (n=10)  Mobilisation (n=8) 
Mean (SD) 
Min
n
, 
Max
m
 
Missing  Mean (SD) 
Min
n
, 
Max
m
 
Missing 
VAS (worst pain) 60 (19) 31, 97 0  65 (18) 28, 81 0 
VAS (average pain) 48 (21) 29,97 0  42 (16) 22,65 0 
SF-36 63 (16) 17, 85 0  59 (17) 21, 93 0 
 n (%)   n (%)  
Chronicity (months) 
  >3 - 6 
  >6 - 12 
  >12 
 
2 (20) 
3 (28) 
5 (42) 
 
1 
  
2 (25) 
2 (25) 
4 (50) 
 
0 
Key: max
m 
=maximum value; min
m 
=minimum value; n= number of participants; SD=standard 
deviation 
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5.17.4 Evaluation of outcome measures used in preliminary study 
Primary outcome measure - Pain 
Although there was an indication of some reduction in median VAS(worst pain) for 
both groups, the changes were not clinically meaningful (being less than 20mm) 
(Figure 5-7).  There was a wider range of VAS(worst pain) scores for participants in 
the Mobilisation group following intervention.  However, the sample size was very 
small and findings from such preliminary studies should not be over-interpreted 
(Thabane et al., 2010).    
The change scores from baseline to post intervention on VAS(worst pain) were 
compared with the Global Rating of Change Score (GROC) for patient-perceived 
change in pain, to consider their comparative responsiveness (Figure 5-8).  There 
was an apparent linear association between change on VAS(worst pain) and GROC 
scores (Figure 5-8), providing some evidence that VAS(worst pain) was a responsive 
measure in the study population.   None of the participants in the preliminary study 
were clinically worse at its endpoint and three were clinically better, two of whom 
were in the Mobilisation group.  In contrast, a comparison of change on VAS(average 
pain) with GROC scores indicated only a  low correlation between them, providing 
some evidence that VAS(average pain) was a less sensitive measure than 
VAS(worst pain).   For this reason, VAS(worst pain) was identified as the primary 
outcome measure in the main trial (Section 5.18.3). 
 
  
 
Figure 5-7 Boxplots for VAS(worst pain) at baseline and 
six week follow-up (n=15) 
Figure 5-8 Change in VAS(worst pain)  compared with 
GROC (n=15) 
               
              GROC=Global Rating of Change score; VAS=Visual Analogue Scale 
Footnote: On Figure 5-7 ◦ represents an outlier value for worst pain. 
                On Figure 5-8 The horizontal red line represents minimal clinically meaningful change on VAS pain 
                          The vertical black line represents  minimal clinically meaningful change on GROC 
Responses in Box A indicate participants with a clinically meaningful improvement on both GROC and VAS 
Responses in Box B indicate participants with a clinically meaningful worsening on both GROC and VAS 
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Secondary outcome measures - Function and disability 
All 15 participants who returned the questionnaire completed the NULI and the SF36.  
There were some irregularities in the completion of both outcome measures.  In five 
cases for the NULI and for eight cases on SF36, participants had circled two adjacent 
numbers and in one case (on NULI) had indicated a response between two 
numerical options.  A method for data entry was put in place for the main trial:  the 
data inputter was given written and verbal instructions that if this occurred in the main 
trial, the middle value was to be inputted.  For example, if a participant chose both 6 
and 7 as a response, or marked in-between these two options, the data was inputted 
as 6.5.  This avoided any data entry bias in the main trial (Delgado-Rodriguez, 2004). 
Secondary outcome measure - Harm 
None of the participants withdrew from the preliminary study and no harms or 
undesirable effects were reported.   
Secondary outcome measure - Cost 
No problems were encountered with capturing data regarding the numbers of days 
off work or mean number of interventions during the intervention period.   
5.17.5 Acceptability of proposed trial methods 
A postal survey (Appendix I) was used to obtain participants’ feedback on their 
experience and any perceived problems with the study (Moffatt et al., 2006). This 
feedback was used to identify if any change was required to the planned methods for 
the main trial.  To aid compliance, the survey was kept short (7 questions were 
utilised), a personalised covering letter was sent to each participant explaining the 
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reason for the survey, and stamped addressed envelopes were issued (Edwards et 
al., 2002b; Edwards et al., 2009).  Despite this, only five questionnaires were 
returned, out of 18 posted to participants.  It was recognised that the limited response 
rate could have led to responder bias (with patients having a positive experience, 
more likely to respond) (Fitzpatrick, 1991).  Responder bias can lead to some 
inappropriate methods from a preliminary study being taken forward into the main 
trial (Edwards et al., 2009). Incentives to encourage response were considered at the 
design stage, including the use of a monetary incentive, recorded delivery and 
telephoning non-responders (Edwards et al., 2009).  The first two strategies have 
been reported to approximately double response rate (Edwards et al., 2002b).  
However, due to the lack of funding at the start, none of these options could be built 
into the study’s design. 
Feedback from the limited survey response was positive. Four of the five 
respondents reported that they were given sufficient information about the study and 
none had felt obliged to participate.  All participants stated that, based on their 
experience, they would be happy to be involved in a future health research study. 
There was positive feedback regarding both the Self-management Booklet and the 
Mobilisation intervention, for example, feedback on the Booklet included “very useful, 
I was able to refer back to it” and “very good, the instructions and diagrams were 
easy to follow”, and the feedback for the Mobilisation included “excellent - very 
professional and best of all - was successful” and “I found this was very good”.  No 
further changes to the Information booklet were identified for use in the main trial.    
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5.17.6 Issues with sample size based on preliminary data 
Thirty has been recommended as the minimum number of participants required in a 
preliminary study to establish the sample size for an adequately powered trial 
(Lancaster et al., 2004).  The number of participants in the preliminary study was less 
than that expected and did not reach the target of 30.  It was not feasible to continue 
recruitment due to time constraints, therefore, it was accepted that additional 
strategies for power calculations were required to determine the required sample size 
for the main trial (Section 5.19).  
5.18 Changes to the methods for the main trial 
The preliminary study provided information that informed some changes to the 
following key features for the main trial: attrition, recruitment and outcome measures. 
5.18.1 Addressing attrition for the main trial 
Postal questionnaires were used for data collection in the preliminary study.  At 6 
weeks post-baseline, there was a 20% loss to follow-up in the Comparator group.  It 
was anticipated that this figure would increase for the longer-term follow-up (at 26 
weeks) and that the primary end point (52 week follow-up) would have a higher than 
acceptable level of attrition (Sackett et al., 2000; Schulz & Grimes, 2002c).  Hence, 
further measures were required to reduce attrition in the main trial. 
The primary method of data collection in the main trial was changed from postal 
questionnaires to follow-up appointments; this was to address attrition as well as to 
enable the incorporation of physical outcome measures at follow-ups (Appendix J). In 
addition: 
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 a) Reminder letters were to be sent to participants one month prior to their 26 and 52 
week follow-up appointments, to encourage their attendance.  
b) Participants who did not attend their follow-up appointments would be contacted 
by telephone, within a fortnight of missing their appointment, to enquire whether an 
appointment could be made at a more convenient time for them.   
Strategies (a) and (b) have been reported to be effective at reducing levels of attrition 
(Nakash et al. 2006). 
c) Participants who did not attend the final appointment (despite the measures stated 
above) would be mailed a condensed version of the questionnaire (Appendix K), 
along with return paid postage to encourage return of completed postal 
questionnaires.   
Incorporating multiple methods of data collection in this way has been advocated as 
effective to reduce attrition (Edwards et al., 2009; Lall et al., 2012).  In addition, 
participants from differing demographic groups have been found to respond to 
different methods of data collection in clinical studies (Edwards et al., 2009; Lall et 
al., 2012). Hence, the incorporation of more than one method of data collection was 
expected to result in a wider response rate and an improved representation of 
treatment effect (Lall et al., 2012).  Funding for £2000 from the Musculoskeletal 
Association of Chartered Physiotherapists (MACP) for the main trial was secured to 
reimburse participants for their travel expenses and for postage costs. 
5.18.2 Addressing recruitment for the main trial 
Two strategies were instigated to enhance recruitment rate to the main trial: - a) 
further centres were included in the trial; and, b) participants were recruited by 
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Assessment Physiotherapists from orthopaedic and musculoskeletal triage services, 
as well as, physiotherapy departments.  
The main trial involved the preliminary study site and a further three National Health 
Service locations across the United Kingdom: two community health centres in 
Birmingham and one orthopaedic centre in Bristol.  It was expected that enhanced 
generalisability would result by the recruitment of participants from a wide 
geographical spread and from primary, secondary and specialist locations (Appel, 
2006).    
5.18.3 Refinement of outcome measures for the RCT 
Identification of a singular primary outcome measure  
The primary outcome measure had been identified as VAS pain.  VAS(worst pain) 
and VAS(average pain) were considered at the preliminary stage. The preliminary 
study found that differences on ‘worst’ pain scores were more responsive to change 
than ‘average’ pain scores when compared to the Global Rating of Change score 
(GROC) (Section 5.17.4). VAS(worst pain) had been used this way in another 
cervicobrachial pain study (Persson et al. (1997; 2001).  Since commencing the trial, 
VAS(worst pain) has been validated as an accurate measure for establishing pain 
over the previous week (Bolton et al.. 2010). VAS(worst pain) was used as the 
primary outcome measure in the main trial.  
VAS(average pain) was considered as a second primary outcome measure, 
however, identification of more than one primary outcome measure would have 
increased the required sample size and necessitated an alteration to the selected 
significance level (set at 0.05 in the preliminary study) to maintain a 5% chance of 
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incorrectly rejecting the hypothesis that mobilisation together with the Self-
Management Booklet was equally as effective as the Self-Management Booklet on its 
own (i.e. to maintain the probability of a false positive result at 0.05)  (Sim & Wright, 
2000; Hulley et al., 2001; Freemantle et al., 2003; Zlowodzki & Bhandari, 2009).  
Additional functional outcome measures  
During the initial planning of the trial, all the selected outcome measures related to 
patient reported outcome measures (PROMs), which had been advocated for use in 
clinical studies (Fitzpatrick et al., 1998).  The selected PROMs represented the 
participant’s perspective of their outcome, which is justifiably important (Dawson et 
al., 2010). In contrast, performance based outcomes (PBOs) have been criticised as 
not being directly meaningful for the patient (Peat, 2002).  However, PBOs are less 
open to self-reporting bias (Dodorico McDonald 2008; Jackson, 2008). Independent 
reviews of the preliminary study criticised the work for not including PBOs because 
participants in the study could not be blinded to the intervention they received, which 
could have biased answers when completing the PROMs at follow-up.   If, at the time 
of completing their follow-up questionnaire, participants were able to recall their 
responses at baseline, there was potential to bias findings from the study. 
In the main trial, PBOs were included to ensure that some outcome measures were 
completed by an independent assessor to improve the methodological quality of the 
trial (Dodorico McDonald 2008; Jackson, 2008).   The Assessment Physiotherapists 
were the outcome assessors in the main trial and were blinded to treatment 
allocation throughout the duration of the trial. There was moderate evidence from 
multiple randomised studies (Noseworthy et al., 1994; Burkhoff et al., 1999; Oesterle 
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et al., 2000) that failure to blind the outcome assessor could exaggerate the effect-
estimate for an intervention by up to 69% (SD 29-87%) (Hróbjartsson & Boutron, 
2011), strengthening the rationale for having included PBOs in the main trial. 
The requirement to add PBO measures and the strategy to address attrition rate 
resulted in a decision to collect data at clinic appointments. 
Cervical active range of motion 
Cervical spine movement is a PBO (Jull et al., 2008). The measurement of cervical 
active range of motion has been used as an outcome measure in previous studies 
addressing cervicobrachial pain (Howe et al., 1983; Klaber Moffett et al., 1990; 
Ragonese, 2009).  There was low evidence to support cervical range as a valid tool 
to measure immediate post-intervention change in neck pain patients (Dvir & 
Prushansky, 2000; Prushansky & Dvir, 2008).  However, it was unclear whether the 
studies by Dvir & Prushansky (2000, 2008) included patients with cervicobrachial 
pain, which limited interpretability of their findings for this patient population.   
Klaber Moffett et al. (1990) used cervical range as an outcome measure for chronic 
cervicobrachial pain subjects, at three month follow-up.  Whilst this was not a 
validation study, the results were consistent with PROMs used in the same study, 
indicating that cervical range of motion might be a responsive measure over a more 
extended duration.  
The main trial used a simple inclinometer to measure cervical range of movement 
(Figure 5-9), as used in other cervicobrachial clinical studies (e.g. Klaber Moffett et 
al., 1990) and more recent studies (e.g. Ragonese, 2009).  There was low evidence 
from three studies with consistent results, that inclinometers are reliable when used 
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in this context (Hole et al., 2000; Wainner et al., 2003; Gelalis et al., 2009). Intra-
observer reliability was reported as being moderate to high in one study on patients 
with cervicobrachial pain (n=50): Intra-class correlation coefficient values range from 
0.63 (95% CI 0.40 to 0.78) for left side bend, to 0.84 (95% CI 0.70 to 0.95) for 
extension (Wainner et al., 2003).  An improvement of 10 degrees (or more) of change 
from baseline has been reported as being clinically meaningful and can be 
considered to represent an increase in range which leads to a functional 
improvement (Klaber Moffett et al., 1989; Sterling et al., 2002; Fletcher & Bandy, 
2008). 
 
 
Figure 5-9: Simple inclinometer used to measure cervical  
AROM 
(positioned to measure flexion and extension) 
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Use of the inclinometer was taught to Assessment Physiotherapists in a training 
session led by the Principal Investigator, to ensure consistency of approach.  
Practice was continued until the Principal Investigator was satisfied that 
standardisation had been achieved. 
 
The movements of flexion, extension and side-bend were measured with participants 
seated upright. Rotation was measured with participants in a supine position (Klaber 
Moffett et al., 1989; Sterling et al., 2002; Fletcher & Bandy, 2008). The inclinometer 
was placed on the participant’s head and the dial set to zero in a resting position (as 
reported in Cleland, 2007).  The Assessment  Physiotherapists were instructed to 
keep the inclinometer in contact with the same point on the head, whilst the 
participant moved into the plane of movement, for example, flexion.  When the 
participant had reached as far as they could in thier range of movement, the 
Assessment Physiotherapist took the recording from the dial on the inclinometer.  
Only one measure per movement was recorded to ensure uniformity. 
A summary of the outcome measures is given in Table 5-4 
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Table 5-4: Summary of outcome measures used in main trial 
Outcome measures Scale Representation Comments  
Primary outcome measure 
for pain 
   
VAS(worst pain) 
 
0 to 100 Higher scores represent a higher 
level of perceived pain 
Clinically meaningful difference is 
20mm 
(Hayes & Wooley, 2000; Dworkin et al., 
2008; Vernan & Humphreys, 2008) 
Secondary outcome 
measures for pain 
   
VAS(average pain) 0 to 100 Higher scores represent a higher 
level of perceived pain 
 
Clinically meaningful difference is 
20mm 
 (Hayes & Wooley, 2000; Dworkin et al., 
2008; Vernan & Humphreys, 2008) 
 
GROC -6 to +6 Negative scores indicate a 
worsening; positive scores 
indicate an improvement. 0 
represents no change 
 
Clinically meaningful difference is 2 
points on scale (Jaseschke et al., 1989; 
Michener et al. 2013) 
Change in pain medication 4 point  
scale 
A higher number indicates an 
increased need for pain 
medication 
(Doleys & Doherty, 2000) 
Secondary outcome 
measures for function and 
disability 
   
NULI 0 to 100 Higher scores represent reduced 
level of function 
0=no functional limitations 
100= severe functional 
limitations 
 
[((sum of all applicable scores)-(number 
of applicable items)) /6x (number of 
items)]. (Stock et al., 2003; Stock, 
2006) 
 
MCS SF36v2 
(RAND) 
0 to 100 Higher scores represent good 
health 
0=poor  mental health 
100= good mental health 
Scores are coded depending on which 
of two categories they are in.  
Sum (coded scores)/number of 
answered items.  Scores can be 
calculated with up to 50% of data 
missing. (Litwin, 1994;Ware, 2002)  
 
Cervical AROM 
 
0 to120 
degrees 
Higher scores represent a 
greater degree of movement 
Clinically meaningful difference is 10 
degrees (Klaber Moffett et al., 1989; 
Sterling et al., 2002; Fletcher & Bandy, 
2008). 
 
Secondary outcome 
measures for  cost 
   
Physiotherapy utilisation 
 
1 to 12 Higher number of appointments 
relate to higher costs 
 
Time off work 
 
 
4 point scale 
 
Higher number represents a 
greater amount of time off work 
Represents time off work for 
cervicobrachial pain  for the preceding 
month only 
Secondary outcome 
measures for  Harm 
   
Reported number of harmful 
effects 
Three point 
scale 
Mild harm, moderate harm, 
severe harm 
Based on the Common Terminology 
Criteria for Adverse Events v3.0,( 2006) 
Key: AROM= Active Range of Motion; GROC= Global Rating of Change scale; MCS SF36=Mental 
Component Scale Short-Form 36; NULI=Neck and Upper Limb Index; TAMPA= Tampa scale of 
kinesiophobia; VAS=Visual Analogue Scale. 
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Fear of Movement (kinesiophobia) 
The use of cervical movement as the physical outcome measure led to consideration 
of factors that could influence the validity of this tool.  Cervicobrachial pain has not 
been related to kinesiophobia specifically, but moderate evidence has associated 
reduced levels of function with increased levels of kinesiophobia in cervical spine and 
upper limb disorders (Kori et al., 1990; Roelofs et al., 2007; Bränström & Fahlström, 
2008; Hudes., 2011; Vernon et al., 2011; Verson et al., 2011; Howell et al., 2012).   
The Tampa Scale of Kinesiophobia (TSK) is a 17-item psychological scale designed 
to measure fear of movement (Kori et al., 1990; Roelofs et al., 2007; Bränström & 
Fahlström, 2008; Hudes, 2011). Scores range from 17 to 68 with higher scores 
relating to a higher level of kinesiophobia (Kori et al., 1990; Roelofs et al., 2007; 
Bränström & Fahlström, 2008; Hudes, 2011). Other measures to evaluate 
kinesiophobia were considered, including the Fear of Pain Questionnaire (Roelofs et 
al., 2007), the Pain Anxiety Symptoms Scale (Rodlofs et al., 2007) and the Fear 
Avoidance Beliefs Questionnaire (Swinkels-Meewisse et al., 2003).  Appropriateness 
of this choice was strengthened in a later systematic review (n of studies= 37) 
evaluating the psychometric properties of pain-related fear measures in chronic 
musculoskeletal pain (Lundberg et al., 2011) where it was concluded that the TSK 
was the best available tool to measure kinesiophobia.   
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5.19 Calculation of the sample size for the main trial 
The sample size for the main trial was determined through statistical methods using 
the identified primary end point, VAS(worst pain) at 52 weeks, together with 
evidenced values for: 
(i) the minimal clinically meaningful difference in a comparable patient population 
(Hulley et al., 2001); (ii) an estimate of standard deviation (SD) in the population of 
interest (Wittes, 2002; Zhong, 2009); (iii) the effect size calculated from (i) and (ii); 
and, (iv) adjustment for participant withdrawal (Cohen, 1992a; Kelly et al., 2003; 
Zhong, 2009; Machin & Fayers, 2010).  
5.19.1 Primary outcome measure and estimation of effect size 
The primary outcome measure (VAS(worst pain)) was a measure for the worst pain 
in the neck and arm over the previous week, measured on a 0 -100mm VAS scale 
(Section 5.11.1).  The minimal clinically meaningful difference (MCMD) on VAS 
(worst pain) for patients with cervicobrachial pain was established as 20mm (Section 
5.11.112) and the SD for VAS(worst pain) for patients in the trial population was 
estimated using data from the preliminary study (Lancaster et al., 2004; Thabane et 
al., 2010).  This was justified since no changes were made to eligibility criteria for the 
main trial.   The upper 99% confidence limit (CI) for the variance was used to 
estimate the value for SD because use of the standard deviation from the preliminary 
study could have led to an under-estimated value due to its small sample size (n=18) 
(Lancaster et al., 2004). 
Using baseline data (Table 5-3), the estimated variance for VAS(worst pain) = 
322.02, n=18 
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Following the method in Daly et al. (1995, pages 289 & 674)  
 
99% CI variance (worst pain) = (n-1) * estd var   to   (n-1) * estd var 
       χ2.005, n-1  χ2.995, n-1 
 
 
     =    17 x 322.02    to    17 x 322.02 
       35.72           5.70 
 
 
      = 153.26       to      960.41 
 
The χ2 values were obtained from statistical tables (Murdoch & Barnes, 1974) 
 
So, estimated SD (worst pain)  = sqrt (960.41) = 30.99   using the upper limit 
 
Leading to an effect size   =  MCMD / estimated SD for VAS(worst pain) 
 
=    20 / 30.99  
 
= 0.65 
 
A size of 0.65 represented a moderate to large effect (Cohen, 1992a) on VAS(worst 
pain).  
5.19.2 Statistical Hypotheses 
Statistical hypotheses were based on the primary objective (Section 5.2). The 
primary hypotheses, regarding worst pain experienced by patients with 
cervicobrachial pain, were stated as:  
H0:  There is no difference in effectiveness of self-management and the lateral 
glide mobilisation when compared with self-management alone 
H1:  There is a difference in effectiveness of self-management and the lateral glide 
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mobilisation when compared with self-management alone 
Two sided statistical hypotheses and tests were selected since existing evidence was 
inconclusive on the effectiveness or otherwise of the lateral glide mobilisation (Hulley 
et al, 2001; Sim & Wright, 2000; Portney & Watkins, 2000). A statistical significance 
level of 0.05 ( the probability of incorrectly rejecting H0 in favour of H1) and a power of 
0.80 (the probability of correctly rejecting H0 in favour of H1) were selected to 
estimate the sample size (Cohen, 1992a; Hulley et al., 2001; Wittes, 2002; Kelly et 
al., 2003; Machin & Fayers, 2010; Sim & Wright, 2000; Zhong, 2009).  
A significance level (also referred to as Type I error) of 0.05 has been reported as 
being a ‘typical’ value in health care research (Portney & Watkins, 2000; Cohen, 
1992a & b) or within the conventional range of values (Hulley et al, 2001; Zhong, 
2009), and was considered to be the highest acceptable value  (Portney & Watkins, 
2000; Biau et al., 2010). It equated to a 5% chance of incorrectly concluding that the 
lateral glide technique had an additional effect when delivered in conjunction with 
self-management. 
 A power of 0.8 was reported as conventional (Cohen, 1992b; Zhong, 2009) and has 
frequently been used in health care research (Machin & Fayers, 2010). It equated to 
an 80% chance of correctly rejecting the assumption of no additional effect of the 
lateral glide technique when used in conjunction with self-management.   
 
Based on an effect size = 0.65, significance level =0.05, power = 0.80, the required 
sample size was 34 per group (Hulley et al., 2001, p85; Jones et al., 2003b p456), or 
total=68.   See Figure 5-10  
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Figure 5-10 Nomogram for the calculation of sample size in main trial 
 [Adapted from Jones et al. 2003b p456] 
5.19.3 Adjustment for participant withdrawal in main trial 
An 11% attrition rate was allowed for at each of the three measurement periods, 
adjusting the sample size to account for participant withdrawals (Sim & Wright, 2000). 
Using the formula in Machin and Fayers (2010) (previously discussed in Fayers & 
Machin (2000):  
Adjusted n (allowing for attrition) =  .       unadjusted n          .         =   .   68   . 
       (1-anticipated attrition rate)3  (1-0.11)3 
 
     =         96 
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Hence, it was estimated that 96 participants would be required for the trial, with 48 
participants randomised to each of the two trial groups. 
This adjustment equated to 42% adjustment at the 3rd follow-up time point (52 
weeks). 
The choice of 11% attrition was largely pragmatic (Fayers & Machin, 2000; Machin & 
Fayers, 2010). Loss to follow-up at six-weeks in  the preliminary study was 17%, and 
consideration of reported losses to follow-up in other cervicobrachial pain studies 
indicated losses to follow-up of 2.5% to 32% at 52 weeks follow-up ( Table 5-5).   
Table 5-5:  Attrition rates in cervicobrachial pain studies 
Author n 
Intervention 
Pain 
outcome 
measure 
Attrition rates 
Bernaards et al., (2007) 466 Behavioural therapy NRPS 
26 wks= 16% 
52 wks= 32% 
Kuijper et al., (2009) 205 
Manual therapy and 
exercise 
VAS 26 wks= 6% 
Persson et al., (1997; 2001) 81 General physiotherapy VAS 52 wks= 2.5% 
Walker et al., (2008) 58 
Manual therapy and 
exercise VAS 52 wks= 6% 
Key:  n= number of participants; NPRS = Numerical Rating of Pain Score; VAS = Visual Analogue 
Scale; wks = weeks 
 
5.20 Data analysis plan for the main trial 
The Principal Investigator, who conducted the analyses, was blind to group allocation 
until all analyses had been completed.  Summary statistics (for example: n, mean, 
standard deviation; or, median, interquartile ranges, minimum and maximum; or, 
percentage and 95% CI) were computed on full data sets for each intervention group.  
In addition, boxplots, line, bar or scatter graphs, as appropriate, were used to present 
the data diagrammatically.  The primary research objective was addressed using 
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Analysis of Covariance (ANCOVA) to evaluate between-group differences on 
VAS(worst pain), the primary outcome measure, at the primary end point (52 weeks), 
with adjustment for important confounding variables. Several authors have 
recommended this approach in preference to an analysis of change scores (Laird et 
al., 1992; Everitt, 1994; Portney & Watkins, 2000; Vickers & Altman, 2001).  Multi-
level Modelling (MLM) was the main method used for longitudinal analyses of other 
continuous outcomes. Other statistical methods (for example, Mann-Whitney for 
evaluating ordinal data, and, Spearman’s rho when testing for correlation) were used 
to evaluate some of the secondary and exploratory outcome measures. Checks were 
conducted on the assumptions underlying the use of statistical tests (Walker & 
Almond, 2010). 
5.20.1 Baseline characteristics 
Baseline comparisons across groups included demographic data (e.g. age, gender) 
and clinical data (e.g. pain level and chronicity).  Data were summarised using 
parametric or non-parametric statistics, as appropriate.  The summary data were 
tabulated by intervention group to provide information on between-group differences 
(Sim & Wright, 2000). Visual comparison of initial baseline VAS(worst pain) scores 
identified how effective stratification had been at achieving balance between the 
groups. 
There has been debate about the meaning of findings from statistical tests on inter-
group differences at baseline (Altman, 1985; Senn, 1994; Roberts & Torgerson, 
1999; Dumville et al., 2006; Turk et al., 2008; Berger, 2009; Fayers & King, 2009; 
Berger, 2010).  Statistical between-group differences at baseline have been criticised 
as an approach to identify variables that could influence results (Altman, 1985; Senn, 
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1994; Roberts & Torgerson, 1999; Dumville et al., 2006; Turk et al., 2008).  
CONSORT stated that: ‘Tests of baseline differences are not necessarily wrong, just 
illogical. Such hypothesis testing is superfluous and can mislead investigators and 
their readers’ (Moher et al., 2010, p.17).  
Historically, testing for baseline differences has been used to consider whether a) 
randomisation was achieved effectively and b) any between-group differences at 
baseline were likely to influence results at follow-up (Berger, 2010).  However, 
statistically significant between-group differences might occur through chance alone.  
It is well documented that multiple statistical testing on baseline data can lead to 
multiplicity i.e. one or more statistically significant between group differences 
identified as a result of chance rather than representing a real effect (Fayers and 
King, 2009).  In general, inter-group differences have been tested using baseline 
values for each primary and secondary outcome measure in an RCT.  However, 
statistically significant tests at baseline do not necessarily constitute evidence of poor 
randomisation or of a true difference between the groups at the start of a study 
(Fayers and King, 2009).  This reasoning has led to the use of statistical approaches 
such as ANCOVA and MLM (Multi-level Modelling) that incorporate potential baseline 
confounders in the statistical analysis and, thereby, account for any important 
baseline between group variability (Field, 2009) .   Increasingly, papers published in 
high quality journals (with high impact factors) such as The Journal of American 
Medical Association (Impact factor 29.978) and The British Medical Journal (Impact 
factor 17.215) are publishing randomised controlled trials that do not report statistical 
tests conducted on baseline data (Reignier et al., 2013; Pinock et al., 2013).  Whilst 
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this is not yet commonplace, it is likely to become the more conventional approach in 
the future.   
Based on the reported evidence, it was decided not test for statistically significant 
inter-group differences at baseline. 
5.20.2 Attrition 
Attrition could be due to loss to follow-up (e.g. patient not attending a follow-up 
appointment) or to incompletion of outcome measures (e.g. a participant attending 
the follow-up appointment, but not completing an outcome measure on a 
questionnaire) (Howard et al., 1986). Both causes of attrition were recorded at all 
time points as: 
 Number of participants lost to follow-up, by intervention group 
 
 Number of participants who did not complete the primary outcome measure, 
by intervention group 
 
Attrition was recorded for each intervention group to support consideration of 
between-group differences.  This was important because imbalances in attrition 
across groups might bias trial results (Fewtrell et al., 2008). In partiular, if a large 
number of participants receiving mobilisation were to drop-out due to dissatisfaction 
with the intervention, and no-one dropped-out of the Comparator group, values of 
outcomes for responders in the mobilisation group could be positively biased, 
potentially leading to a large difference between the groups (Machin & Fayers, 2010) 
and a Type 1 error.  The potential for response bias was considered through 
independent t-tests (when appropriate) on baseline values for important trial 
confounders (age, baseline VAS(worst pain), SF36), with participants assigned to 
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one of two groups according to whether they responded or not to the primary 
outcome at baseline. 
5.20.3 Data Monitoring  
All data were captured on paper forms and entered manually into an Excel database. 
Other methods of data collection and data entry were considered, including direct 
electronic data capture and double entry, however such systems were not available 
for this trial.  An audit to evaluate a random 10% of the data was used to identify 
issues with accuracy of data entry (Appendix L).  There was no standard approach to 
ensure accuracy of data entry, but checking a 10% random sample has been 
reported as providing an adequate check (Dixon & Pearce, 2010). In addition, SPSS 
syntax files were programmed to identify whether any inputted values were outside 
the expected range (Appendix M).   
5.20.4 Analysis of change – Primary outcome measure - VAS(worst pain) 
Primary and secondary analyses 
The main analysis was to test between-group differences on the primary outcome 
measure, VAS(worst pain). The primary analysis was at 52 weeks (long-term effects) 
and the secondary analysis at 6 weeks (short-term effects).   Inter-group differences 
on VAS(worst) pain at 52 weeks and at 6 weeks were assessed using analysis of 
covariance (ANCOVA).  ANCOVA has been reported to have higher statistical power 
than tests on mean change scores (Vickers, 2001). Several authors have 
recommended ANCOVA in preference to an analysis of change scores because 
important, baseline covariates can be accounted for, providing a more powerful test 
on inter-group differences (Laird et al., 1992; Everitt, 1994; Portney & Watkins, 2000; 
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Vickers & Altman, 2001). Covariates used in this trial comprised gender, age, mental 
health, chronicity and ‘worst’ pain at baseline (justified in Section 2.4).   
An ‘intention to treat’ approach (ITT) was followed for the analysis of data.   This 
method analysed all participants according to the group to which they were 
randomised. Although this approach could have under-estimated the effect of the 
lateral glide mobilisation, it retained the balance in participant characteristics 
provided by the randomisation process and, hence, avoided a potential source of 
bias in the results (Hulley et al., 2001). This approach has been considered to be the 
gold standard for the analysis of data collected in clinical studies (Moher et al., 2010). 
Two aspects were considered for the analysis a) missing data, and b) non-adherence 
to protocol (Moher et al., 2010).  If inadequately addressed, these factors could have 
led to misinterpretation of the results (Heritier et al., 2003; Moher et al., 2010).  
Missing data:  The choice was to impute the missing values or exclude participants 
without an outcome (Moher et al., 2010).  Imputation requires strong assumptions, 
potentially leading to underestimation or overestimation of the treatment effect 
(Moher et al., 2010).  No one method of imputation was preferred in the literature 
(Wood et al. 2004).  Omitting missing data has been considered reasonable when 
the level of missing data is low and there is a balance of missing data across groups 
(Moher et al., 2010).  Unfortunately, it was unclear from the literature what 
constituted a ‘reasonable’ level of missing data.  It has recently been reported that up 
to 20% of missing data is acceptable (OCBEM, 2011; SIGN, 2012).  Based on the 
different opinions, if missing values exceeded 20% and/or there was an imbalance of 
missing data between groups, the plan for analysis was to impute data using 
methods for both the worst case imputation and the best case imputation. No clear 
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guidance was found in the literature on what constituted an imbalance of missing 
data. It was decided to consider between-group differences 20% or less as an 
acceptable level of imbalance.  
Protocol violations: Some participants might not have received the randomised 
intervention or received additional intervention to that outlined in the protocol.  
Exclusion of data for participants who violated the protocol could bias results (Moher 
et al., 2010).  The CONSORT group advocated analysing groups as per 
randomisation – as long as missing data, deviations from protocol and co-
interventions were reported in a clear and transparent way (Moher et al., 2010).  
Tertiary analysis 
Tertiary analysis on the primary outcome measure used multi-level modelling (MLM).  
There were two key reasons for this choice: 
1. It provided a longitudinal evaluation (across time) of the data  
2. Missing data were accommodated in this approach.  
A longitudinal analysis evaluated treatment effect over time and graphs displayed the 
pattern of change over time for each group (Pocock et al, 2007).  Unlike repeated 
measures analysis of variance, MLM could accommodate missing data and any 
general trend in the outcome over time (Gueorguieva & Krstal, 2004; Quene & van 
den Bergh, 2004; Misangyi et al., 2006; Field, 2009; West, 2009; Peugh, 2010; Kahn, 
2011).   A forward approach was used to include variables into the model, one at a 
time.  The selected order was: time from baseline (input as 0, 6, 26, or 52 to model 
the weeks from baseline at which data were collected, to account for any overall 
underlying trend in the outcome), potential covariates (SF36, chronicity, gender and 
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age) and intervention group (coded as 0 or 1).  Covariates were added one at a time, 
in the order of their relative importance as judged from published literature in related 
areas of research (Section 2.4). Non-significant covariates were omitted from further 
analysis (Bursac et al., 2008). Intervention group was the last variable added to the 
model (Appendix N), so that any effect on outcome due to an underlying trend or 
covariates was taken into account before testing for effect of the intervention 
(Greenland, 2000; Maas & Snjders, 2009; Quene & Bergh, 2004; Dedrick et al., 
2009; Peugh, 2010). The use of stepwise methods, such as this, has been 
controversial.  Some authors have criticised them for introducing bias by excluding 
previously identified, important covariates (Steyerberg et al., 2000; Thompson, 2001).  
However, others have reported that these criticisms constitute only a minor problem 
(Wahlby et al., 2002; Dartois et al., 2007) and, providing that the methods are used 
logically (for example, retaining a predictor variable with a very strong level of 
evidence to support its inclusion even when found to be statistically non-significant 
during the analysis), that they may prevent spurious error due to the inclusion of too 
many covariates, particularly, when evaluating data longitudinally (Armitage et al., 
2002; Field, 2009). 
Time was labelled as a random effect to account for deviations from the expected 
follow-up times (Field, 2009).  It was anticipated that the combined findings from 
analyses using ANCOVA and MLM would provide stronger evidence on the primary 
outcome measure (Table 5-6).  
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Table 5-6: Planned approaches to data analysis for the Primary outcome 
measure VAS(worst pain) 
Analysis Statistical Test Evaluation of intervention 
Primary analysis ANCOVA at 52 weeks  Long-term effects 
Secondary analysis ANCOVA at 6 weeks Short-term effects 
Tertiary analysis MLM across all time points Longitudinal effects 
Key: ANCOVA=Analysis of Covariance; MLM=Multi-Level Models  
 
5.20.5 Secondary outcome measures 
Methods for the statistical analyses of data on secondary outcome measures are 
reported in Table 5-7.  Longitudinal analysis from baseline to 52 week follow-up used 
MLM’s and analysis of short-term effects (ie. at six week follow-up) used parametric 
or non-parametric tests as appropriate.  All tests were conducted using a significance 
level of 5% and results used with caution since no adjustment was make for multiple 
testing (Section 5.20.8).  
A correlation was computed for the association between six week scores on the 
Global Rating of Change score (GROC) with VAS(worst pain) to test for  any 
association between patient perceived improvement in pain and the primary outcome 
measure (VAS(worst pain)).  Spearman’s rho (rs) was used because data from 
GROC were at an ordinal level of measurement.  Spearman was selected in 
preference to the Kendall’s tau because it has been reported as being the more 
powerful non-parametric test of correlation (Siegal & Castellan, 1988; Walker & 
Almond, 2010).  Scatter diagrams were drawn to visually show any association (Sim 
& Wright, 2000). A correlation coefficient of 0 represented no association and plus 1 
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or minus 1 indicated perfect association between the variables tested (Walker & 
Almond, 2010). 
MLMs were also conducted to analyse the longitudinal effects of intervention on 
secondary outcome measures for pain (VAS(average pain)), function and disability 
(NULI, SF36 & cervical AROM).  The methods were the same as those used for the 
tertiary analysis on the primary outcome measure (Section 5.20.4), whereby a 
forward approach was used adding time (0, 6, 26 and 52 weeks), co-variates (SF36, 
chronicity, gender and age). Tampa score for kinesiophobia was added as a 
covariate to potentially be taken forward into the model (if found statistically 
significant) when analysing cervical AROM as this had been identified as a possible 
confounder specific to this outcome measure (Section 5.18.3).  Side of symptoms 
was added as a covariate to potentially be taken forward for cervical rotation and side 
bend measures as it was unknown if the unilateral nature of the condition could affect 
these unilateral measures. Interventional group was added as the last step in the 
model. 
Use of medication and cost (relating to time off work) were ranked with higher points 
indicating the need for more medication or increased time off work, with ‘no pain 
medications’ ranked at 0, ranging up to ‘stronger/needing to start taking medications’ 
ranked at 3.  The non-parametric Mann-Whitney test was used for between-group 
comparisons for all ordinal data (Field. 2009; Sim & Wright, 2001; Walker & Almond, 
2010).   
Reported costs relating to physiotherapy utilisation were analysed as non-parametric 
data because of the small data range (between 2 to 12 appointments, based on 
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patients being able to return up to twice a week for six weeks).  There were no 
published, standardised NHS cost utility index measures that were appropriate for 
use in this research, therefore, mean numbers of attendances per group were 
converted to monetary values using a local departmental costs for staff time from the 
hospital Trust  where the preliminary and main studies were conducted.   
Harm was expressed as the number (and percentage) of participants who had 
reported harms associated with an intervention (Table 5-2) and a descriptive analysis 
was conducted to consider the incidence rates of harm (Ioannidis et al., 2004).   
For secondary outcomes where MLM was not possible, only the six week follow-up 
period was analysed.  It was recognised that the secondary outcomes had no 
statistical power and it was possible that a greater level of variation could occur over 
a longer period of time.   
Table 5-7 Planned method of analysis for secondary outcome measures  
Outcome measures Statistical Test 
Pain:    
VAS(average pain)  
GROC* with VAS(worst pain) 
Use of medication 
 
MLM 
Spearman’s rho correlation at 6 weeks 
Mann-Whitney test at 6 weeks 
 
Function & Disability:  
NULI, MCS SF36 (PROs) 
Cervical AROM (PBO) 
 
 
 
MLM 
MLM 
 
Cost: 
Time off work 
Physiotherapy utilisation 
 
Mann-Whitney test at 6 weeks 
Mann-Whitney test at 6 weeks  
Harm: 
Reported number of harmful effects 
 
 
Expressed as a % at 6 weeks 
Key: ANCOVA=Analysis of co-variance; AROM= Active Range of Motion; GROC=Global Rating of 
Change; MCS SF36=Mental Component Scale Short-Form 36; MLM=multi-level models; NULI=Neck 
and Upper Limb Index; PBO = Performance Based Outcome measure; PRO = Patient Reported 
Outcome measure; VAS=Visual Analogue Scale; * measure of patient-perceived change. 
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5.20.6 Exploratory analyses plan 
Exploratory analysis focused on evaluating whether the presence of a neuropathic 
component or a preference to receiving the lateral glide had influenced values of the 
primary outcome measure VAS(worst pain) (Table 5-8). 
Analysis of neuropathic cervicobrachial pain 
Spearman’s rho correlation (Walker & Almond, 2010) was computed between 
baseline values for S-LANNS and the primary outcome measure VAS(worst pain) to 
evaluate if a higher neuropathic component (scores of 12 or more) correlated with a 
change in pain outcome in the short-term. A Spearman’s rank correlation was 
computed since there was no evidence to support a linear association (Sim & Wright, 
2005; Field, 2009; Walker & Almond, 2010). It had been theorised that patients with a 
neuropathic component of the condition would be less likely to respond well to 
manual therapy (Hall, 2009) and a study was being conducted to evaluate this 
association for lumbar radiating pain (later reported to identify an association 
(Schäfer et al. 2011)). A correlation was analysed at six week follow-up to explore 
any short-term association with this theory.  
Analysis of mechanically sensitised cervicobrachial pain 
ANCOVA was used to analyse whether patients who were mechanically neutrally 
sensitised (i.e. had a positive upper limb nerve extensibility (ULNE) test) had 
between-intervention group differences on mean scores for VAS(worst pain) at six 
weeks.  ANCOVA was used to analyse the data in the same way as had been used 
for the main cohort of participants. It was recognised that the trial had not been 
powered for this, however, it would enable comparisons to be made to post-
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intervention pain outcomes of other cervicobrachial studies that had stipulated the 
presence of a positive upper limb nerve extensibility (ULNE) test as a prerequisite for 
inclusion (Allison et al., 2002; Cowell & Phillips., 2002; Coppieters et al., 2003; 
Ragonese, 2009). 
Analysis of intervention preference 
ANCOVA was used to test whether participants’ preferences influenced outcome on 
VAS(worst pain). ‘Intervention’ and ‘preference’ were used as fixed factors, with 
baseline VAS(worst pain) as the covariate. Preference was analysed in the short-
term (six weeks) because any additional treatment that participants had after the 
intervention period could have included manual therapy intervention, potentially 
leading to a type II error in the results. 
Table 5-8 Planned method for exploratory analysis 
Outcome measure Statistical Test 
S-LANSS correlating with VAS(worst pain)  Spearman’s rho correlation at 6 
weeks 
ULNE (+ve) with  VAS(worst pain) ANCOVA at 6 weeks  
Participant preference with VAS(worst pain) ANCOVA at 6 weeks 
Key: ANCOVA=Analysis of covariance; S-LANSS= Self-report Leeds Assessment of Neuropathic 
Signs and Symptoms; ULNE= Upper Limb Nerve Extensibility test; VAS=Visual Analogue Scale. 
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5.20.7 Satisfying assumptions for use of the selected statistical tests 
Incorrect conclusions might be drawn when the assumptions underlying statistical 
analyses are violated (Petrie & Sabin, 2005; Field, 2009).  Assumptions were 
checked for all statistical tests conducted for this trial (Table 5-9).  It was possible that 
assumptions relating to normally distributed data were achieved through the random 
allocation across groups (Walker & Almond, 2010).  Statistical tests such as 
Pearson’s skewness coefficient and z-score for skewness were considered, however 
as larger samples (30 or more) tend to normalise sampling distribution of erroneous 
variables, significance tests were not considered necessary (Field, 2009; Walker & 
Almond, 2010).   
Findings from tests on other assumptions e.g. homogeneity of variance, were 
reported alongside the results.  
Table 5-9:  Assumptions underlying use of statistical tests 
Statistical Test Assumptions 
ANCOVA Data measured on an interval or ratio level of 
measurement    
Groups are independent 
Homogeneity of inter-group variances (Levene’s test) 
Distribution of the data approximates to a normal 
distribution(sample greater than 30) 
(Field, 2009; Almond & Walker; 2010) 
MLM Repeated measures taken over time 
Groups are independent 
Homogeneity of variance (Goodness of fit- chi-square) 
Distribution of data approximates to a normal distribution 
(sample greater than 30) 
(Field, 2009) 
Spearman’s rho 
correlation 
Both variables are measured on the same participants 
Minimum of 4 data points per scale 
(Almond & Walker; 2010) 
Mann-Whitney test Groups are independent 
Can be used for ordinal data 
Minimum of 4 data points per scale 
(Field, 2009; Almond & Walker; 2010) 
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5.20.8 Considerations for Multiplicity 
The Initiative on Methods, Measurement and Pain Assessment in Clinical Trials 
(IMMPACT) recommended testing multiple outcomes in a clinical study to enable a 
more holistic understanding of the effectiveness of an intervention in a specific 
population (Turk et al., 2006). However, conducting statistical tests on multiple 
outcome measures increases the size of the overall Type I error (retaining the 
statistical null hypothesis when it is not true), potentially leading to the incorrect 
reporting of one or more statistically significant effects (Senn & Bretz, 2007; Turk et 
al., 2008; Wittes, 2012). This is known as multiplicity. Statistical strategies to address 
multiplicity include the use of Bonferroni-corrected alpha or significance level (Hung 
et al., 2007; Turk et al., 2008; Wittes, 2012) to reduce the overall chance of a Type I 
error (Walker & Almond, 2010). However, in some circumstances, adjusting the value 
of alpha may lead to an increase in the Type II error (rejecting the statistical null 
hypothesis when it is true) (Turk et al., 2008; Wittes, 2012).  The IMPACT group 
recommended that, for additional outcome measures, providing supportive or 
exploratory information are given, adjustment for multiplicity was unnecessary (Turk 
et al., 2008). Therefore, adjustment for multiplicity was not included in this trial.  
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5.21 Summary of design and methods used in the clinical trial 
The methods selected for the main trial were based on a critical consideration of the 
methods used in previous studies, information from audits (to inform recruitment) and 
the preliminary study (to establish feasibility of trial design and methods). Choice of 
methods for the data analyses was based on relevant articles in the research 
literature and information in research texts. The aim was to further the understanding 
of whether manual therapy (in the form of the lateral glide) could benefit patients with 
cervicobrachial pain.  
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6 RESULTS FROM THE RANDOMISED CONTROLLED 
TRIAL 
6.1 Introduction to results 
A randomised controlled trial was conducted according to the design and methods 
described in Chapter 5. The aim of the trial was to investigate whether the lateral 
glide mobilisation was effective in the management of cervicobrachial pain.  This 
chapter will present the results, in line with relevant sections of the Consolidated 
Standards of Reporting Trials (CONSORT) statement (Schulz et al, 2010). 
6.2 Participant flow 
All data were obtained from one of the trial sites (Section 6.3 discusses why data 
from only one site were included). Assessment Physiotherapists identified a total of 
286 patients with cervicobrachial pain who were suitable for physiotherapy.  Of these, 
174 were ineligible to participate due to co-existing upper limb pathology (n=57), 
being older than 65 years of age (n=22) and other reasons (n=66) such as 
involvement in litigation, the presence of bilateral symptoms or presence of red flags 
(Figure 6-1).  Some participants had multiple reasons for ineligibility (n=29).  
Eligible participants (n=112) were invited to attend the first appointment with a Trial 
Physiotherapist (Section 5.4.2). Thirteen patients decided not to participate in the 
trial; 99 gave informed consent and were randomised to receive lateral glide 
mobilisation and self-management (n=49; Mobilisation group) or self-management 
alone (n=50; Comparator group). The randomisation procedure resulted in a balance 
of numbers across groups (Figure 6-1).  One participant in the Mobilisation group 
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withdrew after starting treatment due to dissatisfaction with the intervention because 
he did not believe that he was actually receiving treatment.   
Ninety two percent (n=46) of participants in the Comparator group and 86% (n=42) in 
the Mobilisation group completed assessments at the primary end point (52 weeks) 
(Figure 6-1). Completion numbers exceeded the minimum number required for the 
primary analysis i.e. 34 per group (Section 5.19).  Loss to follow-up was below the 
reported acceptable level of 20% at each time point (Sackett et al., 2000; Schulz & 
Grimes, 2002c) (Figure 6-1).   
Six participants who attended the 6 week follow-up (n=2 Comparator group; n=4 
Mobilisation group), and 2 participants who attended at the 52 week follow-up (n=2 
Mobilisation group) did not complete VAS pain scores, which could have been due to 
positioning of the VAS scales in  the questionnaire (on the reverse side of the front 
page). Overall, there was a balanced level of attrition across groups for the primary 
outcome measure at 6 (n=8 Comparator group; n= 6 Mobilisation group) and 52 
week follow-up (n=4 Comparator group; n=7 Mobilisation group), thus, imputation 
tests for missing data were not conducted later in the analysis (Section 5.20.4). 
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Randomised and registered into the trial (n=99) 
E
n
ro
lm
e
n
t 
A
ll
o
c
a
ti
o
n
 
Allocated to self-management  
(Comparator) 
(n=50) 
Did not receive allocated treatment (n=0) 
Withdrew from trial (n=0) 
 
Received allocated intervention (n=50) 
 
 
Loss to follow-up at 6 weeks 
n=6 (12%) 
Analysis for primary outcome at 6 weeks 
 (n=42; 84%) 
 
Analysis for primary outcome at 26 weeks 
(n=46; 92%) 
 
Analysis for primary outcome at 52 weeks 
 (n=46; 92%) 
 
F
o
ll
o
w
-u
p
 
A
n
a
ly
s
is
 
Excluded (n=187) 
   Ineligible (n=174) 
Upper limb pathology (n=57);  
multiple reasons (n=29); age (n=22); 
litigation (n=14); bilateral symptoms 
(n=13); red flags (n=12); duration (n=8); 
language (n=5); compliance (n=5); 
thoracic outlet (n=4); systemic condition 
(n=2);planned other treatment (n=2); 
cervical surgery (n=1) 
 
   Eligible, but not recruited (n=13)  
 No explanation (n=3); 
 wanted other physiotherapy (n=3) 
wanted manual therapy (n=2);  
 Already better (n=1); did not attend  
(n=1); family advised against  
involvement (n=1); booked in with wrong 
physiotherapist (n=1); 
unable to commit to follow-up (n=1) 
 
 
 
Individuals assessed for eligibility (n=286) 
Allocated to lateral glide and self-
management (Mobilisation) 
(n=49) 
Did not receive allocated treatment and 
withdrew from trial (n=1) 
 
Received allocated intervention (n=48) 
 
 
 
Loss to follow-up at 6 weeks 
n=2 (4%) 
Loss to follow-up at 26weeks 
n=4 (8%) 
Loss to follow-up at 26 weeks 
n=10 (20%) 
Loss to follow-up at 52 weeks 
n=4 (8%) 
Loss to follow-up at 52 weeks 
n=5 (10%) 
Analysis for primary outcome at 6 weeks 
 (n=43; 88%)  
 
Analysis for primary outcome at 26 weeks 
(n=39; 80%) 
  
Analysis for primary outcome at 52 weeks 
 (n=42; 86%) 
  
Figure 6-1: Participant flowchart of the trial (Adapted from Moher et al., 2010) 
Footnote:  For each Group, at each endpoint, the number of participants who were eligible for 
inclusion in analysis of the primary outcome measure= the number of participants in that Group 
less the number who were lost to follow-up and/or did not complete VAS(worst pain) at that 
endpoint. 
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6.3 Recruitment 
Participants were recruited from 7th July 2009 to 30th August 2011.   Initially, four 
centres were included as part of the trial: two community primary care centres in 
Birmingham, one acute general hospital in the West Midlands and one orthopaedic 
centre in Bristol. However, neither community centre recruited any participants during 
the first year of the trial.  Whilst a combination of events contributed to this, the major 
reason was changes to the musculoskeletal service at each centre that resulted in a 
noticeable negative effect on staff morale and resignation of several staff, including 
those who had been trained to participate in the research trial.  Additional staffing 
and service pressures prohibited commitment from the local collaborator at one of 
the centres and the research co-ordinator at the other went on maternity leave. 
Consequently, it became unfeasible to run the trial at these sites and participation of 
the two community centres was discontinued one year into the trial. 
There were also difficulties at the orthopaedic centre, with only three participants 
being recruited over one year.  The local collaborator attributed the low recruitment 
(two participants in the first four months) to a period of annual leave affecting many of 
the staff involved with the trial.  When recruitment did not improve (over the next two 
months), the Principal Investigator arranged a meeting with the local collaborator and 
research co-ordinator.  The key issue was that potential participants were not being 
seen by Assessment Physiotherapists, so, were not being identified for the trial.  
Although a number of strategies were put in place to address this, further issues 
prevailed, including maternity leave of clinical staff, sickness absence and role 
change of clinical staff involved in the trial.  Given these difficulties, the local 
collaborator felt unable to continue overseeing the project and, therefore, 
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participation of the orthopaedic centre was discontinued.  Data from the three 
participants recruited from this site were excluded from the data analysis, since it has 
been reported that recruitment imbalance across sites may lead to loss of study 
power (Senn, 1998; Lin, 1999).  Although statistical models have been developed to 
address imbalance in multi-centre studies (Ruvuna, 1994; Vierron & Giraudeau, 
2009), when extreme imbalance exists (as in this trial) excluding participants has 
been advocated as a more practical option (Pickering & Weatherall, 2007).  
Ninety nine participants were recruited over a period of 25 months from the acute 
general hospital in the West Midlands. Average rate of recruitment increased over 
the duration of the trial (Figure 6-2) 
 
Figure 6-2: Recruitment from the West Midlands site over the course of the trial  
 
The increase was achieved through the following actions by the Principal 
Investigator: a) advertising the trial to local general practitioners in March 2010, 
resulting in an increased number of GP referrals for patients with cervicobrachial pain 
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to the physiotherapy department; b) informing orthopaedic consultants at the Trust, in 
July 2010, about the trial during a verbal presentation on physiotherapy 
developments within the Trust, resulting in a substantial rise to the number of 
participants referred by the orthopaedic team in July 2010. 
6.4 Characteristics of Trial Physiotherapists 
Five physiotherapists delivered the intervention.  They had been qualified at least 2 
years, with between 1 and 4 years’ experience in musculoskeletal physiotherapy; one 
had never used the lateral glide and 4 had sometimes used it (Table 6-1). The 
majority of Trial Physiotherapists did not have a preference at the start of the trial, but 
developed a preference in favour of the lateral glide by the end (Table 6-1).   
Table 6-1: Characteristics of Trial Physiotherapists (n=5) 
 
Trial Physiotherapists 
Time Characteristic 
 
n(%) 
Start of trial Number of years qualified:  
   2 - 3 
   4 - 5 
   >5  
 
3 (60) 
1 (20) 
1 (20) 
 Number of years in MSk PT:  
  1 -2  
  3 -4 
  >4 
 
3 (60) 
1 (20) 
1 (20) 
 Familiarity of lateral glide:  
  Never used 
  Sometimes used 
  Frequently used 
 
1 (20) 
4 (80) 
0 (0) 
 Preference to mgt: 
  Self-mgt with mobilisation 
  Self-mgt 
  No preference  
 
1 (20) 
0 (0) 
4 (80) 
End of trial Preference to mgt  
  Self-mgt with mobilisation 
  Self-mgt 
  No preference 
 
4 (80) 
0 (0) 
1 (20) 
Key:  mgt= management; MSk PT=musculoskeletal physiotherapy; n= number of Trial  
                     Physiotherapists 
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6.5 Variability in participant follow-up  
6.5.1 Follow-up time point 
Deviations from the planned follow-up time points of 6, 26 and 52 weeks post the 
commencement of intervention (Table 6-2) were due to reasons such as holidays, 
sickness and work commitments. Such reasons were expected in a pragmatic clinical 
trial (Gueorguieva & Krystal, 2004; Kwok et al., 2008). It was recognised that this 
could have had a confounding effect for analyses using ANCOVA, but were 
addressed by using the MLM analyses.  
Table 6-2: Participant follow-up times (in weeks) 
 
Intervention 
 
Planned 
follow-up 
points  
 
Comparator (n=50) 
  
Mobilisation(n=49) 
 Mean (SD) Min
n
, Max
m
 Missing  Mean (SD) Min
n
, Max
m
 Missing 
 
6 weeks 
  
 
7 (2) 
 
4,16 
 
8 
  
6 (2) 
 
4, 12 
 
6 
26 weeks 27 (3) 22,37 4  27 (4) 23,40 10 
 
52 weeks 
 
55 (5) 
 
47,70 
 
4 
  
53 (9) 
 
48,107 
 
7 
 
Key Max
m 
=maximum data point; Min
m 
=minimum data point; n= number of participants;  
       SD= standard deviation  
 
6.5.2 Variability in method of follow-up 
Different methods for data collection were used for some of the outcome measures at 
52 weeks (final outcome time point). Most participants (n= 78; 88%) completed the 
standard questionnaire at final outcome time point. Eleven participants (12%), who 
did not attend the 52 week review appointment, completed a shortened version of the 
171 
questionnaire via the postal system.  The postal questionnaire was used by 9(10%) 
and 2(2%) of the Comparator and Mobilisation groups, respectively.   
6.6 Baseline data of participants 
No statistical tests were conducted on baseline differences as identifying whether a 
variable was statistically different or not, was not the method for selecting 
confounders for the main analyses (Section 5.20.1). However, an appreciation of 
between-group characteristics was included to provide information to support 
arguments when interpreting the results.  
Baseline demographic data (Table 6-3) indicated that participants in the two groups 
had similar characteristics.  The mean age of participants was 47 years, in each 
group.  There were slightly fewer female participants in the Comparator group (n=24; 
47%), compared with the Mobilisation group (n=27; 53%). 
The range of occupations was similar across groups.  More participants in the 
Mobilisation group (n=10) had an extended time off work (>16 days) compared to the 
Comparator group (n=3). Thirty-five participants in the trial smoked.  The majority of 
smokers were male (n=20). Thirty per cent (n=15) in the Mobilisation group smoked 
compared with 40% (n=20) in the Comparator group.   
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Table 6-3: Demographic characteristics for randomised participants, at 
baseline (n=99) 
 
Intervention 
 
Variables  
 
Comparator (n=50) 
 
  
Mobilisation(n=49) 
 Mean (SD) Min
n
, Max
m
 Missing  Mean 
(SD) 
Min
n
, Max
m
 Missing 
Age(years) 
  
47 (11) 18,64 0  47 (11) 21,65 0 
 n(%)   n(%)  
Gender 
 Females 
  
 
24(47) 
 
 
0 
  
27(53) 
 
 
0 
Occupation 
 Retired 
 Unemployed 
 Desk worker 
 Manual work 
 Other  
 
3(6) 
3(6) 
14(28) 
20(40) 
9(18) 
 
 
1 
  
4(8) 
3(6) 
10(20) 
22(45) 
10(20) 
 
0 
Sickness 
(days) 
 None 
 1 - 5 
 6 -10 
 11 -15 
 >16 
 Not 
applicable 
  
  
 
 
35 
1 
2 
2 
3 
7 
 
0 
 
  
 
35 
0 
1 
0 
10 
3 
 
0 
Smoker 
Yes 
20(40) 0  15(30) 2 
Key:  Max
m 
=maximum data point; Min
m 
=minimum data point; n= number of participants;  
       SD= standard deviation  
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Baseline clinical characteristics were similar across groups, with no clinically 
meaningful differences (Table 6-4). The majority of participants (78% Comparator 
group; 73% Mobilisation group) were mechanically neutrally sensitised (positive 
ULNE), had symptoms in a C5/6 distribution (44% Comparator group; 59% 
Mobilisation group), had pain with sensory dysfunction (55% Comparator group; 56% 
Mobilisation group) and had symptoms for greater than one year (42% Comparator 
group; 40% Mobilisation group).  The majority of participants were right arm 
dominant; however, there was no apparent relationship between arm dominance and 
side affected by cervicobrachial pain.   
  More participants in the Mobilisation group had received physiotherapy for their 
cervicobrachial pain in the past.  Benefit from previous physiotherapy was less in the 
Mobilisation group (47%) compared to the Comparator group (92%); however past 
physiotherapy experience did not affect preference for intervention-type.  
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Table 6-4:  Clinical characteristics for randomised participants, at baseline 
(n=99)  
 Intervention 
 
Comparator (n=50) 
 
Mobilisation (n=49) 
 
Variables Mean (SD) Min
n
, Max
m
 Missing  Mean (SD) Min
n
, Max
m
 Missing 
VAS(worst pain) 
 
65(20) 3, 96 0  63 (22) 0, 97 0 
SF-36 
 
65(17) 18, 87 0  60 (18) 22, 91 0 
VAS(average pain) 
 
48(19) 2, 89 0  47 (20) 0, 89 0 
NULI 30(17) 7,78 0  36 (19) 0,88 0 
TAMPA 
 
37(6) 24, 49 0  37(7) 23, 60 1 
S-LANSS 
 
11(5) 0, 24 3  11(5) 3, 24 4 
 n (%)  n (%) 
 
Chronicity 
(months) 
2 - 3 
 
5(10) 
 
0 
  
6(12) 
 
0 
 >3 - 6 10(20) 11(22) 
 >6 - 12 14(28) 13(25) 
 >12 21(42) 19(40) 
ULNE test  Positive 39 (78) 0  36(73) 0 
WAD Yes 
 
6 (12) 
 
0 
 
 
 
5 (10) 
 
 
1 
Dominant arm 
 
Right 45 (92) 1  47 (96) 0 
Side involved 
    
Right 
 
27 (54) 
 
0 
  
28 (57) 
 
0 
Distribution  
 
C4/5   
 
22(18) 
 
0 
  
11(22) 
 
0 
 C5/6 9(44) 29(59) 
 C6/7 14(28) 5(10) 
 C7T1 5(10) 4(8) 
Dysfunction    Pain only 9(18) 1 
 
11(23) 1 
Pain & sensory change 27(55) 27(56) 
Pain, sensory & motor change 13(27) 10(8) 
Preference 
  
None 
To control 
To lateral glide 
 
36 (72) 
2 (4) 
12 (24) 
 
0 
  
36 (74) 
2 (4) 
11 (22) 
 
0 
Previous 
physiotherapy 
 Yes 14 (29) 
 
1 
 
19 (39) 
 
0 
Benefit from 
previous 
physiotherapy 
 Yes 12 (92) 
 
1 
 
9 (47) 
 
0 
Key: NULI= Neck and Upper Limb Index; n= number of participants; SF-36= Short-from 36; S-
LANSS= Self Leeds Assessment of Neuropathic Signs and Symptoms; SD= standard deviation; 
TAMPA= Tampa scale of kinesiophobia; ULNE= Upper Limb Nerve Extensibility; VAS= Visual 
Analogue Scale; WAD= Whiplash associated disorder 
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6.6.1 Baseline characteristics of responders versus non-responders 
Important trial variables at baseline were analysed for participants who completed the 
VAS(worst pain) outome (i.e. responders) and those who did not complete the 
VAS(worst pain) outcome (i.e. non-responders) at the primary end point (52 week 
follow-up).  Table 6-5 shows that no statistically significant differences were found on 
age, VAS(worst pain) and SF36. More male participants responded in the 
Comparator group compared to the Mobilisation group, but, the same trend was not 
seen for females. Increased levels of chronicity led to an increase in response rate in 
the Comparator group, however this did not seem to affect response rate in the 
Mobilisation group.  
Table 6-5:  Potential baseline confounding variables for responders and non-
responders, by intervention group, on key variables at 52 week follow-up  
 Non-responders  Responders  
Variable Comparator 
Mean (SD) 
Mobilisation 
Mean (SD) 
 Comparator 
Mean (SD) 
Mobilisation 
Mean(SD) 
 
P value  
Age 52(10) 41(7)  47(11) 49(11) 0.33 
VAS(worst 
pain)  
71(6) 68(33)  65(20) 63(22) 0.41 
SF36  68(4) 53(22)  65(17) 59(18) 0.37 
 n(%) n(%)  n(%) n(%)  
Gender  
Female 
Male 
 
2(4) 
1(2) 
 
3(6) 
4(8) 
  
22(43) 
25(52) 
 
24(47) 
18(38) 
NA 
Chronicity 
(months) 
2 - 3 
>3 - 6 
>6 - 12 
>12 
2(18) 
0(0) 
1(4) 
0(0) 
 
 
1(9) 
2(10) 
1(4) 
3(8) 
  
 
3(27) 
10(47) 
13(50) 
21(53) 
 
 
5(46) 
9(43) 
12(42) 
16(40) 
NA 
Key: n = number of participants; SD= standard deviation; NA= not applicable 
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Footnote: p= probability from Independent sample t-test between responders to non-responders;       
Responder= participants who responded to 52 week follow-up on VAS(worst pain);  
Non-responder= participants who did not respond to 52 week follow-up on VAS(worst pain). 
6.7 Protocol violations at each follow-up  
6.7.1 Protocol violations at six-week follow-up 
In this trial, all participants received their randomised intervention. There was one 
protocol violation during the intervention period (defined as the period up to the six 
week follow-up).  A participant in the Mobilisation group received additional treatment 
(acupuncture).  This participant later withdrew and did not attend any follow-up 
period.    
6.7.2 Protocol violations beyond six week follow-up 
Forty-seven participants (47%) received additional treatment following the 
intervention period (Table 6 6).  Although this was a seemingly high level of 
additional treatment, there was no statistically significant inter-group difference (for 
responders at one year) on the use of additional treatment between the end of the 
intervention period and one year follow-up (p= 0.93).   
Table 6-6: Treatment received beyond the intervention period (6 weeks to one year) 
 Intervention 
 
  
 
 
Additional Treatment 
Comparator 
 
n (%) 
Mobilisation 
 
n (%) 
Total p value 
None  
 
15 (30) 13 (27) 28  
Some 
 
23 (46) 24 (49) 47  
Unknown 
 
12 (24) 12 (24) 24  
Total 50 49 99 p=0.93 
 
Key: n = number of participants; p= probability from Chi-Square test 
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Most additional treatment included other forms of physiotherapy intervention, including acupuncture.  
None of the participants went on to receive any injection therapy.  Two participants went on to receive 
surgery to the cervical spine; both were in the Mobilisation group. 
6.8 Primary outcome measure - VAS(worst pain)  
Scores on VAS(worst pain) varied from 0 to 97mm in the Comparator group and  0 to 
100mm in the Mobilisation group (Table 6-7, Figure 6-3).   Mean scores ranged from 
65 (baseline) to 37 (52 week follow-up) in the Comparator group and 63 (baseline) to 
40 (26 weeks) in the Mobilisation group.  
Table 6-7: Summary statistics for VAS(worst pain) at each time point 
 
Key: max
m 
=maximum value; min
m 
=minimum value; n= number of participants; SD=standard 
deviation; Q1=lower quartile; Q3=upper quartile 
 
6.8.1 Primary analysis (long-term effects) 
There was a mean decrease of 28mm for the Comparator group and 21mm for the 
Mobilisation group for VAS(worst pain) at 52 week follow-up compared to baseline 
(Table 6-7).  This indicated that there was a clinically meaningful improvement, on 
average, for participants in both groups.  
 Intervention 
 Comparator Mobilisation 
Time point: n (%) 
Mean 
(SD) 
Median 
(Q1,Q3) 
min
m
, 
max
m
 
 n (%) Mean (SD) 
Median 
(Q1,Q3) 
min
m
, 
max
m
 
Baseline 
 
50(100) 65(20) 70(50,78) 3,96  49(100) 63(22) 71(46,78) 0,97 
6 week follow-
up 
 
42(84) 46(28) 44(22,72) 1,94  43(88) 49(29) 54(27,73) 0,100 
26 week follow-
up 
 
46(92) 40(31) 38(10,71) 0,93  39(80) 40(28) 40(12,66) 0,84 
52 week follow-
up 
46(92) 37(32) 29(6,6) 0,97  42(86) 42(30) 44(8,97) 0,94 
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There was no statistically significant difference in mean scores on VAS(worst pain) 
between groups at follow-up 52 weeks, using a covariate analysis  (p=0.37; 95% CI -
17.76 to 6.61) (Table 6-8). 
Table 6-8:  VAS(worst pain) at 52 weeks (n=88) using ANCOVA  
  95% CI 
p-value 
 Mean difference 
between baseline 
and 52 weeks 
Lower 
bound 
Upper 
bound 
 
Between  intervention 
difference  
 
 
-5.57 
 
-17.76 
 
6.61 
 
0.365 
Covariates 
 
 Age (years) 
 
 Gender 
 
 VAS(worst pain) at  baseline 
 
 SF36 at baseline 
 
 Chronicity a baseline 
 
 
 
 
-0.30 
 
8.95 
 
-0.51 
 
-0.39 
 
4.28 
 
 
-0.86 
 
-2.99 
 
-0.82 
 
-0.75 
 
-1.90 
 
 
0.25 
 
20.90 
 
-0.20 
 
-0.28 
 
10.46 
 
 
0.281 
 
0.139 
 
0.002* 
 
0.035* 
 
0.172 
Key: CI= confidence interval; n= number of participants; SF-36= Short-from 36 
   
Footnote:  Differences in mean VAS(worst pain) computed as follow-up minus baseline 
    * indicates a statistically significant finding at 0.05 
                  Levene’s test for homogeneity p=0.78, therefore heterogeneity did not violate the test 
 
 
6.8.2 Secondary analysis (short-term effects, 6 week follow-up) 
There was a mean decrease of 19mm for the Comparator group and 14mm for the 
Mobilisation group for VAS(worst pain) at 6 week follow-up compared to baseline 
(Table 6-7).  This indicated that there was no clinically meaningful improvement, for 
participants in either group.  
There was no statistically significant difference in mean scores on VAS(worst pain)  
between groups at follow-up 6 weeks, using a covariate analysis (p=0.52; 95% CI -
14.72 to 7.44) (Table 6-9). 
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Table 6-9: ANCOVA analysis for VAS(worst pain) at 6 weeks (n=85) 
 
  
Mean  
difference between 
baseline and 6 weeks 
95% CI  
 Lower bound Upper 
bound 
 
p-value 
 
Between intervention  
Difference (at baseline) 
-3.64 -14.72 7.44 0.515 
Covariates 
 
 Age (years) 
 
 Gender 
 
 VAS(worst pain)  
   
 SF36  
 
 Chronicity 
 
 
 
 
0.13 
 
2.35 
 
0.66 
 
-0.07 
 
6.53 
 
 
 
 
-0.42 
 
-8.68 
 
0.37 
 
-0.41 
 
0.97 
 
 
0.67 
 
13.38 
 
0.95 
 
0.26 
 
12.09 
 
 
0.640 
 
0.673 
 
0.000* 
 
0.663 
 
0.022* 
Key: CI= confidence interval; n= number of participants; SF-36= Short-from 36   
 
Footnote:  Differences in mean VAS(worst pain) computed as follow-up minus baseline 
     * indicates a statistically significant finding 
                  Levene’s test for homogeneity p=0.79, therefore heterogeneity did not violate the test 
6.8.3 Tertiary analysis (longitudinal effects) 
Using MLM (Section 5.20.4), there was a statistically significant decrease in 
VAS(worst pain) over time (p=0.001) (Figure 6-7).  After accounting for time and 
statistically significant baseline covariates (SF36 p=0.0005; age p= 0.049) there was 
no statistically significant difference in mean VAS(worst pain) scores (p=0.808;        
95% CI -6.81 to 8.73) between the Comparator and Mobilisation groups over time  
(Figure 6-7). Details of this analysis are given in Appendix O. 
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Figure 6-3 Boxplots for VAS(worst pain) 
over  time 
 
                    
Figure 6-4 Boxplots for VAS(average 
pain)  over time 
 
                  
  
 
Figure 6-5 Boxplots for NULI over time 
 
 
Figure 6-6 Boxplots for SF36 over time 
 
 
                                             ◦ represents an outlier value. 
Key for figures 6-3 to 6-6: 
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Figure 6-7 Longitudinal VAS(worst pain) 
(MLM) 
 
Figure 6-8 Longitudinal VAS(average 
pain)  (MLM) 
 
  
Figure 6-9 Longitudinal NULI (MLM) 
 
Figure 6-10 Longitudinal SF36 (MCS) 
(MLM) 
 
Key for Figures 6-7 to 6-10:       Comparator group 
                                                     Mobilisation group 
                                                CI= Confidence Interval 
Footnote:  A reduction in scores on VAS and NULI represent an improvement.  
                 Increases in scores on SF36 (MCS) represent an improvement. 
The 95% CI’s are for individual interventions and not the difference between interventions 
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6.9 Secondary outcome measures for pain 
The secondary outcome measures on pain were ‘average pain over the past week’ 
(VAS(average pain)), Global rating of change (GROC) and use of medication (meds) 
6.9.1 VAS(average pain)  
VAS(average pain) varied from 0 to 93 in the Comparator group and 0 to 94 in the 
Mobilisation group (Table 6-10, Figure 6-4).  Mean scores ranged from 48 (baseline) 
to 28 (52 week follow-up) in the Comparator group and 48 (baseline) to 30 (26 
weeks) in the Mobilisation group. There was a mean decrease of 20mm for the 
Comparator group and 15 for the Mobilisation group at 52 week follow-up compared 
to baseline (Table 6-10). This indicated that there was a clinically meaningful 
improvement for the Comparator group only.  The mean between-group difference 
from baseline to 52 week follow-up was 5mm, which was not a clinically meaningful 
difference. 
Using MLM, there was a statistically significant decrease in VAS(average pain)  over 
time across both groups at six weeks (p=0.001) and 26 weeks (p=0.03), but not at 
one year (p=0.08) (Figure 6-8).  After accounting for time and statistically significant 
baseline covariates (SF36 p<=0.005; age p=0.04), there was no statistically 
significant difference in mean VAS(average pain) scores (p=0.867; 95% CI -5.91 to 
7.00) between the Comparator and Mobilisation groups  (Figure 6-8).  
.  
 
 Table 6-10: Summary statistics for secondary outcome measures for pain at each time point 
 Intervention 
 
 Comparator 
 
Mobilisation 
Time point: 
n (%) Mean 
(SD) 
Median 
(Q1,Q3) 
min
m
, 
max
m
 
 n (%) Mean 
(SD) 
Median 
(Q1,Q3) 
min
m
, max
m
 
VAS(average pain)          
Baseline 
 
50(100) 48(20) 48(31,63) 2,89  49(100) 48(21) 51(30,60) 0,89 
6 week follow-up 
 
42(84) 36(23) 32(19,57) 2,93  44(90) 40(26) 39(16,61) 0,90 
26 week follow-up 
 
46(92) 29(24) 24(6,50) 1,81  39(80) 30(23) 28(6,48) 0,75 
52 week follow-up 35(70) 28(24) 22(8,50) 0,84  52(86) 33(27) 32(8,55) 0,94 
GROC          
6 week follow-up 43(86) 2(2) 3(1,4) -5,6  44(90) 2(3) 2(0,4) -4,6 
 
 
  
n (%) 
   
n (%) 
Use of medication  
(at 6 week follow-up)   
     
41(82)  
 
 44(90)  
 
     No meds  14(28)   12(25) 
     Weaker meds  2(4)   6(12) 
     Same meds  23(46)   21(43) 
    Stronger meds or started to 
take meds  
 2(4)   5(10) 
Key: max
m 
=maximum value; meds= medication; min
m 
=minimum value; n= number of participants; SD=standard deviation; Q1=lower quartile; 
Q3=upper quartile
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6.9.2 Global rating of change score 
GROC scores varied from -5 to 6 in the Comparator group and -4 to 6 in the 
Mobilisation group at 6 week follow-up, meaning that the range for a perceived 
worsening was greater in the Comparator group by one point (Table 6-10, Figure 6-
11).  Mean scores were 2 across groups indicating that, on average, both groups had 
achieved a clinically meaningful improvement (Table 6-10).   
 
 
Figure 6-11: GROC scores at 6 week follow-up (perceived changes in pain from 
baseline) 
Footnote:  interpretation for GROC scores.  –ve signs indicates worsening of pain, +ve signs indicates 
lessening of pain 
0 no change 
    2 minimal clinically meaningful difference 
   3 moderate clinically meaningful difference 
   4 large clinically meaningful difference 
   5 very large clinically meaningful difference 
Perceived higher pain Perceived lower pain 
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There was a moderate association (Spearmans rho = 0.69; p<0.001) between GROC 
and VAS(worst pain) at six weeks (Figure 6-12). No participant was clinically worse 
on both outcome measures (VAS(worst pain) score > or equal to 20 and GROC 
score < or equal to  2; Figure 6-12, box B).  Twenty-seven of the participants were 
clinically improved on both outcome measures (box A), 13 of which were in the 
Mobilisation group. 
 
 
  
Figure 6-12: VAS(worst) difference in pain score (from 6-week follow-up to 
baseline) compared with GROC at six weeks follow-up 
Key: GROC=Global Rating of Change score; VAS=Visual Analogue Scale 
Footnote:  Red dotted line represents clinically meaningful difference on VAS 
     Black dotted line represents clinically meaningful difference on GROC 
     Box A indicates a clinically meaningful improvement on both GROC and VAS 
                 Box B indicates a clinically meaningful worsening on both GROC and VAS 
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6.9.3 Use of medication 
Approximately half the participants (n=44; 52%) were using the same medications at 
six week follow up as at baseline (Table 6-10).  There was no statistically significant 
between-group difference on medication use at 6 week follow-up (Mann-Whitney Z 
score  = -0.49; p=0.63).  
6.10 Secondary outcome measures - function & disability 
The Neck and Upper Limb Index (NULI) scores varied from 0 to 83 in the Comparator 
group and 0 to 95 in the Mobilisation group (Table 6-11, Figure 6-5).  Mean scores 
ranged from 30 (baseline) to 19 (26 and 52 week follow-ups) in the Comparator 
group and 36 (baseline) to 26 (26 and 52 weeks) in the Mobilisation group.  There 
was a mean decrease of 11 points for the Comparator group and 10 points for the 
mobilisation group on NULI at 26 week follow-up compared to baseline.  This 
improvement was maintained in both groups at 52 weeks (Table 6-11). 
 
 
 
 
 
  
Table 6-11: Summary statistics for secondary outcome measures for function and disability at each time point 
 
Intervention 
 
Comparator Mobilisation 
Time point: 
n (%) Mean 
(SD) 
Median 
(Q1,Q3) 
min
m
, 
max
m
 
 n (%) Mean 
(SD) 
Median 
(Q1,Q3) 
min
m
, 
max
m
 
NULI          
Baseline 
 
50(100) 30(17) 23(17,45) 7,78  49(100) 36(19) 36(19,51) 0,88 
6 week follow-up 
 
44(88) 24(15) 20(11,37) 2,64  45(92) 30(22) 28(10,44) 0,95 
26 week follow-up 
 
46(92) 19(17) 14(6,30) 0,83  39(80) 26(20) 23(7,42) 1,76 
52 week follow-up 36(72) 19(17) 12(6,32) 0,53  42(86) 26(20) 19(9,40) 0,69 
SF36          
Baseline 
 
50(100) 65(17) 67(56,80) 18,87  49(100) 59(18) 58(45,76) 22,92 
6 week follow-up 44(88) 66(18) 68(53,80) 21,95  44(90) 62(18) 63(49,77) 13,95 
26 week follow-up 
 
46(92) 72(15) 77(63,86) 36,93  39(80) 64(20) 71(43,80) 21,95 
52 week follow-up 
 
36(72) 70(16) 78(55,83) 37,97  42(86) 64(19) 70(47,79) 22,92 
 
Key: max
m 
=maximum value; min
m 
=minimum value; NULI= Neck and Upper Limb Index; n= number of participants; Q1=lower quartile; Q3=upper 
quartile, SD=standard deviation; SF36 (MCS) = Short-form 36 (Mental Component Summary); Tampa= Tampa scale of kinesiophobia. 
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Using MLM, there was a statistically significant decrease in NULI over time at six 
weeks (p=0.001) and 26 weeks (p=0.01), but not at one year (p=0.19) (Figure 6-9).  
After accounting for time and statistically significant baseline covariates (gender 
p=0.04; chronicity p=0.04), there was a statistically significant difference in mean 
NULI scores (p=0.03; 95% CI -13.53 to -0.92) between the Comparator and 
Mobilisation groups, favouring the effectiveness of the Comparative intervention 
(Table 6-12, Figure 6-9). 
 
The SF36 (MCS) scores varied from 18 to 97 points in the Comparator group and 13 
to 95 in the Mobilisation group (Table 6-11, Figure 6-6).  Mean scores ranged from 
65 (baseline) to 72 (26 week follow-up) in the Comparator group and 59 (baseline) to 
64 (26 and 52 weeks) in the Mobilisation group (Table 6-11, Figure 6-6).  There was 
a mean increase of 5 points in both groups at 52 week follow-up.   
 
Using MLM, there was no statistically significant decrease in SF36 (MCS) over time 
at any of the follow-up periods (p>0.05).  After accounting for time and statistically 
significant baseline covariates (gender p=0.01; chronicity p=0.00), there was no 
statistically significant difference in mean SF36(MCS) scores (p=0.07;95% CI -0.37 to 
12.07) between the Comparator and Mobilisation groups  (Table 6-12, Figure 6-10).  
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Table 6-12: Participant based outcome measures: MLM between-group analysis 
Outcome 
measure 
Estimate 
of effect 
95% CI 
p-value 
Lower 
bound 
Upper 
bound 
NULI 6.91 -13.53 -0.92 0.03* 
SF36 (MCS) 
 
5.85 -0.37 12.07 0.07 
 
 
6.10.1 Cervical Active Range of Movement (AROM)   
Cervical active range of motion varied from 10 to 100 in the Comparator group and 5 
to 95 in the Mobilisation group (Table 6-13).  Mean scores varied from 35 (baseline 
right side bend) to 72 (left rotation at 52 weeks) in the Comparator group and 34 
(baseline right side bend) to 69 (left rotation at 26 weeks) in the Mobilisation group 
(Table 6-13). None of the movements had clinically meaningful difference from 
baseline (a change of 10 ) at any of the follow-up time points. 
 
Key: NULI=Neck and Upper Limb Index; SF36(MCS)=Short-form 36 (Mental Component 
Summary) 
Footnote: * indicates a statistically significant finding 
 
 Table 6-13: Summary statistics for cervical active range of motion at each time point 
 Intervention 
 Comparator  Mobilisation 
Movement n(%) Mean 
(SD) 
Median 
(Q1,Q3) 
min
m
, 
max
m
 
 n(%) Mean 
(SD) 
Median 
(Q1,Q3) 
min
m
, 
max
m
 
Flexion             Baseline 50(100) 49(15) 50 
(39,60) 
20,80  49(100) 47(13) 45 
(40,60) 
15,70 
6 wk  follow-up 44(88) 53(16) 55 
(45,64) 
10,100 45(92) 49(15) 50 
(40,55) 
15,70 
26 wk  follow-up 46(92) 57(15) 60 
(45,70) 
25,90 39(80) 49(15) 50 
(40,60) 
20,85 
52 wk follow-up 36(72) 56(14) 58 
(45,65) 
 
 
25,80 42(86) 51(16) 50 
(44,61) 
15,80 
Extension            Baseline  48(14) 45 
(35,56) 
20,85  46(15) 45 
(40,55) 
15,75 
 6 wk  follow-up  52(14) 50 
(45,60) 
20,100  49(16) 50 
(35,58) 
20,90 
 26 wk  follow-up  51(14) 50 
(45,60) 
10,90  49(15) 50 
(40,60) 
15,80 
 52 wk follow-up  50(14) 50 
(40,60) 
20,80  46(14) 45 
(36,55) 
15,70 
Right 
side bend             
Baseline  35(12) 35 
(25,45) 
10,55  34(10) 35 
(28,41) 
15,60 
 6 wk  follow-up  41(13) 40 
(35,45) 
20,85  39(12) 35 
(30,45) 
15,80 
 26 wk  follow-up  44(14) 40 
(35,50) 
15,85  38(14) 35 
(30,45) 
20,90 
 Key: max
m 
=maximum value; 
min
m 
=minimum value; n= 
number of participants; 
Q1=lower quartile; Q3=upper 
quartile, SD=standard 
deviation; wk= week. 
 
Footnote:  number and 
percentages are shown for 
flexion, but were the same 
for all movement outcome 
measures. 
 52 wk follow-up  42(11) 40 
(35,50) 
20,65  36(12) 35 
(30,45) 
5,65 
Left side 
bend             
Baseline  38(11) 35 
(30,46) 
15,60  35(11) 35 
(25,42) 
15,65 
 6 wk  follow-up  40(13) 40 
(31,45) 
10,85  37(12) 35 
(30,45) 
15,70 
 26 wk  follow-up  45(15) 40 
(34,51) 
20,90  36(14) 35 
(30,45) 
15,85 
 52 wk follow-up  42(13) 40 
(30,50) 
20,70  36(11) 35 
(29,45) 
15,65 
Right 
rotation 
Baseline  65(20) 70 
(55,85) 
20,100  58(17) 60 
(45,70) 
15,95 
 6 wk  follow-up  67(18) 70 
(60,82) 
30,95  63(20) 65 
(51,75) 
15,95 
 26 wk  follow-up  67(18) 70 
(55,80) 
20,95  61(18) 65 
(50,75) 
25,90 
 52 wk follow-up  71(16) 70 
(60,85) 
40,100  64(18) 65 
(50,80) 
30,90 
Left 
rotation           
Baseline  64(18) 69 
(50,80) 
25,95  62(17) 60 
(53,73) 
15,90 
 6 wk  follow-up  69(19) 75 
(55,85) 
30,95  64(19) 65 
(50,75) 
20,95 
 26 wk  follow-up  70(16) 70 
(60,81) 
40,95  69(14) 75 
(57,80) 
35,90 
 52 wk follow-up  72(16) 75 
(61,85) 
35,95  67(18) 65 
(55,85) 
5,90 
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Using MLM, a statistically significant increase in range over time was found at 6 week 
follow-up for flexion, extension and left rotation.  After accounting for time and 
statistically significant baseline covariates for right rotation (age p= 0.02; gender 
p=0.00; side involved p=0.00), left rotation (gender p=0.00), right side bend (duration 
p=0.00), left side bend (age p=0.00) and flexion (gender p= 0.04), there were mixed 
results.  Output from statistical tests indicated no statistically significant findings for 
most movements measured (p<0.05).  Statistically significant results were found for 
left rotation (p=0.04; 95% CI -11.55 to -0.23) and left side bend (p=0.03; 95% CI 0.58 
to 8.49) (Table 6-14, Figures 6-13 and 6-14) 
Table 6-14  Performance based outcome measures:  MLM Between-group 
analyses 
 
Movement Estimate of 
effect 
p-value 95% CI 
Lower bound Upper bound 
Flexion 
 
4 0.11 -0.92 8.93 
Extension 
 
3 0.28 -2.09 7.12 
Right rotation 
 
5 0.12 -1.19 10.62 
Left rotation 
 
6 0.04* -11.55 -0.23 
Right side bend 
 
3 0.06 -1.15 6.92 
Left side bend 
 
5 0.03* 0.58 8.49 
Footnote: * indicates a statistically significant finding 
       Covariates included age, gender and side affected by pain 
  
  
 
 
Figure 6-13 Longitudinal AROM into left rotation 
(MLM) 
Figure 6-14  Longitudinal AROM into left side bend (MLM) 
 
Key for Figures 6-13 to 6-14:     Comparator 
                                                     Mobilisation 
                                                AROM= Active range of motion; CI= Confidence Interval                                            
Footnote:  Increases in scores in AROM represent an improvement.  
                 The 95% CI’s are for each individual intervention and not the difference between interventions   
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6.11 Secondary outcome measures on cost 
6.11.1 Sickness absence 
There was a reduction in the amount of time required off work immediately following 
the intervention period (6 week follow-up) for both groups.  Summary statistics are 
shown in Table 6-15.  
Table 6-15: Time requirements from work due to cervicobrachial pain 
 
 
 
 
 
Key:  n= number of participants 
Data relating to sickness absence were analysed from 75 participants at six week 
follow-up: fewer participants were taking time off from work in the Comparator group 
compared to the Mobilisation group, but this did not reach a statistically significant 
level using a Mann-Whitney test (p=0.079).  
6.11.2 Physiotherapy utilisation 
The amount of physiotherapy intervention required by each participant was recorded 
during the intervention period.  The intervention period was defined as the period 
from baseline to the six week follow-up.  During this period the mean number of 
 
Intervention 
Time off work  
(within last month) 
 
n Comparator 
n (%) 
n Mobilisation 
n (%) 
Baseline 
 No time off 
 Time off 
 Not applicable  
 Missing 
 
50  
35(70%) 
8(16%) 
7(14%) 
0(0%) 
49  
35(71%) 
11(23%) 
3(6%) 
0(0%) 
6 week follow-up 
 No time off 
 Time off 
 Not applicable 
 Missing 
 
50  
34(68%) 
4(8%) 
6(12%) 
6(12%) 
49  
28(57%) 
9(18%) 
8(16%) 
4(9%) 
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attended sessions was more than twice as much for the mobilisation group than in 
the comparator (Table 6-16). This finding was statistically significant using the Mann-
Whitney test (p=0.000). 
Table 6-16: Attended sessions during the intervention period (first 6 weeks) 
Key:  n= number of participants; SD= standard deviation; PT= Physiotherapy 
The average 30 minute ‘unit cost’ for a physiotherapist working at the site was 
£11.75.  Based on this figure, the average cost in the intervention period was £23.50 
for a participant in the Comparator group, and £58.75 for a participant in the 
Mobilisation group.    
6.12 Secondary Outcome Measures on Harm 
Neither intervention led directly to any severe or moderate harm during the course of 
the intervention period (as defined in Table 5-2).  Minor harm was reported during the 
intervention period in the trial (Table 6-17).     
Table 6-17: Table listing minor harms per intervention type 
Self-management (n=99) Lateral glide mobilisation (n=49) 
 
Initially painful to do exercises 
(n=4) 
Ear pain when initially started 
exercises(n=1) 
 
 
 
Temporary pain following the glide, resolved next day 
(n=4) 
Temporary worsening of paraesthesia following glide for 
few hours (n=1) 
Temporary headache following glide, resolved next day 
(n=1) 
Pressure from mobilisations uncomfortable (n=1) 
Slightly dizzy on sitting up following mobilisation (n=1) 
 
Key: n= number of participants   
 
 
Control (n=50) Mobilisation (n=49) 
Quantity of PT sessions 
  Mean (SD) 
  Range 
  Missing 
 
2 (1) 
1 - 4 
2 
 
5 (1) 
1 - 8 
0 
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Minor harm was associated with 5% of self-management intervention compared to 
16% of the mobilisation intervention.  
6.13 Exploratory analyses 
6.13.1 Pain mechanism correlated with VAS(worst pain) 
Baseline S-LANNS scores were correlated with differences in VAS(worst pain) to 
evaluate if a higher neuropathic component (scores of 12 or more) correlated with a 
change in pain outcome in the short-term. No linear association was seen between 
the two measures (Figure 6-15). A two tailed analysis using Spearmans Rho found 
no statistically significant correlation (p=0.74). 
 
Key: S-LANSS= Self Leeds Assessment of Neuropathic Signs and Symptoms; VAS= Visual Analogue 
Scale  
Figure 6-15: VAS(worst pain) (6 weeks minus baseline) compared with SLANSS 
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6.13.2  VAS(worst pain) outcome for patients with positive ULNE test 
The majority of participants in the trial had a positive ULNE test at baseline (n=75; 
77%). There was a balanced number of participants with a positive ULNE in each 
intervention group (Comparator n=39; Mobilisation n=36). Sixty-two participants with 
a positive ULNE test (90%) were analysed at 6 week follow-up, with an equal split 
between the groups (Comparator n=32; Mobilisation n=30).  Analysis of covariance 
for mean between-group difference having accounted for baseline values at 6 weeks 
and covariates used in the main analysis, found  no statistically significant change in 
VAS(worst pain) for this sub-group (p=0.30; 95%.CI -19.02 to 5.94). 
6.13.3 Participant preference 
Table 6-18 summarises preferences participants had prior to randomisation who 
were assessed for VAS(worst pain) at six week follow-up.  Most participants had not 
expressed a preference.  Of those who did, the lateral glide intervention with self-
management was selected more than self-management alone.  There was an equal 
level of preference to receive the lateral glide between the two groups.  
Table 6-18: Participant preference at the start of the trial 
 
An ANCOVA for VAS(worst pain) at six weeks, that used patient preference and 
intervention as fixed factors, found no statistically significant between group 
difference (p=0.81).  There was no evidence of an effect of patient preference on 
short-term outcomes for pain response to intervention. 
 Control (n=50) Mobilisation (n=49) 
Preference for intervention 
  No preference 
  Self- management 
  Lateral glide 
  Missing 
 
30 (60%) 
2   (4%) 
10 (20%) 
8   (16%) 
 
32 (65%) 
1   (2%) 
10 (20%) 
6   (12%) 
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6.14 Summary of results 
To retain the trial hypothesis, a statistically significant between-group difference was 
needed to favour the lateral glide mobilisation in reducing pain at one year.  As 
statistical between-group differences were not found between the lateral glide 
mobilisation and comparator groups, the null hypothesis (no additional effect of 
mobilisation) was retained.  Consistent findings for other pain outcomes and across 
time points supported the likelihood that the lateral glide mobilisation, in this instance, 
did not provide additional affect on pain reduction. 
Scores from self-report measures, NULI and SF36 (MCS), were inconclusive. The 
NULI had a between-group statistically significant result, favouring the Comparator 
group.  SF36 (MCS) between-group scores also found a trend to support the 
Comparator group, but this did not reach a statistically significant level. However, it 
was recognised that these outcome measures were not powered for this trial and 
therefore needed to be interpreted with caution. There were inconsistent findings for 
functional measures relating to performance based outcome measures (AROM), 
however, most movements found no statistical between-group differences. 
There was no significant between-group difference on sickness absence from work 
due to cervicobrachial pain. However, a between-group difference was found on 
Physiotherapy utilisation, with the Mobilisation group requiring approximately double 
the amount of intervention than that of the Comparator group.  Harm associated with 
the mobilisation was also approximately double that of the comparative intervention.  
These findings do not support the addition of the lateral glide to a self-management 
intervention. 
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Further analyses were used to explore the correlation between pain states on 
outcome, or whether a selected sub-group of participants (those who were 
mechanically neutrally sensitive) had different responses to the intervention on the 
primary outcome.  In both instances, there was no evidence of any differences in the 
findings, indicating that neither participants with a neuropathic dominant pain state, 
nor participants who were neutrally mechanically sensitive were more or less 
responsive to different interventions, than in the main study cohort. 
There was some evidence that patient preference for use of the glide had no bearing 
on improved outcome.  An unexpected finding was that therapist preference 
favouring the lateral glide developed during the course of the trial.  Although the 
sample for this was small, and interpretation therefore limited, it is interesting that the 
directional preference for the therapists was converse to some of the trial outcomes.   
The next chapter will discuss and evaluate the merits and limitations of this trial 
compared to others, to enable a clear understanding for the value of the lateral glide 
in cervicobrachial pain.  
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7 DISCUSSION 
7.1 Introduction to discussion   
This chapter focuses on the findings of the systematic literature review and main trial 
to critically analyse how manual therapy, and specifically the lateral glide, contributes 
to the management of cervicobrachial pain.  The key outcome measure of pain is 
evaluated in detail. Secondary outcome measures are related to function and 
disability.  Other factors that are considered include:  risk of harm, patient values, 
patient preferences and cost (Balshem et al., 2011) to enable recommendations and 
conclusions to be drawn from this body of research.   
7.2 Summary of thesis findings 
7.2.1 Systematic literature review 
The systematic literature review evaluated the effectiveness of non-invasive 
management for cervicobrachial pain.  It identified that, in general, the provision of 
manual therapy with exercise had a low level of evidence to support its use in 
reducing pain.  There was variability in the manual therapy techniques used in the 
included studies, with the most frequently reported manual technique being the 
lateral glide mobilisation. Studies that reported the use of the lateral glide 
mobilisation consistently reported a positive effect on pain (Allison et al., 2002; 
Coppieters et al., 2003; Ragonese et al., 2009).  However, in the majority of these 
studies (Allison et al., 2002; Ragonese et al., 2009), the lateral glide was used as 
part of a manual therapy package, therefore, it was not clear how much improvement 
in pain was due to the lateral glide mobilisation, or, due to co-interventions used.   
Only one study evaluated the effectiveness of the lateral glide as a singular treatment 
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modality (Coppieters et al., 2003) and reported that the mobilisation provided a 
statistically significant decrease in pain.  There were limitations with this study: it was 
not powered, between-group differences were not reported and only immediate pain 
response was evaluated.  However, the results of the study by Coppieters et al. 
(2003) were consistent with findings from other studies in which the lateral glide 
(used in isolation) was effective in reducing pain in neck and upper limb disorders 
(Vincenzino et al., 1996, 1998; McClatchie et al., 2009; Sterling et al., 2010).  
However, as with Coppieters et al. (2003), these studies only evaluated the 
immediate effects of the technique.  A need was identified for a statistically powered 
clinical trial to evaluate whether the lateral glide was effective in reducing pain in 
either the short or long-term for patients with cervicobrachial pain.  Short-term 
assessment was to establish post-interventional effects and long-term assessment 
was to justify the efficacy of treatment.  It had been reported that both of these time-
frames were important to establish the clinical value of interventions, particularly in 
chronic forms of musculoskeletal disorders (Hurwitz et al., 2008; Derry et al., 2012).   
7.2.2 Randomised clinical trial 
A randomised clinical trial was selected as the most suitable method for detecting a 
clinical effect of the lateral glide mobilisation on pain. The trial was successful in 
recruiting 99 participants, with a balanced number randomised to each intervention 
group: the Mobilisation group (the lateral glide with self-management) and the 
Comparator group (self-management alone).  Sufficient participants were retained in 
each group at the primary, long-term follow-up (52 weeks), and at the short-term 
follow-up (6 weeks), to provide statistical power for analyses on the effectivenss of 
the lateral glide.   
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Baseline participant characteristics 
Demographic characteristics 
Key demographic characteristics included age and gender. Participants were equally 
balanced on age, but there were slightly more females in the Mobilisation group.  As 
baseline age and gender had been established as potential covariate parameters in 
the main analysis (Finocchietti & Trindade 1973; Kostova & Koleva 2001; Kaki, 
2006), any aspects of confounding were addressed.  
The prevalence of smoking in this trial cohort was higher than the national average at 
35 participants (35%).  In 2009/10, the national figures for people who smoked in the 
UK generally, and West Midlands specifically, was 21% (Cancer Research, UK, 
2012). There were no gender differences in the regional statistics, however in this 
trial 44% of the males smoked compared to 29% of the female participants.  This 
trend was consistent with previous reports that male smokers might have a higher 
prevalence for developing cervicobrachial pain (Kostova & Koleva, 2001). 
Participants in the Comparator group had a higher number of male smokers, but 
there were no published data to suggest that this would adversely affect prognosis 
and, therefore, outcome. 
Participants in the Mobilisation group had taken more time off work prior to starting 
the trial compared to those in the Comparator group, but there was no evidence to 
indicate that an increased time off work resulted in a poor prognosis for this 
condition. 
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Clinical characteristics 
There was no evidence from key baseline clinical data (Table 6.4) that the mean 
VAS(worst pain) scores were different across groups, indicating effective stratification 
(Sim & Wright, 2000; Schulz & Grimes, 2002a).  It had been reported that higher 
scores on VAS pain at baseline needed to be reduced by a greater amount to detect 
a clinically meaningful difference (Bird and Dickson, 2001; Tubach et al., 2004; 
Emshoff et al., 2011).  Achieving similar mean baseline scores (with similar variation) 
within each group for the primary outcome measure enabled a higher level of 
confidence when interpreting mean change scores for VAS(worst pain) (Emshoff et 
al., 2011).  
 Other clinical factors (including pain type (S-LANSS), fear avoidance (TAMPA), 
whiplash associated disorder, chronicity, treatment preference and positive neural 
tests (ULNE)) had similar values across groups. There was no evidence of a 
difference in baseline mean values on function and disability scores (NULI and SF-
36). As baseline disability levels had been established as covariate parameters in the 
main analysis, any aspects of confounding have been addressed in the analyses. 
Mean scores for the SF36 MCS in this trial (mean= 63) were better than had been 
reported elsewhere.  Scores in this trial were higher than UK norm-based scores 
(mean=50) (Jenkinson et al., 1999), and higher than those previously reported for 
patients with cervicobrachial pain (mean= 45) (Daffner et al., 2003).  It is not known 
whether geographic differences accounted for this disparity; as the work by Daffner 
et al. (2003) was based in the United States. 
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One of the largest between-group differences at baseline was the response to 
previous physiotherapy.  Less than half the responders who had received 
physiotherapy in the Mobilisation group reported a previous benefit to physiotherapy 
(n= 9; 47%), whereas nearly all participants in the Comparator group reported a 
positive response (n= 12; 92%).  There is very low evidence from one longitudinal 
cohort study (n=2793 over a 5 year period) that past experience of physiotherapy 
might predict future response to intervention (Joling et al., 2002).  However 
limitations of the methods used to establish outcome effect from intervention in Joling 
et al.’s study (2002), means that no strong conclusions could be made. It is possible 
that the disparity between previous intervention responses could have had a 
confounding effect on the outcomes of the current trial, negatively biasing results in 
the Mobilisation group. 
Protocol violations 
A high percentage of participants (n=47; 47%) received additional treatment following 
the intervention period (beyond six-week follow-up).  Although the groups were well 
balanced on numbers receiving additional intervention, they were not balanced on 
intervention type.  Two participants in the Mobilisation group received surgery 
compared to none in the Comparator group.  This could indicate that receiving 
mobilisation, might lead to a greater dependence on receiving future treatment, 
possibility due to moving the locus of control away from the patient, leading to 
interventions that involve higher risk and greater cost (Joling et al., 2002).  However, 
other factors could have accounted for this finding.  For example, the two participants 
who had surgery could have been the most debilitated and were most likely to have 
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required surgery at outset, yet, by chance they were randomised to the Mobilisation 
group. 
Variability around follow-up 
There was some variation around planned and actual follow-up times due to 
availability of participants.  Twenty-three participants returned for their 6 weeks 
follow-up prior to the planned six week time slot.  The majority of these (19 
participants) returned one week earlier, and four participants returned two weeks 
earlier, than planned.  The mean follow-up for the 52 week follow-up (primary end 
point) was similar across the groups with the majority of participants (n= 81; 82%) 
who attended the follow-up, doing so within one month of the planned follow-up time.  
There was one outlier in the Mobilisation group who completed final follow-up at 107 
weeks following baseline, (over double the planned follow-up time).  This participant 
had not attended the planned follow-up appointment, but had returned to the 
department for persisting problems with cervicobrachial pain on a separate occasion, 
one year later, at which point the participant agreed to complete the follow-up 
questionnaire and have physical outcome measures recorded.   It had been expected 
that there would be some variability in return time-points; therefore the MLM included 
‘time’ as a random factor as part of the model to account for this variation. 
Most participants (n= 78; 88%) completed the standard questionnaire at the final (52 
week) time point. The postal questionnaire was used by 9(10%) and 2(2%) of the 
control and intervention groups, respectively.  Some authors have indicated that 
different administration methods may lead to bias (Erhart et al., 2009).  However, 
criticisms related to using a combination of patient-complete and administrator 
complete methods.  For example, a patient might feel compelled to respond more 
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positively if verbally answering questions rather than completing a questionnaire 
independently (Erhart et al., 2009).  This could introduce administration bias if both 
methods were adopted in the same study.  In this trial, both methods captured data 
using a patient-complete method, thereby making any administration bias unlikely 
(Hawthorne, 2003). 
There were no statistical between-group differences on baseline key variables age, 
pain (VAS(worst pain)) and mental health (SF36, MCS) for participants who 
responded compared with those who did not respond at 52 weeks follow-up.  There 
were some gender and chronicity differences, with male participants, and participants 
with more chronic symptoms, being more likely to respond in the Comparator group 
compared to the Mobilisation group.  The MLM had the ability to account for this 
variation by nesting data variables per individual, thereby overcoming differences 
between differing levels of variability in response rate between groups (Field, 2009).   
 Between-group differences at follow-up 
Pain 
This trial was powered to evaluate a 20mm between-group difference for the worst 
pain (in the previous week), at long-term follow-up (52 weeks post baseline) on a 
visual analogue scale for pain.  The results found no evidence of between-group 
differences (p=0.37; CI -17.76 to 6.61), indicating that for this cohort of patients, there 
was no additional, long-term benefit from receiving the lateral glide.  
The analysis at 52 weeks was based on an intention to treat principle, with all 
participants analysed according to their intended intervention.  However, a large 
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proportion of participants received additional treatment prior to 52 weeks (n=47; 
47%), which introduced additional sources of variation in the intervention actually 
received by participants in each group. This additional variation could have 
confounded the results for the long-term measures. It was therefore not possible to 
ascertain whether the between-group differences at 52 weeks represented a ‘true’ 
level of effectiveness of the lateral glide. 
Within the intervention period (first six weeks), all bar one of the participants received 
the protocol intervention as the only treatment received.  The one participant who 
received additional treatment during this period withdrew from the trial. This meant 
that analysis at six weeks effectively became a per-protocol analysis and was more 
likely to reveal the ‘true’ level of effectiveness for the lateral glide.  Analysis at this 
follow-up time found no between-group difference on VAS(worst pain) (p=0.52; 95% 
95% CI -14.72 to 7.44).  Interestingly, a trend in pain reduction was greater in the 
Comparator group than the Mobilisation group (19mm compared to 14mm 
respectively).  This finding contrasted to studies reporting positive immediate effects 
of pain relief in response to the lateral glide (Vincenzino et al., 1996, 1998; 
Coppieters et al., 2003; McClatchie et al., 2009; Sterling et al., 2010).  This indicates 
that the pain relieving effects from the lateral glide might not extend beyond an 
immediate or very short-term effect.   
The longitudinal analysis showed that there was an improvement over time in pain 
VAS(worst pain) (p=0.001) for both groups which resulted in a clinically meaningful 
improvement (exceeded 20mm of change) at primary end point (52 weeks).  Without 
a no-intervention control, it was unknown if trends for improvement reflected a natural 
history of reduced pain over time, or, that both forms of intervention were effective. A 
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trend was observed between groups from 26 to 52 weeks: participants receiving 
mobilisation had an increase in pain whereas the trajectory for the Comparator group 
continue to improve (Figures 6-3 and 6-7). A similar trend was found for 
VAS(average pain) (Figures 6-4 and 6-8).  It might be that dependence on more 
passive intervention (such as the lateral glide mobilisation) moved the locus of 
control away from the participants in the Mobilisation group, resulting in them being 
less able to manage their symptoms and/or have a greater risk of re-occurrence of 
symptoms (Biurrun et al. 2002; Swenson, 2003; Peres et al., 2010; Mitrovich, 2011).   
Outcome measures evaluating self-perceived change in pain (GROC) and pain 
medication usage were evaluated in the short-term (6 week follow-up).  Correlation 
analysis for changes in VAS(worst pain) to patient perceived change (Figure 6-12) 
found a moderate linear trend between the two measures (Spearman’s rho=0.69) 
which supported validity for each, strengthening interpretation.   A trend for a greater 
level of improvement in the Comparator group compared to the Mobilisation group 
was found, which was consistent with findings from the VAS outcome measures.  
These findings contrasted to the results of the preliminary study, highlighting that 
without a powered study, very different interpretations might be made.   No significant 
between-group difference (p=0.63) for pain medication usage was identified.  
Outcome measures for pain including VAS(worst pain) , VAS(average pain), GROC 
and pain medication usage, consistently found that the lateral glide was no more 
effective in reducing pain than the comparative intervention in the short-term. 
 
 
209 
Function and disability 
The results from functional patient reported outcome measures in this trial found a 
statistically significant difference in mean NULI score across time (p=0.03; 95% CI -
13.53 to -0.92) between the Comparator and Mobilisation groups, favouring the 
effectiveness of the comparative intervention (Figure 6-9). A similar trend was seen in 
SF36 (MCS) (Figure 6-10), but this did not reach statistical significance (p=0.07; 95% 
CI -0.37 to 12.07).   
The estimate of effect on participant reported functional measures was small. Both 
the NULI and the SF36 MCS are measured on a 0 to 100 scale.  The NULI had a 
between-group effect of 7, which may be considered as the comparative intervention 
being 7% more effective than the lateral glide mobilisation.  No clinically meaningful 
differences have been reported on this outcome measure from which to draw 
comparisons.  The SF36 (MCS) had a between-group effect of 6, equating to the 
comparative intervention being 6% more effective than the lateral glide mobilisation.  
Within-group differences in the SF36 MSC (from baseline to 52 weeks) were +5.4 for 
the Comparator group, and +4.8 for the Mobilisation group.  It has been reported that 
change scores need to reach +5.8 to represent a clinically meaningful difference 
(Ware, 2000 p 3134).  
The results from performance based functional outcome measures (cervical active 
range of motion) produced mixed results in this trial.  Statistically significant results 
were found for left rotation (p=0.04; 95% CI -11.55 to -0.23) and left side bend of the 
cervical spine (p=0.03; 95% CI 0.58 to 8.49), favouring the effectiveness of the 
comparator intervention (Figures 6-13 and 6-14).  It was possible that multiplicity 
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(conducting statistical tests on multiple outcome measures) increased the rate of 
error accounting for the variability in findings for cervical range across time i.e. 
significant findings resulted by chance. 
The estimate of effect on performance based outcome measures was small.  AROM 
into left rotation showed the greatest between-group effect as 6 degrees.  None of 
the movements had clinically meaningful difference from baseline (a within-group 
change of 10 ) across time (Klaber Moffett et al., 1989; Sterling et al., 2002; Fletcher 
& Bandy, 2008).  
Cost –effectiveness  
Cost was considered in relation to sickness absence and treatment costs. The results 
of this trial found no statistically significant between-group difference in sickness 
absence at 6 week follow-up (p=0.08).  There was a trend that participants in the 
Comparator group required less time off work at this time point.   
The mean number of attended sessions during the intervention period for the 
Mobilisation group was greater (n=5; SD=1) than the Comparator group (n=2; SD=1).  
This was a statistically significant difference (p<=0.0005). The costs to provide 
intervention for the Mobilisation group were double that of the Comparator group. 
If more expensive interventions show little or no therapeutic advantage compared to 
less expensive interventions, then, the interventions with less cost should be the 
preferred intervention (Tonelli, 2012).  This trial was not powered to evaluate cost-
effectiveness; therefore, the findings of this trial provided a low grade level of 
evidence, that the addition of the lateral glide was not cost-effective. 
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Harms  
Only minor harm was associated with both interventions in this trial.  An interventional 
difference of 11% was found, with more harm being reportedly associated with the 
mobilisation.  In most cases, minor harm was described as a temporary increase in 
pain following intervention.  This type of response to intervention has been defined as 
‘treatment soreness’ and is considered not to cause any long-term harm (Adams & 
Sims, 1998). It has been reported to occur in response to non-invasive therapy for 
spinal pain (Furlan et al., 2010). It is not clear why it occurs in some but not all 
individuals.   No evidence was found in the literature to substantiate whether 
treatment soreness is just a transient effect, or, whether it has the potential to cause 
long-term harm. Identifying long-term harm is obviously important to determine.  
Providing that long-term harm is not associated with treatment soreness, transient 
soreness is likely to be acceptable to a patient if benefit from the intervention extends 
beyond the initial soreness period.  
Pain mechanism   
In this trial, there was no evidence that a neuropathic pain state (S-LANSS score of 
12 or greater) affected outcome on pain response (VAS(worst pain)) at six-week 
follow-up (p= 0.74). This would suggest that either the S-LANSS tool was not 
effective in evaluating pain mechanism for this population, or, the response to 
treatment was not pre-determined by pain mechanism. The lateral glide has not been 
established to be a mechanism dominant intervention i.e. it does not selectively affect 
nerve or somatic tissue structures; it has the potential to affect both (Section 4.2.2).  
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Therefore, a mechanism dominant sub-category might not necessarily result in a 
different intervention response.   
Participants with a positive ULNE (nerve mechano-sensitivity) had no statistically 
significant between-group difference for VAS(worst pain) at six weeks (p=0.30; 95% 
95% CI -19.02 to 5.94), as was the case for the analysis including all participants 
(with and without a positive ULNE) (p=0.52; 95% CI -14.72 to 7.44).  As the majority 
of participants included in the trial had a positive ULNE test (n=75; 77%), it is 
possible that the presence of nerve mechano-sensitivity is a frequently associated 
feature of this condition.  Despite the majority of patients having nerve mechano-
sensitivity (positive ULNE), only the minority had a positive neurogenic pain 
mechanism (12 or more on S-LANSS) (n=44; 46%). This indicated that either it was 
possible to have mechanical neutrally sensitivity without having a dominant nerve 
pain mechanism, or, the S-LANSS and/or ULNE were not tests that could specifically 
identify a nerve dysfunction in this patient group.   
Participant preference  
In this trial, participant preference did not affect outcome on VAS(worst pain) at 6 
week follow-up (p=0.81).  Previous studies on the lateral glide have not evaluated 
patient preference, so there is no specific indication of the effect preference might 
have. However, findings from a recent systematic literature review (Pradya et al., 
2013) reported that patients with strong preferences could turn down involvement in 
a study to enable them to receive a preferred treatment, thereby reducing the ability 
to detect an effect of preference on outcome (Pradya et al., 2013).  This was unlikely 
to be the case in this trial, as only two patients were not recruited due to their 
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concern that they might not receive the mobilisation.  Data from this trial was limited 
and not powered to detect preference, therefore provides only very low evidence that 
preference for the lateral glide does not affect outcome on pain.  
Trial Physiotherapist characteristics 
At the start of the trial, one of the five Trial Physiotherapists had a preference for the 
lateral glide mobilisation, whereas by the end of the trial this had changed to four of 
the five (Table 6.1).  There is disparity between the results of the trial and the change 
of opinion of the therapists. This change could have been influenced by the clinician 
patient relationship.  A patient might feel obliged to be more optimistic about their 
response to an intervention, particularly when it involves a level of physical contact 
i.e. ‘hands on’ intervention.  Participants in the Mobilisation group might have felt 
compelled to report positive responses to the therapist delivering the intervention, or, 
it could be that, as participants in the Mobilisation group, they had more 
appointments with the therapist.  The therapist could have been exposed to a greater 
level of positive feedback from participants in the Mobilisation group, thus biasing 
their own opinion about the apparent ‘success’ of the intervention.  This finding 
reflects the current belief that that much of health care is based on the experience of 
a physiotherapist, which is concerning if experience in itself is subject to bias (Daykin 
& Richardson, 2004; Pincus et al., 2006). This leads to question why patients in the 
Mobilisation group returned for twice as much intervention than the Comparator 
group.  The trial was designed to enable the Trial Physiotherapist together with the 
participant to determine how much intervention was required.  If the Trial 
Physiotherapist believed the mobilisation was effective they might have influenced 
the decision to continue with treatment over more episodes resulting in higher costs.  
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The results from this trial provide no substantive evidence to support this belief. 
Alternatively, it was possible that there was a true benefit to the participants, but that 
the nature of the trial was not sensitive enough to detect this.  It has been suggested 
that the rigour of study conditions used in RCTs do not reflect the complexity of the 
real world and are therefore not effective in revealing the ‘truth’ for the effectiveness 
of an intervention (Grapow et al. 2006; Cartwirght & Munro, 2010; Kerry et al., 2012). 
Alternative frameworks to RCTs have been suggested as ways to identify ‘truths’ in 
health care, such as the use of large cohort studies (Grapow et al., 2006).  However, 
methods that adopt a more candid approach to research and may increase risk of 
bias and chance also lose some of the rigor associated with the randomised 
controlled design (Sim & Wright, 2000).  
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7.3 Comparison of findings to current literature 
Comparisons may be made to previous studies on cervicobrachial pain relating to 
pain, function & disability, harm and pain mechanism.  Comparisons to cost 
effectiveness or preference were not possible, as no other studies evaluating the 
lateral glide mobilisation have considered these factors. 
7.3.1 Pain 
The results of this trial did not find that manual therapy (in the form of the lateral 
glide) provided any preferential reduction in pain compared to a comparator in the 
short or long-term.  This finding is in contrast to previous studies that have found 
beneficial effects from providing the lateral glide mobilisation for cervicobrachial pain 
in the short-term (Allison et al., 2002; Ragonese, 2009) (Table 3-3).  Since 
completing the systematic literature review (Chapter 3) and commencing the main 
trial, a further study has reported that the lateral glide, added to exercise and advice, 
has a beneficial effect on short-term pain reduction (Nee et al., 2012).  The disparity 
between the results of this trial with other randomised studies might be explained by 
the different methods used. These include statistical power, homogeneity, dose and 
delivery of intervention, the provision of additional intervention within protocols and 
duration of follow-up.  
Trial power 
This trial was the only study with statistical power to evaluate a clinically meaningful 
change in pain.  It has been well documented that interpretations from small, 
underpowered studies, or studies that evaluate pain as secondary analyses but have 
not been powered for that purpose, could lead to erroneous conclusions (Moher et 
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al., 2010); therefore the results from this trial (with no statistically significant between-
group findings for pain outcome measures) provides the best available current 
evidence for short and long-term effectiveness.   
Homogeneity  
None of the other studies conducted their research in the UK.  It is possible that 
geographic location could be responsible for differing outcomes, however, all studies 
were conducted in developed countries with similar culture, meaning responses 
across populations are likely to be comparable.  Some of the studies used a self-
selection method of recruitment (Allison et al., 2002; Nee et al., 2012).  There is 
moderate evidence that participants who choose to be involved in a clinical study (in 
response to advertising) do not represent the general population well, leading to self-
selection (or volunteer) bias (Eysenbach & Wyatt, 2002; Hernan et al., 2004; Oswald 
et al., 2012).   
The disparity between findings of this trial and other similar studies (Allison et al., 
2002; Nee et al., 2012) could be attributed to methods in the selection process, 
including the presence of a positive ULNE.  The presence of a positive ULNE as a 
pre-requisite for inclusion (Allison et al., 2002; Coppieters et al., 2003; Nee et al., 
2012) was one of the key differences between this trial and other randomised studies 
evaluating the lateral glide. For this reason, an exploratory sub-group analysis was 
conducted on participants with a positive ULNE.  The majority of participants in the 
trial had a positive ULNE test (n=75; 77%) with an equal balance between the two 
intervention groups (Comparator n=39; Mobilisation n=36). Results from the sub-
group analysis found a non-significant difference on VAS(worst pain) at six weeks 
(p=0.30; 95% CI -19.02 to 5.94).  Whist it was recognised that this analysis was not 
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powered, it does indicate that the inclusion of a positive ULNE was unlikely to 
account for the differences seen on pain outcomes. 
Dose and delivery of intervention 
Only one other study clearly specified both the dose and delivery of the lateral glide 
(Nee et al., 2012).  Differences between this trial and that of Nee et al. (2012) 
included the following:  Nee et al. (2012) used a ‘pulling’ technique (as opposed to 
‘pushing’ technique) to provide the translatory oscillation.  Mobilisations were 
administered to multiple levels of the cervical spine (as opposed to the one level 
used in this trial) for two, 30 second doses (compared to three 60 second doses).  
Although low evidence supported that similar effects might be gained by using 
different mobilisation approaches in general (Cleland et al., 2005; Aquino et al., 
2009) (Section 4.2.3), other studies that have reported the use of multi-level lateral 
glide mobilisations in their cervicobrachial pain studies (Coppieters et al., 2003; 
McClatechie et al., 2009; Ragonese, 2009) have had consistently positive effects on 
pain as an outcome.  It is therefore possible that the difference in approaches to the 
lateral glide could have accounted for differences in outcome for pain in this trial 
compared to the study by Nee et al. (2012).   
Provision of additional manual therapy treatment 
Two randomised studies used the lateral glide with other mobilisation techniques as 
part of a manual therapy package of care (Allison et al., 2002; Ragonese, 2009).  
Coppieters et al. (2003) and Nee et al., (2012) used the lateral glide as a singular 
mobilisation technique, as was the situation in this trial.  Unlike this trial, both 
Coppieters et al. (2003) and Nee et al. (2012) found evidence to support the use of 
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the lateral glide technique to reduce cervicobrachial pain to a greater degree than a 
comparator in the immediate and short-term.   For Nee et al. (2012), both intervention 
groups (comparator and mobilisation) were advised to stay active, however only the 
mobilisation group received the education and exercises as well as the mobilisation, 
thus, the improvement found in their study might be attributed to the exercise and 
education component of the physiotherapy intervention rather than the lateral glide 
component.   Coppieters et al. (2003) used an ultrasound comparator and gave the 
lateral glide as the sole intervention (no advice or exercises added).  Limitations with 
their study included methodological flaws (lack of power, no between-group 
difference reporting) which could have biased results.  However, this finding along 
with others supports the immediate effect of the lateral glide in other neck and upper 
limb disorders (Vincenzino et al., 1996, 1998; McClatchie et al., 2009; Sterling et al., 
2010). 
Duration of follow-up 
This trial was the only randomised study that followed-up participants over an 
extended period of time.  Other cervicobrachial pain studies evaluating pain ranged 
from the immediate effects (Coppieters et al., 2002) to 8 weeks following baseline 
(Allison et al., 2002) (Table 7.1).  This suggests that the lateral glide mobilisation 
might be effective for a short duration following its administration but does not 
provide information on long-term outcomes. This limits support for the clinical 
usefulness of the lateral glide mobilisation for the treatment of cervicobrachial pain as 
longer term benefit would be desirable to make treatment cost effective, however, 
long-term outcomes might be problematic in isolating the effects for specific 
interventions.     
 Table 7-1:  The lateral glide mobilisation effect on pain outcomes for chronic cervicobrachial pain 
Study Study design 
 
Participants 
 
Recruitment Participant 
classification 
and chronicity 
Interventions & assessment points 
 
Outcome 
measures  
Results 
Allison et 
al. (2002) 
 
Australia 
RCT with crossover 
design 
 
3 groups: 
A: Neural PT with 
exercise; n=10 
 
B: Articular PT with 
exercise; n=10 
 
C: No treatment; 
n=10 
 
n=30 
Mean age 54 
F=20 (67%) 
 
Self-selected 
from 
advertisement 
Neurogenic 
cervicobrachial 
pain  
Positive ULNE. 
Mean duration of 
symptoms: 
26 months 
(chronic) 
 
A: Cervical lateral glide, shoulder girdle 
oscillation, muscle re-education and home 
exercise. 
 
B: Glenohumeral and thoracic mobilisation, 
and home exercise. 
 
 
Treatment is given over an 8/52 period.  
Quantity of treatment not specified.  
 
Assessment at baseline, 4/52 and 8/52.  
VAS pain,  
SF McGill. 
 
 
 
 
 
 
 
 
 
Significant between-
group differences in 
improvement of mean 
VAS pain for A 
compared to B at 8/52 
(p=0.03).   
 
No statistically 
significant between-
group differences on SF 
McGill (p=0.15). 
 
 
Coppieters 
et al. (2003) 
 
Australia 
 
 
 
 
RcT 
 
2 groups: 
A: Cervical 
mobilisation (lateral 
glide used a 
contralateral ’pulling 
technique’); n=10 
 
B: Therapeutic 
ultrasound; n=10 
n=20  
Age range 
35- 63 
Mean age 48. 
F=16 (80%) 
 
 
 
 
 
 
Physiotherapy Neurogenic 
cervicobrachial 
pain 
Positive ULNE. 
Mean duration of 
symptoms: 
2.7 months 
(sub-
acute/chronic) 
 
A: Single session of lateral glide  
mobilisation to the cervical spine to one or 
more of C5,6,7,T1. 
 
B: Single session of therapeutic ultrasound 
to most painful area. 
 
Assessment at baseline and immediately 
following treatment in response to the 
ULNE. 
 
NPRS in 
response 
to ULNE 
 
 
 
 
 
 
 
 
No between-group 
differences were 
reported.  Significant 
immediate improvement 
in mean pain reduction 
pre compared to post 
treatment for A 
(p<0.005), but not for B 
(p=0.28).  
Nee et al. 
(2012) 
 
Australia 
 
 
RcT 
 
2 groups: 
A: Cervical 
mobilisation with 
exercise  
(lateral glide used a 
contralateral  
‘pulling technique’); 
n=40 
 
B: Advice to 
continue usual 
n=60 
Age range 
18-60 
Mean age 47 
F=38 (63%) 
 
 
 
 
 
Self-selected 
from 
advertisement 
 
Neurogenic 
cervicobrachial 
pain 
Positive ULNE 
Mean duration of 
symptoms: 
26 weeks 
(Chronic) 
A: Lateral glide cervical  mobilisations: 
Two sets of 30 second mobilisations to 
C4,5,6,7, education and nerve gliding 
exercises for 4 treatments over two weeks. 
Advised to stay active 
 
B: Advised to stay active 
 
Assessment at baseline and 3-4 weeks 
following commencement of physiotherapy 
 
 
 
NPRS 
 
 
 
 
 
 
 
 
 
 
 
 
Significant between-
group differences in 
improvement of mean 
VAS pain for A 
compared to B at 3-4/52 
(p<0.05) 
  
Neck pain - 0.9 (95% CI 
-0.5 to -1.3) 
Arm pain -0.7 (95% CI -
0.3 to -1.1) 
 
 
 Key:     C= cervical vertebra; F= female; n= number of participants; NPRS= Numeric Pain Rating Scale; PT= Physiotherapy; RCT= Randomised 
controlled trial; RcT= Randomised clinical trial; SF McGill= Short-form McGill Questionnaire; VAS= Visual Analogue Scale.  
  
activities; n=20   
Ragonese 
(2009) 
 
USA 
 
 
 
 
 
 
RcT 
 
3 groups: 
A: Manual PT; n=10 
 
B: Exercise PT; 
n=10 
 
C: Combined 
manual and 
exercise PT; n=10 
 
n=30  
Age range or 
mean not 
stated. 
F=19 (63%) 
 
Physiotherapy Cervical 
radiculopathy 
Definition: neck 
and/or upper 
extremity 
symptoms. 
 
Presence of either 
a positive 
spurlings test or 
cervical distraction 
test or ipsilateral 
cervical rotation 
less than 60° or 
ULNE test. 
 
Chronicity not 
stated 
 
 
A: Cervical lateral glide and thoracic 
mobilisations and neural dynamic 
techniques for the median nerve. 
 
B: Deep neck flexor, lower and middle 
trapezius  and serratus anterior 
strengthening (supervised) 
 
C: combined approaches of A and B 
 
Treatment given three times a week for 
3/52 for each intervention group. 
 
Assessment at baseline, 1/52, 2/52 and 
3/52. 
NPRS 
 
 Significant between-
group differences for 
reduced mean pain for 
C compared to A and B 
(p<0.01) at 3 week 
follow-up. 
 
Salt, (2013) 
(This trial) 
 
UK 
RcT 
2 groups: 
A Cervical 
mobilisation with 
self-management 
(lateral glide used a 
‘pushing 
technique’); n=49 
 
B: Self-
management; n=50 
n=99 
Age range 
18-65 
Mean age 47 
F=52 (53%) 
 
Physiotherapy Cervicobrachial 
pain 
Mean duration of 
symptoms: 
One year 
(Chronic) 
 
 
A: Lateral glide (pushing) cervical glide 
mobilisations: 
Three sets of 60 second mobilisations to 
C5/6 and self-management. Up to 6 weeks 
of treatment. 
 
B: Self-management. 
 
Assessment at baseline and at 6 weeks, 26 
weeks and 52 weeks following baseline 
VAS(worst 
pain) 
 
 
Non-significant between 
group difference  for A 
compared to B at 6 
weeks (p=0.79) 
52 weeks (p=0.37) 
Longitudinal (p=0.81) 
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To summarise, there was a very low grade of evidence that the lateral glide 
mobilisation was more effective in providing an immediate reduction in pain.  There 
was very low evidence from conflicting results that the lateral glide (coupled with a 
self-management approach) was more beneficial than self-management approaches 
in the short-term. There was a moderate grade of evidence that the lateral glide 
(coupled with self-management) provided no additional benefit on pain compared to 
a bio-psychosocial approach of self-management used in isolation, in the long-term 
(Table 7-2). 
Table 7-2: The lateral glide effects on reducing pain in cervicobrachial pain  
Grade Evidence 
Moderate 
 
 
The lateral glide with self-management is no more effective in reducing pain in 
the long-term compared to self-management alone (this trial)  
 
Very Low The lateral glide with advice and exercise is more effective at reducing pain in 
the short-term compared to advice to stay active (Nee et al., 2012) 
 
The lateral glide with self-management is no more effective in reducing pain in 
the short-term compared to self-management alone (this trial) 
 
 The lateral glide is more effective in the immediate reduction of pain than 
ultrasound treatment (Coppieters et al., 2003) 
 
Footnote:  Refer to Table 2-3 for interpretation of grades 
7.3.2 Function and disability 
Evidence that the lateral glide improved function and reduced disability in 
cervicobrachial pain, in the short-term was conflicting.  Both Ragonese (2009) and 
Nee et al. (2012) found between-group statistically significant improvements in the 
Neck Disability Index (a patient-report measure), favouring the intervention with the 
lateral glide up to one month following baseline (p<0.05).  Nee et al. (2012) also 
found between-group statistically significant differences on the patient specific 
functional scale (a patient report measure) favouring the group who received the 
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lateral glide with advice and exercise (p.0.05).  However, there have also been 
reports of no statistically significant between-group differences on the Northwick Park 
Questionnaire (a patient-report measure) and cervical active range of movement 
(performance based outcome measure) (Ragonese, 2009) up to one month post 
baseline indicating a lack of consistency in functional outcome measures.  
The results of this trial found a trend that the addition of the lateral glide to self-
management intervention had a negative effect on outcome relating to function and 
disability in contrast to other studies. None of the studies (including this trial) were 
adequately powered to detect between-group differences for the effects of the lateral 
glide on function.  Consequently, there is no substantive evidence to support or 
refute whether the addition of the lateral glide as part of non-invasive management 
for cervicobrachial pain has an effect on function. 
7.3.3 Harm 
In this trial, 16% of participants in the Mobilisation group reported minor harm that 
they attributed to the lateral glide.  This figure was less than reported elsewhere 
where minor harm constituted 42% for participants receiving the lateral glide 
mobilisation with nerve mobilisation exercises (Nee et al., 2012).  It might be that the 
minor harm reported by Nee et al. (2012) was aggravation from the nerve-based 
exercises rather than the lateral glide specifically.  Neither study found that the lateral 
glide resulted in severe or moderate harm.   
There was a low grade of evidence that the lateral glide had a greater risk for minor 
harm compared to self-management interventions. There was low evidence from 
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non-powered studies that moderate and serious harms were not associated with the 
lateral glide in the short-term. 
7.3.4 Pain mechanism 
There was insufficient evidence to establish whether the presence of a dominant pain 
state could predict which patients would be more likely to respond to manual therapy 
and exercise. Findings from this trial, where no correlation was found, was in contrast 
to findings from Nee et al. (2013) who reported that cervicobrachial patients with S- 
LANSS scores of 12 or more (indicating a dominant neuropathic pain state) had a 
less favourable outcome to manual and exercise therapy interventions in the short-
term.  This contradictory evidence could be due to differences in study methods 
previously outlined (Nee et al., 2012).  For example, in the study by Nee et al., 
(2012), S-LANSS scores were correlated with patients rating their perceived overall 
improvement to treatment on the global rating of change score.  This method of 
analysis was subject to a large self-reporting bias which could have confounded the 
results.  In this trial, whist correlations were also made to a patient reported measure 
(VAS(worst pain)), patients were blinded to their baseline responses, thereby 
reducing self-report bias. 
 
 
 
 
Footnote:   Nee et al., 2013 used the same participant group as for Nee et al., 2012  
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7.4 Limitations: Internal validity 
Key issues around selection, performance and attrition were addressed within the 
framework of the randomised trial, to limit bias.  There were, however, a number of 
aspects which could have affected internal validity.   
7.4.1 A Priori specification 
Reporting methods prior to commencing a study reduces the likelihood of reporting 
bias (Moher et al., 2010; Higgins & Green, 2011; Rushton et al., 2011).  However, at 
the time of writing the protocol and planning the trial, the body of literature advocating 
publishing the full protocol was not available.  This trial was registered; therefore, 
some details of the trial plan, including sample size requirement and key inclusion 
criteria were available.  Also, although not published, a detailed protocol was written 
and then reviewed by the ethics and research and development committees.   
7.4.2 Issues identified with selected follow-up time points 
Follow –up time points were selected as 6, 26 and 52 weeks.  The rationale for this 
choice was: 6 weeks provided a short-term analysis, 52 weeks the long-term analysis 
and 26 provided additional data for a longitudinal analysis and kept participants 
involved in the trial.   
The short-term analysis was at 6 weeks post baseline.  It was recognised that for 
some participants (e.g. those who had received intervention for six consecutive 
weeks), this was a more immediate representation than for those who had received 
one or two interventions during the first two weeks post baseline.  This was accepted 
as a necessary compromise in a pragmatic design (Patsopoulos, 2011). 
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The final time-point was at 52 weeks post baseline.  The rationale for selecting this 
as the primary time-point, over the other time-points was determined at the planning 
stage (Section 5.9).  Between the 6 week and 52 week follow-up, just under half of 
participants received additional treatment (47%).  As both groups were balanced, 
there was no indication that one group was advantaged over another, however, the 
trial at this point was not comparing intervention and comparator as intended, 
therefore caution was needed when interpreting the results at 52 weeks (Smyth et 
al., 2011; Sweetman & Doig, 2011).  
7.4.3 Problems encountered with outcome measures used in the trial 
VAS pain scale 
The primary outcome measure was the visual analogue scale (VAS).  This tool was 
selected overs others as it had been found to be a sensitive, specific and reliable 
measure (van Kleef 1996; Allison et al., 2002; Walker et al., 2008; Kuijuper et al., 
2009) (Section 5.10.1).  During the preliminary study there had been no reason to 
suspect it was not a sound method to evaluate pain.  Across all time points, there 
were 49 occasions (14%) where VAS(average pain) scores exceeded VAS(worst 
pain) scores for the same participant at the same time point. In most cases (47 
occasions) the difference between the scores was small (indicating the ‘average pain’ 
was much the same as the ‘worst pain’) with differences not exceeding more than 
2mm, however on two occasions the difference was substantial (>20mm).  Both 
occasions were from the same participant who consistently rated VAS(average pain) 
higher than VAS(worst pain) suggesting a potential lack of comprehension of the 
outcome measure. 
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On one occasion baseline pain was scored as 0 (indicating the participant had no 
pain) when pain was an inclusion criterion.  Cross-analysis with other scales and 
consulting the participant’s case notes indicated that the VAS scale, in this instance, 
might have been completed in reverse with 0 indicating extreme pain.   
Generally, the VAS outcome measures correlated well with other measures, for 
example the Global Rating of Change (GROC) indicated that validity of the both tools 
for this population were good. 
 Function and disability 
The Short-from 36 (SF36) was a global outcome measure which had been validated 
for use in patients with cervicobrachial pain (Daffner et al., 2003) and had established 
norm-based population scoring, enabling comparisons from this trial to a 
standardised reference point and established clinically meaningful differences to 
assist in the interpretation of results (Ware, 2000).  The Neck and Upper Limb Index 
(NULI) was the selected condition-specific measure chosen because of its content 
validity for this patient population (Stock et al., 2003).  However, the limitation of 
NULI was there was not any population norm-based data or established clinically 
meaningful differences to compare the data from this trial to. The ability to interpret 
change scores found in NULI was therefore limited. 
Pain medication usage 
The use of pain medication was recorded at follow-up to give an indication of change 
in medication use during the course of the trial.  The outcome measure was worded 
to enable identification of participants who had needed to take pain medication since 
the start of the trial (which might indicate an increase in pain), but did not allow for 
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identification of participants who no longer needed pain medication at follow-up when 
they had been using them at baseline as there was no knowledge of baseline 
medication.  In addition, the value of change in pain medication i.e. from a stronger to 
a weaker medication (or vice versa) was dependent on the knowledge the participant 
had about the medication they were taking.  Interpretation of medication usage was, 
therefore, limited. This limitation had not been identified during the preliminary study. 
Cost effectiveness 
This trial was not designed to incorporate a full economic evaluation, but did aim to 
establish any differing trends between the groups. 
The quantity of appointments was used to establish demands on Physiotherapy 
resources.  Participants in the Mobilisation group, on average, used more than twice 
as many appointments as those in the Comparator group.  As there was no 
statistically significant between-group difference on the primary outcome measure at 
six weeks, the comparator intervention could be considered the more cost-effective 
of the two.  But, evaluation was only during the intervention period; therefore the 
long-term cost-effectiveness could not be established.   
Sickness absence due to cervicobrachial pain was established at each time point as 
the number of days taken off from work in the preceding month because of 
cervicobrachial pain.  This data provided an insight into how the condition might 
impact on employment.  However, methods used relied on individuals recalling how 
much time they had off due to their cervicobrachial symptoms.  Recall bias in this 
instance could, have led to inaccuracy.  This was minimised by asking participants to 
recall the sickness they had taken for the preceding month which was considered 
228 
more accurate than for the period across the duration of their involvement in the  trial 
(one year) (Phillips et al., 2008)..     
Harms 
Harm data was collected during the intervention period.  It was not known whether 
any harm resulted from intervention beyond this period of time.  Adverse effects 
following manual therapy to the cervical spine have been reported in the literature 
(Haldeman et al., 2002; Dziewas et al., 2003; Debettw & Les, 2009; Thomas et al., 
2011).  Cervical artery dissection has been recognised as a rare consequence of 
manual therapy, with most reported instances involving techniques using cervical 
rotation and high velocity manoeuvres (Miley et al., 2008), which are not 
characteristics of the lateral glide mobilisation.  At the time of planning the trial, most 
adverse events were reported to have occurred within a few hours of receiving 
manual therapy treatment (Haldeman et al., 2002; Dziewas et al., 2007), however 
more recent figures suggest that effects could be delayed up to weeks or months 
post intervention (Debetw & Leys, 2009; Thomas et al., 2011).  This trial evaluated 
harms in the short-term supported by literature available at the time of planning the 
trial. In light of more recent reports, establishing any development of harm during the 
course of the trial would have been an appropriate additional measure. 
Participant satisfaction 
Patient satisfaction was not evaluated in the trial. Patient satisfaction has, in recent 
years, been recognised to have increasing importance in the development and 
provision of service development and service planning (National Health Service 
Commissioning Board, 2012).  Patient satisfaction has become a frequently used 
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outcome measure in research studies on spinal pain (George & Robinson, 2010; 
Lamb et al., 2010).  In these studies, satisfaction was used to evaluate whether 
patients in one group had a better experience of therapeutic package of care 
compared to another.  However, patient experience may be influenced by multiple 
factors such as how positive a relationship is with a therapist or the waiting times for 
appointments (Alrashdi, 2012).  It has been cautioned that the use of satisfaction as 
an outcome might mislead interpretation for the effectiveness of specific interventions 
(Williams, 2004; Fenton et al., 2012).   
7.4.4  Effect size 
Effect size was a way of quantifying the size of difference between the interventions. 
The sample size for this trial was based on a power calculation, using a moderate to 
large effect size (20mm of change) for the primary outcome measure, VAS(worst 
pain).  Moderate or large effect sizes have been criticised to lead to a type two error 
(rejecting a hypothesis when, it is in fact true) due to insufficient power to detect a 
small yet meaningful change in effect (Machin & Fayers, 2010). If the trial had been 
powered to detect a smaller effect size, it is possible that a statistically significant 
between-group difference might have been detected (Machin & Fayers, 2010). 
However, a smaller effect size is less clinically meaningful and, therefore, results 
from studies using small effect sizes might not be clinically meaningful. 
If one intervention requires greater expenditure compared to another (as in the case 
of this trial), it may be justified as appropriate to have identified at least a moderate 
effect size for interventional effect. The rationale for using this method is thus 
validated. 
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7.5 Limitations: generalisability 
One reason to study chronic cervicobrachial pain was that it was considered to be a 
prevalent condition (Section 2.4.1). Audit data from the preliminary study showed that 
chronic forms of cervicobrachial pain accounted for just 2% of the overall 
musculoskeletal referrals to physiotherapy at a department in the West Midlands.  
This data from the audit indicated a lower prevalence for chronic cervicobrachial pain 
than had been indicated from other studies on neck pain (Persson & Carlsson, 1999; 
Sterling et al., 2002b; Daffner et al., 2003; Antonaci et al., 2006, Vincent, 2010). It 
was possible that the majority of chronic cervicobrachial pain patients were being 
managed in primary care settings, as, at the time of conducting the trial, the UK 
government was trying to ensure that chronic musculoskeletal conditions were being 
managed in primary rather than secondary care settings (Department of Health- NHS 
Improvement Plan, 2004; Department of Health- Musculoskeletal Service 
Framework, 2006).  The main trial was developed to include two primary care 
locations.  Unfortunately the primary care locations failed to recruit anyone to the 
trial, but, it was not clear if this was due to a lack of patients being available or issues 
with staffing and organisational changes in the participating centres. The external 
validity of the trial had some limitations due to the use of a single rather than multi-
centre site.  In addition, use of multiple exclusion criteria impacted on generalizability 
of the trial’s findings. 
7.5.1 Single centre trial 
This was a single-site trial. As participants were recruited over a long duration, results 
should be fairly representative for all patients at this location.  Results of this trial are 
limited to patients who match the characteristics and demographics of those involved 
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in this trial and, therefore, represent a select sample of patients attending 
physiotherapy in secondary care, in the West Midlands.   Data from participants from 
primary or tertiary centres and in different geographic locations would have led to a 
better generalisability, however, as the location used serves a population with mean 
figures for socio-economic UK demographics, it is possible that the results from this 
study may be considered a fair representation for a wider population.   
Discontinuation of sites in this trial was due to a lack of recruitment secondary to 
staffing and changes in organisational structures for service delivery.  Problems with 
recruitment such as these are not uncommon in multi-centre studies (Campbell et al., 
2007; Menon et al., 2008).  Strategies to aid cross-site recruitment might include 
web-based systems for study management and constant monitoring systems by 
dedicated management teams to address problems and seek solutions as soon as 
they arise; however this trial had limited funding and resources, so these strategies 
were not possible.   
The secondary care location (where the trial was conducted) contrasted to the other 
centres by seeing a steady increase in recruitment over the duration of the trial.  One 
factor that might have facilitated recruitment to this site was that all referrals for neck 
and upper limb disorders were seen by physiotherapists who specialised in this field 
of practice. All potential patients with cervicobrachial pain were seen by a member of 
this team and it became part of the culture to recruit in these clinics. An attempt was 
made to roll out this model to the other sites, however due to their generalist way of 
working (all physiotherapists seeing all musculoskeletal conditions); it was not 
feasible to implement this approach.  
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7.5.2 Multiple recruitment criteria 
This trial included eleven criteria.  It has been criticised that too many exclusion 
criteria reduce generalizability (Schulz & Grimes, 2002c).  Exclusion criteria should 
be designed to prevent contraindications and identify patients who are more likely to 
impose a greater loss to follow-up (Schulz & Grimes, 2002c).   
Co-existing upper limb pathology accounted for the largest number of participants 
excluded due to ineligibility (n=57; 33%).  This figure was similar to findings by a 
previous study (Cannon, 2007) suggesting that cervicobrachial pain in the chronic 
form is frequently associated with other upper limb pathology.  Co-existing upper limb 
pathology is not a contraindication nor would it have necessarily imposed a greater 
loss to follow-up, however, if co-existing upper limb pathology had been included a 
greater number of participants might have needed additional treatment, possibly 
including the intervention period.  The presence of upper limb pathology remained a 
valid reason for exclusion in this trial. 
Some exclusion criteria in this trial were based on the prevention of confounding 
effects e.g. age and litigation, however on reflection, as methods for analysis were 
selected to take confounders into account (ANCOVA and Multi-level models), the 
exclusion of these criteria might have been over zealous.   
Sixty-one percent of patients with cervicobrachial pain were excluded based on not 
meeting selection criteria.  This rate was much higher than figures reported in 
previous non-invasive cervicobrachial studies where exclusion rate was consistently 
25% (Allison et al., 2002; Bernnards et al., 2007;  Walker et al., 2008; Kuijper et al., 
2009; Young et al., 2009). Other studies had not included exclusion factors such as 
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co-existing upper limb pathology.  Whist reducing the exclusion criteria in this trial 
might have improved recruitment and enabled better generalisability of findings; it 
could have led to greater heterogeneity, thus masking results.   
7.6 Future recommendations 
Findings from the systemic review revealed the need for the trial.  The results from 
this trial suggest that a minimal intervention approach of self-management might be a 
cost-effective, low risk intervention, however, without a control group, it was not clear 
if the gains made in the Comparator group exceeded that of natural progress over 
time (Maughan & Lewis, 2010). Better knowledge of how chronic cervicobrachial pain 
evolves over time would provide useful information to inform evaluation of 
interventions.  
This trial evaluated one form of physiotherapy with another.  Evaluation of the 
interventions against a no-intervention control would be able to determine the 
effectiveness of specific interventions.  There are issues around a failure to provide 
any intervention when patients present for treatment.  Historically, this has been 
overcome by methods such as using waiting list patients as control participants.  
However, with NHS targets focused on faster access to services, with a maximum 
wait time of 18 weeks for non-urgent appointments such as musculoskeletal 
physiotherapy (Department of Health, 2013), a waiting list control is not usually a 
viable option. Effective placebo treatments are often difficult to achieve in manual 
therapy trials.  Comparative interventions in clinical physiotherapy research trials are 
therefore frequently used.  It is important to highlight that this trial was not designed 
to identify the value of physiotherapy in the management of chronic cervicobrachial 
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pain; however, as the self-management booklet (which was unique in that it provided 
a component of behavioural modification) a future trial to evaluate the effectiveness 
using the booklet could be supported.  
The lateral glide mobilisation had a beneficial effect for some, but not all participants.  
The ability to identify which specific sub-classification of patients will benefit from this 
approach of physiotherapy has yet to be determined.  A cohort study could be 
conducted to identify which patients achieve improvements with the lateral glide 
mobilisation compared to those who do not.  
Prevalence data on chronic cervicobrachial pain is needed to ascertain how much of 
an impact this condition has on society and health care services to justify the 
continued use of resources to support research in this field.  Prevalence statistics for 
the UK population and for patients seeking treatment for the condition across 
primary, secondary and tertiary health care services would inform where best to 
conduct future UK studies in this condition and enable effective recruitment.    
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7.7 Conclusion 
The systematic review and clinical trial have extended the knowledge base for the 
effectiveness of the lateral glide mobilisation on the management of cervicobrachial 
pain.  Evidence from this thesis finds a very low grade of evidence to support the use 
of the lateral glide to reduce pain in the immediate-term, conflicting evidence that the 
lateral glide with self-management is more effective at reducing pain in the short-term 
and moderate evidence that the lateral glide with self-management is no more 
effective in reducing pain in the long-term compared to self-management alone.  
Evidence for effectiveness on function and disability, cost, risk and perceived 
improvement is mixed.  The overall strength of evidence to support recommendation 
of the use of the lateral glide for cervicobrachial pain in clinical practice is low.  
This study is the only one that evaluates the value of the lateral glide as a specific 
mobilisation technique over a prolonged period of time.  In doing so, pragmatic 
problems were encountered including a large number of participants receiving 
additional treatment which had the potential to introduce a confounding effect at 
long–term analysis.  This questions how viable RCT studies are to evaluate specific 
modalities for long-term management in cervicobrachial pain.  Evaluation of 
intervention effects in the short, medium and long-term and a cost analysis is 
appropriate to inform health policy; however different methods to evaluate 
effectiveness might need to be considered for different time-frames to identify the 
true effects of an intervention.  Randomised controlled trials are considered the gold 
standard in research design (Silverman, 2009).  However, heterogeneity in a cohort 
of participants used in RCTs could lead to some confounding of results, which might 
have been the case in this trial.  A well-designed longitudinal observational study 
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might identify clinically important differences among therapeutic options for specific 
sub-groups of patients with a condition.  This method might be considered a more 
appropriate way of providing data on long-term intervention effectiveness and safety 
(Silverman, 2009), and thus more effectively lead to the development of clinical 
practice guidelines.   
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Appendices 
Appendix 1A: GRADE as a tool for evaluating prognosis 
________________________________________ 
From: Guyatt, Gordon [guyatt@mcmaster.ca] 
Sent: 11 September 2012 23:36 
To: Emma Salt 
Cc: s.m.kelly@bham.ac.uk; c.c.wright@bham.ac.uk 
Subject: Re: Query on the use of GRADE for risk and prognostic evaluations 
 
Although not developed for prognosis, turns out GRADE concepts work nicely for 
prognosis 
 
We will be writing more about this 
 
If you were to share your experience using GRADE in this setting we might 
collaborate in future 
 
Sent from my iPhone 
 
On 2012-09-11, at 4:46 AM, "Emma Salt" <EJS495@bham.ac.uk> wrote: 
 
 Dear Professor Guyatt, 
 
I am a PhD student and am currently writing my thesis. I have chosen the GRADE 
approach to evaluate the literature within my thesis. For one of the chapters, I cover 
risk and prognostic factors. I see from one of the series of articles you wrote that 
GRADE has not been developed to answer questions related to risk and prognosis: 
 
 (Guyat et al., 2011 GRADE guidelines 1. Introduction- GRADE evidence profiles and 
summary of finding tables. Journal of Clinical Epidemiology, 64(4): 383-394). 
 
To keep my thesis consistent, I would like to use the GRADE approach for the 
purpose of evaluating risk and prognosis. Is this acceptable? 
 
Emma 
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Appendix B: Medline search for systematic literature review used in thesis 
Searches Terms Results 
1 (cervico ADJ brachial).ti,ab                                 125 
2 Cervicobrach*.ti,ab                                             318 
3 (cervical ADJ radicul*).ti,ab                               750 
4 (cervical ADJ neuralg*).ti,ab   1 
5 (neck ADJ3 arm ADJ pain) ti.ab  175 
6 (trapezius ADJ myalgia).ti,ab      51 
7 1 or 2 or 3 or 4 or 5 or 6             1382 
8 management.ti,ab                       550321 
9 THERAPEUTICS/                           7158 
10 PHYSICAL THERAPY MODALITIES/ OR “PHYSICAL THERAPY (SPECIALITY)”/                             25220 
11 osteopath*.ti.ab                                  3562 
12 exp CHIROPRACTIC/                      2759 
13 exp EXERCISE/ OR EXERCISE THERAPY/ OR EXERCISE MOVEMENT TECHNIQUES/                               90579 
14 PATIENT EDUCATION AS TOPIC/    61295 
15 exp HEALTH EDUCATION/    121501 
16 advice.ti.ab                                 27112 
17 COGNITIVE THERAPY/ OR BEHAVIOR THERAPY/    34258 
18 exp MUSCULOSKELETAL MANIPULATIONS/         12384 
19 
MANIPULATION, CHIROPRACTIC/OR MANIPULATION, ORTHOPEDIC/ OR 
MANIPULATION, OSTEOPATHIC/ OR MANIPULATION, SPINAL/                      
5295 
20 mobili*.ti,ab               134244 
21 exp MASSAGE/       4095 
22 exp TRACTION/   5384 
23 exp ELECTRIC STIMULATION THERAPY/    50907 
24 exp TRANSCUTANEOUS ELECTRIC NERVE STIMULATION/  5221 
25 interferential.ti,ab    289 
26 ULTRASONIC THERAPY/    7701 
27 SHORT-WAVE THERAPY/ OR DIATHERMY/    2657 
28 (laser ADJ therap*).ti,ab             5083 
29 exp HYDROTHERAPY/                 1865 
30 (aquatic ADJ physiotherapy*).ti,ab 5 
31 exp CRYOTHERAPY/                        18038 
32 (heat ADJ treatment).ti,ab     8006 
33 (heat ADJ therap*).ti,ab      148 
34 
8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or17 or18 or 19 or 20 or 21 or 22 or 23 or 24 
or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33   
518328 
35 (randomi* ADJ clinical ADJ trial).ti,ab         12262 
36 (randomi* ADJ trial).ti,ab                  150516 
37 RANDOMIZED CONTROLLED TRIALS AS TOPIC/ OR RANDOM ALLOCATION/                            140982 
38 35 or 36 or 37 209009 
39 7 and 34 and 38    27 
40 Duplicate filtered: [7 and 34 and 38]    27 
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Appendix C: Participant information sheet and consent form 
Participant Information Sheet             (Version 2.2) (19/5/09) 
1. Study title 
Study to investigate the effectiveness of a lateral glide cervical spine mobilisation on cervicobrachial 
(neck and arm) pain. 
 
2. Invitation 
You are being invited to take part in a research study.  Before you decide it is important to understand 
why the research is being done and what it will involve.  Please take time to read the following 
information carefully.  Talk to others about the study if you wish. Ask us if there is anything that is not 
clear or it you would like more information.  Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
 
3. What is the purpose of this study? 
Cervicobrachial pain is the name for symptoms in the arm which originate from the neck.  Symptoms 
usually include pain and sometimes include pins and needles (tingling), numbness and weakness in 
the arm. Physiotherapy often aims to help these problems by using advice, exercises and a variety of 
other treatments.  The extent to whether any treatments are more helpful than others is unclear.  This 
study will aim to establish if one commonly used treatment for this condition is better than another. 
This study is part of a research degree. 
 
4.  Why have I been chosen? 
You have symptoms affecting your neck and arm which have been identified as suitable to receive 
physiotherapy.  If you agree, you will be one of 96 patients to be involved in this study. 
 
5. Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  If you do, you will be given this information 
sheet to keep and be asked to sign a consent form.  You are still free to withdraw at any time and 
without giving reason.  A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
6. What will happen to me if I take part? 
Sometimes we don’t know which way of treating patients is best.  To find out, we need to make 
comparisons between the different treatments.  We put people into groups and give each group a 
different treatment; the results are compared to see if one group is better.  To try to make sure the 
groups are the same to start with, each patient is put into a group by chance (randomly).  You will be 
randomised to either manual therapy with standard physiotherapy or standard physiotherapy alone 
and this allocation will not be changed.  However, we would like to ask whether you do have a 
preference so that we can explore this in relation to treatment. 
 
You will receive your treatment at the physiotherapy department.  Treatment will occur at weekly 
intervals (approximately) for between 1 to 6 weeks which is normal for treatment in a physiotherapy 
department. Each appointment will take up to 30 minutes. 
 
In each appointment the physiotherapist will ask you about your symptoms and perform some physical 
tests on your neck and arm.  If you are in the standard physiotherapy group you will receive an up to 
date booklet consisting of self treatments and advice which the physiotherapist will go through with 
you so you are clear about what you need to do.  If you are in the manual therapy with standard 
physiotherapy group, you will also receive the booklet, but in addition have small pressures applied to 
the bottom of your neck whilst lying down.  
 
7.  What do I have to do? 
You will need to be able to attend the physiotherapy department at the hospital for up to six weekly 
attendances once your treatment has started as would be expected for your normal physiotherapy 
care. 
Additional requirements that are not part of standard physiotherapy practice include the following: 
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 You will be asked to sign the consent form (attached to the back of this paper).   
 You will be required to fill in a questionnaire (so don’t forget your reading glasses if you need them) 
which will ask you questions about your neck and arm pain and how your function and general health 
are affected.  It is best to fill this in by yourself rather than having your friends, relatives or the 
physiotherapist help, to ensure that we have your view of your problems rather than someone else’s. It 
will probably take you 20 minutes to complete the questionnaire. 
 You will be required to return to the physiotherapy department for follow up appointments at six 
weeks, six months and one year following the start of your treatment.  These appointments are 
important for us to evaluate how the treatment you previously received has affected your problem over 
a period of time. At each of these follow up appointments, you will be required to fill in another 
questionnaire (very similar to this first one) and have measurements taken of how much you can move 
your neck and the physiotherapist will measure how much she can move your arm.  If you do not 
attend these appointments we will contact you by phone to arrange an alternative appointment time, 
unless you ask us not to.  You will be entitled to £2.00 for each visit at 6 weeks, 6 months and one 
year to pay for transport and parking fees.  
 
8.  What are the possible disadvantages and risks and side effects of taking part? 
There are no anticipated disadvantages, risks or side effects. 
 
9. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept strictly 
confidential.  Any information about you that leaves the hospital will have your name and address 
removed so that you cannot be recognised from it. 
 
With your consent your GP will be informed of your participation in the study. 
 
10. What if there is a problem? 
In the unlikely event that you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you have any comments, concerns or complaints regarding the care 
you receive please contact the Patient Liaison Service (PALS) on 01283 511 511 extension 5284 or 
3112 (email: pals@burtonh-tr.wmids.nhs.uk).  If you wish to complain about any aspect of the way you 
have been approached or managed relating to the study, please contact Dr Brendan Laverty 0121 414 
7618 (email: b.w.laverty@bham.ac.uk).  
 
11.  What will happen to the results of the research study? 
They will be presented within the university, and used for conference presentations or publication in 
academic journals. 
 
It is hoped that this work will contribute to a better understanding of how physiotherapists can 
effectively treat cervicobrachial (neck and arm) syndrome. 
 
Please contact either Emma Salt or Sue Kelly on the contact numbers below if you would like to obtain 
a summary of the studies findings. 
 
12.  Who is organising and funding the research? 
Researchers at the University of Birmingham. 
 
13.  Who has reviewed the study? 
NHS Research Ethics Committee 
 
14.  Contacts for Further Information  
 Emma Salt   01283 566 333 x5255   EJS495@bham.ac.uk 
      
 Dr Sue Kelly   0121 415 8081   s.m.kelly@bham.ac.uk 
 Research Supervisor  
  
Thank you.  
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Participant Consent Form (version 2.2)    19/5/09 
 
Study to investigate the effectiveness of a lateral glide cervical spine mobilisation on 
cervicobrachial (neck and arm) pain. 
 
 
NAME OF LEAD RESEARCHER: _____________________ 
 
TRIAL ID :       _____________________ 
 
HOSPITAL NUMBER:   _____________________ 
 
          
          Please initial box 
 
1 I confirm that I have read and understand the information sheet dated 
19/05/09 (version 2.2) for the above study and have had the opportunity  
to ask questions and had these answered satisfactorily. 
 
 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care  
or legal rights being affected.         
  
 
3 I understand that sections of any of my medical notes may be looked  
at by responsible individuals from the study team or from regulatory  
authorities where it is relevant to my taking part in research.  
I give permission for these individuals to have access to my records. 
  
    
4 I give permission for my GP to be informed of my participation in this study. 
       
 
5 I agree to take part in the above study. 
 
 
 
6     I am happy to be contacted following completion of the study to  
provide feedback to the  research team. 
 
   
 
____________________________  _________ _________________________ 
Name of Subject     Date  Signature 
 
 
______________________________  _________ _________________________ 
Name of Person taking consent  Date  Signature 
    
 
______________________________  _________ __________________________ 
Researcher     Date  Signature 
 
1 copy for subject; 1 for researcher; 1 (original) to be kept with hospital notes 
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Appendix D: REC letter of approval for main trial 
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Appendix E: Self-management booklet 
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Appendix F: Protocol for Trial Physiotherapists 
Flow diagram for ‘Trial Physiotherapists’   
 
 
 
 
             
                   
 
 
     
 
 
                 
 
 
    
       
 
  
                                    
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient attends appointment and asked whether 
they are willing to participate in the study. Patient 
has opportunity to ask questions. 
Patient wishes to participate? 
Yes 
 Patient signs consent form and becomes trial participant 
 Participant is given the initial trial questionnaire to complete  
Whilst the participant completes the questionnaire in the cubicle you must: 
 Send a letter to the participant’s GP to inform them of the trial (add date and GP address) 
 In the ‘CBP log’, record the date of first treatment. 
 Add the participant’s trial ID number to the consent form and photocopy this twice.  Keep 
the original copy of the consent form in the patient notes and place one copy into the 
‘completed data’ folder for the researcher and give the other copy to the participant. 
No 
●  Continue with usual care   
●  Mark a cross alongside 
 the patient’s initials and 
ID in the CBP log along 
with brief explanation 
why not recruited  
When you return to the cubicle, check the participant has completed 
the questionnaire. Add their trial ID number to the top of their 
questionnaire. You should then fill in ‘details recorded by the Trial 
Physiotherapist – pre intervention form’ (demographic data).    
Measure the VAS (worst) scale on the questionnaire.   
 If they score between 0 – 25 collect a blue envelope  
 If they score between 26 – 74 collect a white envelope 
 If they score between 75 – 100 collect a red envelope 
                      Do not open the envelope yet 
 
 Open the envelope in front of the participant and inform them of 
the contents   (planned treatment) 
 Complete the last question on the pre-intervention form (overleaf) 
 Commence treatment   
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Flow diagram for ‘Trial Physiotherapists’  - Initial treatment pathway 
    
       
  
Inside each envelope states whether the participant receives either the self-
management or self-management with lateral glide cervical mobilisation 
Self-management with lateral glide 
cervical mobilisation   
Self-management  
Record assessment and treatment in standard format in 
the patient notes.   
Record time and any comments on participant comments 
For the self-management group, 
treatment involves going through 
the ‘self management for neck 
and arm pain’ booklet in detail. 
Re-assess myotomes, dermatomes and reflexes 
For self- management with lateral glide group, 
treatment involves going through the ‘self 
management for neck and arm pain’ booklet in 
detail, and then applying a lateral glide 
mobilisation, creating a lateral movement 
away from the symptom side to C5 on C6, 
remembering through the neck in a neutral 
spine position and with slight traction   
Apply grade III oscillations for 60 seconds at a 
rate of 1 oscillation every second. This 
technique may cause a bit of discomfort, but 
shouldn’t cause any pain. Repeat this for a 
further two sets of treatment with an interval of 
one minute between each set to provide three 
sets of treatment in total. 
Book a further appointment for the participant to return for 
a second treatment session (try and make within one 
week later or as soon to one week as possible).Ask the 
participant to bring the booklet with them to all further 
appointments 
 
 
 
Clinical assessment involves: 
● An outline of the subject’s symptoms to establish if there has been any 
change from their initial assessment. If symptoms are worse, further details 
should be recorded such as any additional symptoms or development of red 
flags. 
● Physical examination of myotomes, dermatomes and reflexes of the upper 
limbs.   
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Flow diagram for ‘Trial Physiotherapists’  - 2
nd
 – 6
th
  treatment pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                              
 
 
       
                                 
 
 
 
 
 
 
Is the participant still within five weeks from 
commencing treatment? 
 
For the self-management group, 
treatment involves going through the 
‘self management for neck and arm 
pain’ booklet to establish if the 
participant has put into practice advice 
and is performing exercises correctly. 
Re-assess myotomes, dermatomes and 
reflexes and record treatment in standard way 
For the self-management with mobilisation group, 
treatment involves going through the ‘self 
management for neck and arm pain’ booklet to 
establish if the participant has put into practice 
advice and is performing exercises correctly.  
 Repeat the lateral glide treatment that was given 
on their initial treatment session (same dose, grade 
etc) 
Clinical assessment involves: 
● An outline of the participant’s symptoms to establish if there has been any change 
from their symptom presentation at last appointment. If symptoms are worse, further 
details should be recorded such as any additional symptoms or development of red 
flags. 
● Physical examination of myotomes, dermatomes and reflexes of the upper limbs 
 
 
   
 
 
Participant returns for appointment 
 
   
 
 
Yes  
Book a further appointment for the participant 
to return for a subsequent treatment session   
 
 
 
 
Yes  
Is the participant wishing to return for a 
further session of treatment? 
No 
 Give the participant a follow-up 
appointment with the 
Assessment Physiotherapist. 
(This should be six weeks from 
their first treatment.)   
 Complete the ‘Details recorded 
by the Trial Physiotherapist – 
post intervention’ form. 
 Ensure all the participant trial 
data (with the exception of the 
original consent form) is now 
stored all together in the 
completed data folder (staple 
together if needed). 
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Missed appointments and cancellations 
In instances where treatment appointments are missed or cancelled, further appointments  
will be made based on usual departmental protocols. 
 
It is important for the Trial Physiotherapist to be able to arrange the 6 week re-assessment, and 
complete the participant data post-intervention form regardless of whether the participant has attended 
all agreed treatment sessions or not. 
 
The research lead will be responsible for overseeing that all participants have been contacted for their 
follow-up appointments. 
 
Indications for participants who discontinue the trial 
If a participant decides not to continue with being part of the trial, they are at liberty to do so. In these 
instances participants will not be required to attend the follow-up assessments, however, please make 
sure you still fill in the ‘Details recorded by the Trial Physiotherapist – post intervention’ form and make 
sure it is clear that they received alternative treatment and if possible, the reasons for this. 
 
Adverse incidents for subjects during the trial 
If an adverse reaction occurs and it is suspected that this is as a direct result from any of the treatment 
given in the trial, this must be recorded on both the ‘Adverse incidents during the CBS trial’ sheet and 
a Trust incident form.  Please let the research lead know as soon as possible if this occurs. 
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Appendix G: Comments sheet 
Participant Trial No:  
   Comments of Trial physiotherapists  
i.e. any deviations from basic protocol 
Comments from participant  
i.e. treatment response 
 
Treatment 
session 1 
 
 
 
 
 
Treatment 
session 2 
 
  
 
Treatment 
session 3 
 
  
 
Treatment 
session 4 
 
  
 
Treatment 
session 5 
 
  
 
Treatment 
session 6 
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Appendix H: Serious adverse incidents log 
Subject 
trial 
number 
Date of 
incident 
Nature of incident Outcome Incident form filled? 
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Appendix I: Participant feedback survey with covering letter 
 
 
 
         16th February 2009 
 
 
 
 
 
Dear  
 
 
Re: Feedback from participating in research trial 
 
Last year you kindly agreed to be involved in a pilot research study in the 
Physiotherapy Department at Queen’s Hospital, Burton regarding your neck and arm 
pain. 
 
We are now looking to evaluate how you felt about being involved in the trial to 
inform us what measures we need to address before involving other patients in future 
research trials. 
 
I would be very grateful if you could spend a few minutes to complete the survey and 
return it by post in the pre-paid envelope.  Alternatively, you can contact the research 
lead, Emma Salt either by phone or email. 
 
Yours sincerely, 
 
 
 
 
Emma Salt MSc, MMACP, Grad dip phys. 
MSK Physiotherapy Lead. 
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Survey of involvement in physiotherapy research trial 
 
 
1. Did you feel you were given enough information about what to expect from being involved in 
the research trial? (please circle appropriate answer) 
 
Yes No 
 
If no, then please comment on which aspects you would like to have known more about.  
 ………………………………………………………………………………. 
 ………………………………………………………………………………. 
  
 
2. Did you feel obliged to be involved in the trial? (please circle appropriate answer) 
 
Yes No 
 
If yes, then please comment at which point you felt obliged and how this could have been 
avoided.  
 ………………………………………………………………………………. 
 ………………………………………………………………………………. 
  
 
3. Do you have any comments to make about the questionnaires you filled in? 
……………………………………………………………………………… 
……………………………………………………………………………… 
 
 
4. Please comment on how useful you found the information booklet you received 
…………………………………………………………………………….. 
…………………………………………………………………………….. 
 
 
5. If you received any mobilisation (manipulation) treatment, please comment on how you found 
this. 
………………………………………………………………………………… 
…………………………………………………………………………………  
 
 
6. Were you aware that you were free to withdraw from the trial at any point in time? (please 
circle appropriate answer) 
 
Yes No 
 
 
7. Based on your experience of this trial, would you be happy to participate in another health 
research trial? (please circle appropriate answer) 
 
Yes No 
 
 
Please add any further information you feel would be useful for researchers to know when planning 
trials in physiotherapy. 
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………. 
Thank you. 
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Appendix J: Follow-up questionnaire 
Trial ID ……………        
        (Version 2.1) 
                                                           (18/3/09) 
To be completed by Assessment Physiotherapist 
 
Date of one year assessment…………………… 
 
Has the participant needed further treatment following completion of the 6 month follow up? 
 □  Yes   □  No 
 
If ‘yes’ please give further details 
□  More physiotherapy/osteopathy etc 
□  Acupuncture 
□  Injections to the cervical spine for this problem 
□  Surgery 
□  A combination of treatment 
 
 
Days off sick due to this problem within last month of work : 
□ none    □  1- 5 days    □  6-10 days     □  11-15 days   □  > 15 days    □  Not applicable 
 
Ipsilateral ULNE  
The test should be performed in supine lying in the following sequence: 
scapular depression, shoulder abduction, forearm supination, wrist and finger extension, 
shoulder lateral rotation, elbow extension and contralateral cervical side bend.   
The test was considered positive if any of the following criteria are positive: 
1) symptoms reproduced 
2) side to side differences of >10 degrees elbow extension 
3) contralateral neck side-bending increased symptoms or ipsilateral side-bending decreased 
symptoms when in upper limb tensioned position. 
 
  Positive ipsilateral (same side as symptoms) ULNE?              □yes             □no   
 
AROM Cervical spine  
The test should be performed in sitting using an inclinometer on participants head.  Only one measure 
per movement is needed and this is to be recorded in degrees. 
Flexion  
 
Extension  
 
Right side bend  
 
Left side bend  
 
Right rotation  
 
Left rotation  
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To be completed by the participant 
 
This questionnaire is divided into four parts.  The first part asks what the severity of 
your pain is in the neck and arm and any additional symptoms you may be suffering 
with.  The second part aims to identify how your symptoms affect your health in 
general.  The third part aims to establish how your symptoms are affecting your 
function and the last part asks if there have been any changes since you started your 
physiotherapy treatment.  Some of the questions may be similar, but please try and 
answer every question.  This is not a test and there are no right or wrong answers.  It 
will take you approximately 20 minutes to complete. 
 
 
The Severity of your pain 
 
The following scales help to identify the severity of your pain. 
 
For example if you were feeling moderately high severity of pain/discomfort you 
would indicate it on the line below with an x as such: 
 
example:  
 
no pain         worst pain  
          imaginable   
 
 
However if you were only feeling moderately low pain/discomfort you would indicate it 
on the line like this: 
 
 
no pain         worst pain  
          imaginable 
 
 
 
On the scale below mark an x to indicate the average pain in your neck and arm 
over the last week 
 
no pain         worst pain  
                      imaginable   
 
 
On the scale below mark an x to indicate the worst pain in your neck and arm over 
the last week 
 
no pain         worst pain  
                      imaginable   
 
 
 
 
 
 
x 
x 
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Below are 7 questions about any additional symptoms you may have.  
• Think about how your neck and arm symptoms have felt over the last week.  
• Only circle responses that describe your pain.  
5. In the area where you have pain, does your skin feel unusually hot like a burning 
pain? 
a) NO - I don't have burning pain  (0)  
b) YES - I get burning pain often  (1) 
 
6. Gently rub the painful area with your index finger and then rub a non-painful 
area (for example, an area of skin further away or on the opposite side from the 
painful area). How does this rubbing feel in the painful area?  
a) The painful area feels no different from the non-painful 
area  
(0)  
b) I feel discomfort, like pins and needles, tingling or 
burning in the painful area that is different from the non-
painful area  
(5) 
 
7. Gently press on the painful area with your finger tip then gently press in the 
same way onto a non-painful area (the same non-painful area that you chose in the 
last question). How does this feel in the painful area?  
a) The painful area does not feel different from the non-
painful area  
(0)  
b) I feel numbness or tenderness in the painful area that 
is different from the non-painful area  
(3) 
 
1. In the area where you have pain, do you also have 'pins and needles', tingling or 
prickling sensations?  
a) NO - I don't get these sensations  (0) 
b) YES - I get these sensations often  (5) 
 
2. Does the painful area change colour (perhaps looks mottled or more red) when 
the pain is particularly bad?  
a) NO - The pain does not affect the colour of my skin  (0)  
b) YES - I have noticed that the pain does make my 
skin look different from normal  
(5) 
 
3. Does your pain make the affected skin abnormally sensitive to touch? Getting 
unpleasant sensations or pain when lightly stroking the skin might describe this.  
a) NO - The pain does not make my skin in that area 
abnormally sensitive to touch  
(0)  
b) YES - My skin in that area is particularly sensitive to 
touch  
(3) 
 
4. Does your pain come on suddenly and in bursts for no apparent reason when 
you are completely still? Words like 'electric shocks', jumping and bursting might 
describe this.  
a) NO - My pain doesn't really feel like this  (0)  
b) YES - I get these sensations often  (2)  
278 
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How your symptoms affect your function 
 
This part of the questionnaire is divided into two further sections; in section A, you 
will rate your ability to do a variety of activities based on your condition in the last 
week, by circling the most appropriate number.  For example, circle number “1” if you 
have no difficulty performing the activity, or circle number “7” if you are unable to do 
the activity, or circle any of the numbers in between depending on the amount of 
difficulty you have with the activity or situation in the question.  If you did not have the 
opportunity to perform a certain activity in the past week, please make your best 
estimate on which response would be the most accurate.  It doesn’t matter which arm 
you use to perform the activity.  Please answer based on your ability regardless of 
how you perform the task. 
 
Questions 7 to 10 ask about your work and refer to your usual job tasks.  If you do 
not have a job and were not working at the time of your symptoms starting, answer 
“not applicable” to these questions. 
 
Note that section B (questions 12 to 20), the numbers “1” to “7” refer to how 
frequently you experience the situation in the question (e.g. “1” refers to “never” and 
“7” refers to all the time) 
 
Please check “not applicable” if the question refers to an activity that you do not 
normally do or if the situation described in the question is not related to your neck or  
arm. 
 
281 
 
 
 
282 
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For the following 17 questions, please state your level of agreement if: 
 
1 = strongly disagree 
2 = disagree 
3 = agree 
4 = strongly agree 
 
Please circle most appropriate answer 
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Since the last time you completed this form, would you say your pain has become:  
 
A very great deal better 
□ A great deal better 
□ A good deal better 
□ Moderately better 
□ Somewhat better 
□ A little better 
□ Almost the same, hardly any worse or better at all 
□ A little worse 
□ Somewhat worse 
□ Moderately worse 
□ A good deal worse 
□ A great deal worse 
□ A very great deal worse 
 
 Please mark x in the box which describes your situation the best. 
       
 
 
 
 
 
 
 
 
Since the last time you completed this form, have you needed to take medications for 
the neck and arm pain? Please mark an x in the box that is appropriate to your 
answer. 
 
□ No pain medications  
 
□ Different (weaker) pain medications 
 
□ Same pain medications  
 
□ Different (stronger) medications or  I have needed to start taking medications for  
   the neck and arm pain whereas I wasn’t needing them before 
 
 
 
Thank you for completing this questionnaire 
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Appendix K:  Short-form postal questionnaire (with covering letter) 
Version 2.2 (15.9.10) 
 
Date:  
  
 
 
            
      
Cervicobrachial Pain Trial 
Final reminder 
 
 
 
Dear  
 
Thank you for participating in the above study. 
 
We are sorry that you were unable to attend your last review appointment.  We would be extremely 
grateful if you could answer the enclosed short questionnaire so that we are able to compare how you 
are now with when you joined the study. Once completed, please return the questionnaire in the 
stamped addressed envelope provided. 
 
Your participation is very important so that the results provide physiotherapists with a better 
understanding of how to help people who have neck and arm pain. To achieve this goal, it is essential 
that we find out how people respond in the long-term to different physiotherapy treatments. This is why 
your information is of great value to us. 
 
 
If you have any queries about the questionnaire or any other aspects of the trial, please contact Emma 
Salt on 01283 566 333 x5255 or by email: emma.salt@burtonh-tr.wmids.nhs.uk.  
 
 
Yours sincerely, 
 
 
 
 
 
Emma Salt 
MSc, MMACP, MCSP, Grad dip phys. 
Research lead 
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 Version 2.2 (15.9.10) 
Trial ID …………… 
 
 
 
Short Component Questionnaire for  
Cervicobrachial Pain Trial 
 
 
Date …………… 
 
 
The Severity of your pain 
 
The following scales help to identify the severity of your pain. 
 
 
Example:  
 
For example if you were feeling moderately high severity of pain/discomfort you 
would indicate it on the line below with an x as such: 
 
no pain         worst pain  
          imaginable   
 
 
However if you were only feeling moderately low pain/discomfort you would indicate it 
on the line like this: 
 
 
no pain         worst pain  
         imaginable 
 
 
 
On the scale below mark an x to indicate the average pain in your neck and arm 
over the last week 
 
no pain         worst pain  
                      imaginable   
 
 
On the scale below mark an x to indicate the worst pain in your neck and arm over 
the last week 
 
no pain         worst pain  
                      imaginable   
 
 
 
Please turn over page 
x 
x 
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Since the last time you completed a trial form, would you say your pain has become:  
 
□ A very great deal better 
□ A great deal better 
□ A good deal better 
□ Moderately better 
□ Somewhat better 
□ A little better 
□ Almost the same, hardly any worse or better at all 
□ A little worse 
□ Somewhat worse 
□ Moderately worse 
□ A good deal worse 
□ A great deal worse 
□ A very great deal worse 
 
 Please mark x in the box which describes your situation the best. 
 
 
 
 
 
 
 
 
Since the last time you completed a trial form, have you needed further treatment for 
your neck and arm pain? 
 □  Yes   □  No 
 
If ‘yes’ please give further details 
□  More physiotherapy/osteopathy/ chiropractic’s 
□  Acupuncture 
□  Injections to the cervical spine for this problem 
□  Surgery 
□  A combination of treatment 
 
 
 
 
 
 
Thank you for completing this questionnaire 
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Appendix L: Data check for accuracy of data inputting 
1. Audit check on data – 10% 
a. If >10 % errors, check an additional 10%.  
2. For each outcome measure, check the minimum and maximum values. 
a. If both minimum and maximum recorded values are within the limits for all 
outcome measures, then, proceed. 
b. If one or both extremes are outside the theoretical limits for one or more outcome 
measures: 
i. Check the inputted data against the original data sheets. 
ii. Correct any errors found. 
iii. If “errors” are still present, and there are no other data with which to cross-
check values, set data outside the limits to “missing” (a blank in Excel). 
3. Check “XXX” entries (i.e. missing data). For multi-item outcome measures: 
a. Does any subscale of any outcome measure (e.g. SF36, SLANSS) have more 
than 50% unanswered/missing items for any participant?   
i. If yes, for that participant, set the score on the subscale to “missing” in the 
Excel database  
ii. If no, for that participant, set the score on the subscale to the “mean” score 
across answered items on that subscale (as recommended by developers 
of the outcome measure). 
b. Does any outcome measure have more than 50% unanswered/missing items for 
any participant? 
i. If yes, for that participant, set the score on the outcome measure to 
“missing” in the Excel database. 
ii. If no, for that participant, set the score on the outcome measure to the 
“mean” score across answered items or use weightings as specified by the 
developers of that outcome measure. 
4. Check XX entries (i.e. non-applicable items on multi-item outcome measures).  
a. These “non-applicable” items should correspond to items within outcome 
measures that do not necessarily apply to all participants (e.g. NULI): 
i. If the XX are consistent with point (a): compute score as recommended for 
the outcome measure 
1) Change XX to missing (blank cell) in the Excel database, if 
consistent with (i). 
ii. If the XX are not consistent with point (a): then, check inputted data 
against the original data sheets.  
5. Following completion of the above checks, compute participant scores for each outcome 
measure following rules specified by  the developers (or, latest published criteria, as 
appropriate)  
      Independent person to check a sample of data. 
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Appendix M:  Range of minimum and maximum scores per outcome measure 
No recorded data items were outside the minimum or maximum values for any outcome 
measure: 
Outcome measure scores at baseline 
 VAS  
(average 
pain) 
VAS 
(worst 
pain) 
S-LANSS NULI TAMPA SF36 
min 0 0 0 0 23 17.65 
max 89 97 24 88.33 60 91.67 
 
Outcome measure scores at 6 week follow-up 
 VAS      
(average  
pain) 
VAS  
(worst 
pain) 
S-LANSS NULI TAMPA SF36 GROC 
min 0 0 0 0 20 12.5 -5 
max 93 100 24 95 53 94.74 6 
 
Outcome measure scores at 26 week follow-up 
 VAS 
(average 
pain) 
VAS 
(worst 
pain) 
S-LANSS NULI TAMPA SF36 GROC 
min 0 0 0 0 18 21.74 -6 
max 81 93 24 83.33 50 94.74 6 
 
Outcome measure scores at 52 week follow-up 
 VAS 
(average 
pain) 
VAS 
(worst 
pain) 
S-LANSS NULI TAMPA SF36 GROC 
min 0 0 0 0 17 22.37 -6 
max 94 97 21 68.63 52 97.06 6 
Key: GROC= Global Rating of Change score; NULI= Neck and Upper Limb Index;  
SF36= Short-Form 36 (Mental component summary); S-LANSS= Self Leeds Assessment  
of Neuropathic Signs and Symptoms; VAS= Visual Analogue Scale. 
 
Footnote: 
Possible score range: 
VAS:    0 to 100 
S-LANSS:  0 to 24 
NULI:  0 to 100 
TAMPA: 17 to 68 
SF36:  0 to 100 
GROC:  6 to -6 
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Appendix N:  Strategy for building the MLM  
MLM was calculated using linear ‘mixed models’on SPSS version 19 
 
 
‘Dependent variable’ was the outcome measure of interest e.g. VAS(worst pain) 
 
‘Fixed factors’ were defined as the intervention (group),  baseline covariates that 
could affect outcome (e.g. age) and time in months post baseline at which data were 
collected for each particpant.  
 
Follow-up time points were also identified as ‘Random factors’ to model variation 
around the planned follow-up time points  
 
The model was built in three phases: 
 
 
1) Analysis across time 
The dependent variable (e.g. VAS(worst pain) was modelled as a function of (i) time, 
(ii) time and time squared, and (iii) time, time squared and time cubed, to account for 
any underlying pattern of change in worst pain over time.  
 
2) Adding covariates 
Covariates were tested for addition to the model, one at a time, in the order of their 
“importance” as identified from the literature reviews.   Non-significant covarites were 
not included in the model, so that only significant covaraiates were taken forward to 
stage three of the modelling. 
 
3) Adding intervention 
The intervention was  the last variable to be added to the model, to assess intergroup 
differences after adjustment for time and effects of important covariates.  
 
This approach was recommended by Field (2009) and compared the profile of 
change across the intervention groups, with adjustment for time and important 
covariates. 
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Appendix O:  MLM example (dependent variable = VAS(worst pain)) 
Phase I- Analysis across time 
VAS (worst pain) as a linear function of Time across baseline and all follow-up 
time points (i.e. modelling change over time as a straight line)  
 
 
Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Residual 569.553610 49.499889 11.506 .000 480.348795 675.324512 
TIME [subject = ID]  .255197 .066067 3.863 .000 .153642 .423878 
 
 
 
 
Information Criteria 
-2 Log Likelihood 3360.262 
Akaike's Information Criterion (AIC) 3368.262 
Hurvich and Tsai's Criterion (AICC) 3368.376 
Bozdogan's Criterion (CAIC) 3387.773 
Schwarz's Bayesian Criterion (BIC) 3383.773 
The information criteria are displayed in smaller-is-
better forms. 
 
 
 
 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 56.503849 1.787819 266.319 31.605 .000 52.983790 60.023907 
TIME -.397717 .081666 167.325 -4.870 .000 -.558945 -.236489 
 
Tests of Fixed Effects 
Source Numerator df Denominator df F Sig. 
Intercept 1 266.319 998.870 .000 
TIME 1 167.325 23.718 .000 
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Time as a quadratic function of time (a curve) 
 
Tests of Fixed Effects 
Source Numerator df Denominator df F Sig. 
Intercept 1 265.536 899.276 .000 
TIME 1 308.569 28.340 .000 
TIME * TIME 1 274.460 15.466 .000 
 
 
 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 60.531394 2.018526 265.536 29.988 .000 56.557042 64.505746 
TIME -1.319023 .247771 308.569 -5.324 .000 -1.806557 -.831488 
TIME * TIME .017743 .004512 274.460 3.933 .000 .008861 .026624 
 
 
 
Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Residual 539.373792 46.859377 11.510 .000 454.924878 639.499181 
TIME [subject = ID]  .261716 .065383 4.003 .000 .160391 .427051 
 
 
 
Information Criteria
a
 
-2 Log Likelihood 3345.198 
Akaike's Information Criterion (AIC) 3355.198 
Hurvich and Tsai's Criterion (AICC) 3355.368 
Bozdogan's Criterion (CAIC) 3379.586 
Schwarz's Bayesian Criterion (BIC) 3374.586 
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Time as a cubic function of time (a curve) 
 
 
Tests of Fixed Effects 
Source 
Numerator 
df 
Denominator 
df F Sig. 
Intercept 1 264.764 771.246 .000 
TIME 1 268.859 19.076 .000 
TIME * TIME 1 265.856 10.551 .001 
TIME * TIME * TIME 1 266.407 8.165 .005 
 
 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 63.828283 2.298352 264.764 27.771 .000 59.302909 68.353657 
TIME -3.498383 .800974 268.859 -4.368 .000 -5.075363 -1.921404 
TIME * TIME .142090 .043745 265.856 3.248 .001 .055960 .228221 
TIME * TIME * TIME -.001612 .000564 266.407 -2.858 .005 -.002723 -.000501 
 
 
 
 
Information Criteria 
-2 Log Likelihood 3337.160 
Akaike's Information Criterion (AIC) 3349.160 
Hurvich and Tsai's Criterion (AICC) 3349.400 
Bozdogan's Criterion (CAIC) 3378.427 
Schwarz's Bayesian Criterion (BIC) 3372.427 
 
 
Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Residual 522.959942 45.452063 11.506 .000 441.050044 620.081791 
TIME [subject = ID]  .267611 .065495 4.086 .000 .165646 .432342 
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Phase II- Adding covariates 
SF36(MCS) as covariate 
 
Type III Tests of Fixed Effects 
Source 
Numerator 
df 
Denominator 
df F Sig. 
Intercept 1 355.365 235.601 .000 
TIME 1 268.794 20.057 .000 
TIME * TIME 1 266.037 11.331 .001 
TIME * TIME * TIME 1 266.588 8.872 .003 
SF36t1 1 356.524 17.692 .000 
 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 85.120502 5.545568 355.365 15.349 .000 74.214244 96.026759 
TIME -3.533629 .789018 268.794 -4.479 .000 -5.087071 -1.980187 
TIME * TIME .145096 .043104 266.037 3.366 .001 .060228 .229963 
TIME * TIME * TIME -.001656 .000556 266.588 -2.979 .003 -.002751 -.000561 
SF36t1 -.343011 .081550 356.524 -4.206 .000 -.503390 -.182632 
 
 
Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Residual 507.672864 44.107549 11.510 .000 428.183572 601.918789 
TIME [subject = ID]  .231125 .059350 3.894 .000 .139723 .382318 
 
 
Information Criteria
a
 
-2 Log Likelihood 3242.891 
Akaike's Information Criterion (AIC) 3262.891 
Hurvich and Tsai's Criterion (AICC) 3263.534 
Bozdogan's Criterion (CAIC) 3311.555 
Schwarz's Bayesian Criterion (BIC) 3301.555 
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Chronicity as covariate 
 
Type III Tests of Fixed Effects 
Source 
Numerator 
df 
Denominator 
df F Sig. 
Intercept 1 352.814 115.480 .000 
TIME 1 265.577 19.671 .000 
TIME * TIME 1 262.896 11.231 .001 
TIME * TIME * TIME 1 263.453 8.836 .003 
SF36t1 1 352.012 16.401 .000 
Chronicity 1 351.307 .067 .796 
 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound 
Upper 
Bound 
Intercept 84.000392 7.816797 352.814 10.746 .000 68.627014 99.37377
0 
TIME -3.538241 .797773 265.577 -4.435 .000 -5.109006 -
1.967476 
TIME * TIME .146076 .043588 262.896 3.351 .001 .060249 .231902 
TIME * TIME * TIME -.001671 .000562 263.453 -2.972 .003 -.002778 -.000564 
SF36t1 -.342776 .084641 352.012 -4.050 .000 -.509241 -.176311 
Chronicity .368080 1.421178 351.307 .259 .796 -2.427008 3.163167 
 
 
Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Residual 513.289538 44.862595 11.441 .000 432.47956
5 
609.199073 
TIME [subject = ID] Variance .229579 .059820 3.838 .000 .137765 .382583 
 
Information Criteria
a
 
-2 Log Likelihood 3285.791 
Akaike's Information Criterion (AIC) 3301.791 
Hurvich and Tsai's Criterion (AICC) 3302.210 
Bozdogan's Criterion (CAIC) 3340.723 
Schwarz's Bayesian Criterion (BIC) 3332.723 
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Gender as a covariate 
 
Type III Tests of Fixed Effects 
Source 
Numerator 
df 
Denominator 
df F Sig. 
Intercept 1 356.462 200.085 .000 
TIME 1 268.404 20.121 .000 
TIME * TIME 1 265.678 11.388 .001 
TIME * TIME * TIME 1 266.232 8.924 .003 
SF36 (baseline) 1 356.268 16.886 .000 
Gender 1 355.011 .644 .423 
 
 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 83.518633 5.904411 356.462 14.145 .000 71.906775 95.130491 
TIME -3.541355 .789489 268.404 -4.486 .000 -5.095735 -1.986975 
TIME * TIME .145553 .043131 265.678 3.375 .001 .060630 .230476 
TIME * TIME * TIME -.001662 .000556 266.232 -2.987 .003 -.002757 -.000567 
SF36(baseline) -.336643 .081922 356.268 -4.109 .000 -.497754 -.175532 
Gender 2.297121 2.863332 355.011 .802 .423 -3.334105 7.928346 
 
 
Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Residual 508.245183 44.188185 11.502 .000 428.615183 602.669192 
TIME [subject = ID]  .226980 .058926 3.852 .000 .136461 .377543 
 
Information Criteria 
-2 Log Likelihood 3319.426 
Akaike's Information Criterion (AIC) 3335.426 
Hurvich and Tsai's Criterion (AICC) 3335.840 
Bozdogan's Criterion (CAIC) 3374.448 
Schwarz's Bayesian Criterion (BIC) 3366.448 
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Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Residual 508.245183 44.188185 11.502 .000 428.615183 602.669192 
TIME [subject = ID]  .226980 .058926 3.852 .000 .136461 .377543 
 
 
Age as covariate 
 
Type III Tests of Fixed Effects 
Source 
Numerator 
df 
Denominator 
df F Sig. 
Intercept 1 356.891 132.694 .000 
TIME 1 268.880 19.188 .000 
TIME * TIME 1 266.202 10.709 .001 
TIME * TIME * TIME 1 266.747 8.350 .004 
SF36(baseline) 1 356.250 18.406 .000 
Age(years) 1 354.121 3.886 .049 
 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept 97.931094 8.501488 356.891 11.519 .000 81.211786 114.650403 
TIME -3.451461 .787928 268.880 -4.380 .000 -5.002755 -1.900167 
TIME * TIME .140848 .043040 266.202 3.272 .001 .056105 .225590 
TIME * TIME * TIME -.001604 .000555 266.747 -2.890 .004 -.002697 -.000511 
SF36(baseline) -.348025 .081122 356.250 -4.290 .000 -.507563 -.188488 
Age(years) -.264635 .134252 354.121 -1.971 .049 -.528667 -.000603 
 
 
Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Residual 504.929349 43.880764 11.507 .000 425.850488 598.692862 
TIME [subject = ID]  .221860 .057925 3.830 .000 .132997 .370098 
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Information Criteria 
-2 Log Likelihood 3316.215 
Akaike's Information Criterion (AIC) 3332.215 
Hurvich and Tsai's Criterion (AICC) 3332.629 
Bozdogan's Criterion (CAIC) 3371.237 
Schwarz's Bayesian Criterion (BIC) 3363.237 
 
 
 
 
Phase III- Adding intervention 
 
Type III Tests of Fixed Effects 
Source Numerator df Denominator df F Sig. 
Intercept 1 101.996 74.231 .000 
TIME 1 202.255 26.637 .000 
TIME * TIME 1 200.545 14.602 .000 
TIME * TIME * TIME 1 200.746 11.270 .001 
SF36(baseline) 1 97.623 9.995 .002 
Age(years) 1 98.536 2.130 .148 
Intervention 1 96.686 .060 .808 
 
Estimates of Fixed Effects 
Parameter Estimate Std. Error df t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Intercept 97.836011 11.427608 102.307 8.561 .000 75.17022
1 
120.5018
00 
TIME -3.434363 .665426 202.255 -5.161 .000 -
4.746425 
-
2.122302 
TIME * TIME .139078 .036396 200.545 3.821 .000 .067310 .210847 
TIME * TIME * TIME -.001576 .000469 200.746 -3.357 .001 -.002502 -.000650 
SF36(baseline) -.353473 .111809 97.623 -3.161 .002 -.575364 -.131582 
Age(years) -.265687 .182055 98.536 -1.459 .148 -.626944 .095571 
[Intervention=Comparator] .956164 3.914184 96.686 .244 .808 -
6.812728 
8.725055 
[Intervention=Mobilisation] 0
a
 0 . . . . . 
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Type III Tests of Fixed Effects 
Source Numerator df Denominator df F Sig. 
Intercept 1 101.996 74.231 .000 
TIME 1 202.255 26.637 .000 
TIME * TIME 1 200.545 14.602 .000 
TIME * TIME * TIME 1 200.746 11.270 .001 
SF36(baseline) 1 97.623 9.995 .002 
Age(years) 1 98.536 2.130 .148 
Intervention 1 96.686 .060 .808 
 
 
 
Estimates of Covariance Parameters 
Parameter Estimate Std. Error Wald Z Sig. 
95% Confidence Interval 
Lower Bound 
Upper 
Bound 
Residual 353.068915 35.862645 9.845 .000 289.334007 430.8434
39 
Intercept [subject = ID]  233.263658 54.143583 4.308 .000 148.003483 367.6395
53 
TIME [subject = ID]  .118850 .045983 2.585 .010 .055676 .253706 
. 
 
Information Criteria
a
 
-2 Log Likelihood 3242.891 
Akaike's Information Criterion (AIC) 3262.891 
Hurvich and Tsai's Criterion (AICC) 3263.534 
Bozdogan's Criterion (CAIC) 3311.555 
Schwarz's Bayesian Criterion (BIC) 3301.555 
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